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Objective: To systematically identify, appraise and synthesis evidence of the formulation 
specific effects and population specific responses of probiotics in inflammatory arthritis (IA).  
Methods: MEDLINE (PubMed), CINAHL, EMBASE, and SCOPUS databases were searched for 
studies utilising probiotics and an intervention of inflammatory arthritis. The Joanna Briggs 
Institute (JBI) method was used to conduct the systematic review. A single reviewer 
undertook screening and data extraction. Two independent reviewers assessed the quality 
of evidence using JBI tools. 
Results: A total of 154 full text articles were retrieved and of these twelve eligible studies 
were reviewed. Of these, ten (83%) were randomised controlled trials and two (17%) were 
quasi-experimental studies. Four studies included a variety of spondyloarthopathies (SpA). 
Eight studies focused on rheumatoid arthritis (RA). Probiotics were supplied for a median 
timeframe of 60 and mode of 56 days (range 7-365 days). Overall, 17 different probiotics 
were supplied in colony forming units (CFU) per 24hrs ranging from 1x 108 to 2.25 x 1011. 
The genus of probiotic most commonly supplied was Lactobacillus.  
There was no statistical difference in the relative risk (RR) of minor adverse effects between 
probiotic and control groups (RR 1.02, 95% CI 0.69 to 1.51) when including nil event studies 
and no major adverse effects reported. However, effects were more often reported for 
studies on SpA. Meta-analysis identified a statistically significant benefit of probiotics on 
quality of life with a standard mean difference (SMD) effect size -0.37 (CI-0.59, -0.15), 
p=0.01 with subgroup analysis favouring Lactobacillus-only formulations. Negative effects 
sizes related to the reduction in quality of life scores that utilise a higher score to indicate 
worsening symptoms and more impact upon daily living. Small but statistically significant 
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reductions in pain, p=0.006 with a mean difference effects size -8.97 (95%CI -15.38, -2.56), 
were identified independent of formulation. Meta-analysis confirmed the known 
statistically significant benefit of probiotics on the inflammatory marker C-reactive protein 
p=0.017 with a mean difference effects size -2.34 (95%CI -4.26, -0.41), with subgroup 
analysis demonstrating a greater difference in RA and combined Bifidobacterium and 
Lactobacillus formulations. The clinical significance of these small changes is questioned. 
Conclusion: This review indicates a potential differential benefit to combined formulations 
of Bifidobacterium and Lactobacillus compared to purely Lactobacillus formulations, with 
respect to reducing pain, lowering C-reactive protein and improving quality of life. It also 
suggests altered benefits dependant on the type of inflammatory arthritis with less benefit 
and more frequently reported side effects for individuals with SpA compared to RA. 
Generalisability of results to clinical practice is limited by the dominant demographic of 
older individuals, with established disease beyond the ‘therapeutic window of intervention’ 
for Inflammatory arthritis. Small but statistically significant benefits require confirmation 
using clinical studies with greater consideration to confounding factors of age, gender, diet 
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CHAPTER ONE Introduction  
1.1 Structure of the thesis 
 
This thesis is structured in four chapters. The first chapter provides a broad introduction to 
the topic under review, in order that the following methodology and results sections can be 
understood in context.  
 
The introduction begins by explaining the common forms of inflammatory arthritis and the 
need for exploring adjuvant interventions to current care, despite the advances in 
pharmacotherapy in the past ten years. This chapter then goes on to provide a background 
to the development of modern-day probiotics and explores the current understanding of 
their mechanisms of action, with the resulting benefits and safety issues.  To appreciate the 
range of probiotic actions and their allocation to specific strains, the introduction also 
contains a section on the phylogeny and classification of probiotics.  An explanation of 
common outcome measures applied in rheumatology is provided to rationalise the 
outcomes selected for the systematic review. Finally, the introduction concludes by 
examining the current systematic reviews that have been undertaken in the area. This 
serves to justify the construction of this systematic review and the gaps in the literature it 
aims to address.   
 
The second chapter outlines the methodology of the review including the population, 
intervention, comparators and outcomes of the studies to be included as well as the 
justification and explanation of studies excluded from the review.  
The third chapter provides the results of the systematic review process and includes the 
PRISMA flowchart, details of the quality appraisal of all included studies, forest plots for 
comparison of effect sizes, where appropriate, and a narrative summary of the results of the 
included studies. 
 
The fourth and final chapter provides the discussion of the overarching thesis topic. It starts 
with a discussion of the evidence of the efficacy of probiotics according to outcomes of the 
systematic review and progresses to discuss the evidence relevant to specific forms of 
inflammatory arthritis or specific formulations of probiotics. The impact of study quality, 
population characteristics and the probiotics strains supplied are discussed along with 
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sources of bias and reliability in outcome measurement. The thesis is concluded with 
consideration of the limitations of the review, suggested areas for future research and 
recommendations for practice.  
A brief overarching conclusion is provided prior to the references and appendices. 
 
1.2 Inflammatory arthritis  
Chronic inflammatory arthritic diseases have a multifactorial aetiology characterised by 
auto-antibody production and systemic features. Synovial inflammation induces pannus and 
joint destruction unless aggressively managed early by disease modifying therapies. 
Inflammatory arthritis can be highly disabling with immense personal, social and economic 
costs. Healthcare costs alone for rheumatoid arthritis (RA) in Australia were estimated at 
$550 million in 2015.1(p.3) Worldwide, the prevalence of RA has been estimated at 0.24% and 
responsible for 4.8 million disability-adjusted life years (95% CI 3.7 million to 6.1 million) in 
2010.2 With the number of people with arthritis estimated  to rise to 5.4 million people by 
2030 this correspondingly creates a higher burden of disease and costs to individuals and 
governments.3 The family of spondyloarthropathies (SpA) including psoriatic arthritis, 
ankylosing spondylitis, reactive arthritis, inflammatory bowel disease associated arthritis 
(also known as enteropathic arthritis) and undifferentiated SpA have considerable variation 
in reported prevalence estimates.4However, recent estimates of disease impact suggest the 
burden from SpA is similar to that experienced by those living with RA.5 Disease burden can 
be estimating in many ways, increasingly patient reported outcomes (PROMs) are viewed as 
effective measures of the impact and burden of disease, as serum measures of systemic 
inflammation such as C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) do 
not correlate strongly to other markers of disease activity or functional or quality of life 
outcomes.6  
 
1.3 Aetiology of inflammatory arthritis and the role of dysbiosis 
Whilst debate continues over the aetiology of inflammatory arthritis, a multifactorial 
aetiology is generally accepted. There is emerging evidence that microbial dysbiosis at 
mucosal sites (in concert with environmental triggers) can be involved in the disease in 
genetically predisposed individuals.7 Key findings supporting this theory include that 
elevated serum-related auto-antibodies have been found in early RA without clinically 
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evident synovitis, suggesting that pathology develops outside of the joint.8 The gut has been 
suggested as one key mucosal site which may trigger auto immune reactions in distant sites 
such as the joints. This hypothesis stems from identification of dysbiotic gut microbiota  in 
individuals with early stage auto-immune inflammatory RA, which can be partly normalised 
after treatment.8,9 Such is the specificity of the dysbiotic changes that genetic markers of 
these gut microbes can be used to identify individuals with RA from a control group.10 
Microbial dysbiosis has been most widely researched in people with RA, but there is growing 
evidence to link microbial dysbiosis with the whole clinical spectrum of inflammatory 
arthropathies.  Studies are now emerging on the gastrointestinal microbiota in people with 
SpA and juvenile idiopathic arthritis.  Evidence exists which supports an even closer link 
between gut microbiota and the pathogenesis of SpA than observed in RA.  
 
Subclinical gut inflammation has been estimated to occur in up to 70% of patients with 
ankylosing spondylitis and up to 100% of patients with psoriatic arthritis.11,12 This 
association may have been masked by a lack of reportable bowel symptoms despite the 
prevalence of colonoscopic changes in patients with psoriatic arthritis and psoriasis.12 
Similarly, subclinical evidence of gut inflammation has been found on magnetic resonance 
enterography of a sample population of juvenile arthritis patients. Whilst the small sample 
size in this study may increase the likelihood of type II error, the prevalence of clinically 
diagnosed inflammatory bowel disease is also higher for individuals with juvenile arthritis 
than in the general population.13,14 Whilst gut changes have been identified in RA there 
remains debate between researchers as to whether intestinal inflammation is a primary 
abnormality or occurring as a result of the effects of medications, such as non-steroidal anti-
inflammatories.15  
 
1.4 Current management options and limitations 
Pharmaceutical management using disease modifying anti-rheumatic drugs (DMARDS) 
remains the mainstay of intervention for inflammatory arthritis, often coupled with non-
pharmacologic management strategies. However, adverse drug effects are commonly 
experienced, and remission is not guaranteed. About 20% to 40% of patients treated with 
newer version biological disease modifying anti-rheumatic medications– the tumour 
necrosis factor inhibitors - fail to achieve a 20% improvement in American College of 
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Rheumatology criteria and more lose response over time (secondary failure or acquired 
therapeutic resistance).16,17 In juvenile arthritis, new pharmaceutical therapy has increased 
the likelihood of attaining inactive disease in up to 70-90% of children within two years, yet 
sustaining remission remains problematic for almost 50% of all children.18 Similarly in 
ankylosing spondylitis only a certain percentage of patients achieve partial remission which 
may prompt the search for alternative management options.19  New studies indicate that, 
with the application of the new targeted biological medications, there may be much higher 
rates of sustained clinical remission, potentially up to 50% of patients with ankylosing 
spondylitis may now achieve remission, highlighting a defined window of opportunity for 
effective intervention.20 However, this trial excluded patients with later disease (defined as 
more than 12 weeks after diagnosis) and those with more extensive disease (defined as 
poly‐articular disease, five swollen joints or more).18 
 
Even for those who can access biologics, who can respond and sustain that response over 
time – there are patients who are unwilling to accept ongoing pharmacotherapeutic 
interventions or look to supplement them with alternative therapies.21 As earlier diagnosis 
and intervention becomes the norm, there is also a possibility that a greater number of 
individuals will perceive early provision of disease modifying anti-rheumatic medications as 
an overly aggressive and unwarranted management strategy and look for alternative and 
adjuvant approaches given the lesser magnitude of their symptoms. A recent systematic 
review into the patient perceived health service needs in inflammatory arthritis identified 
that there are many different drivers that may encourage the high rate of complementary 
and alternative medicine use.22 The review identified patients’ perceptions of an ongoing 
need for symptom management, a desire for more holistic consultations and shared 
decision making,  alongside financial disincentives and negative past experiences of 
traditional pharmaceutical management, may all play pivotal roles in the use of 
complementary therapies  in inflammatory arthritis care.22 
 
1.5 Complementary and supplementary therapy usage 
The use of supplementary and complementary therapies by patients as a means to seek, or 
maintain, symptom control remains high, and a search for adjuvant interventions to reduce 
the burden of disease in inflammatory arthritis remains common.22  As specific data of 
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probiotic usage in rheumatology clients is lacking, this review aims to generate capacity for 
clinicians to understand the likelihood of benefits and harms from the application of current 
probiotic formulations and be confident in discussing these. Such discussions form part of a 
holistic approach desired by patients and that are perceived by patients to improve 
communication and their feeling of autonomy in the ongoing management of their 
condition.22 
 
Despite a lack of rigorous trials, probiotics are a booming business. The global probiotics 
market totalled $US 34 billion in 2015 and is set to grow to $US50 billion by 2020.23 Whilst 
levels of probiotic supplementation in rheumatology populations in Australia are unknown, 
research has provided evidence that up to a third of the community does use probiotics 
with little concern about side effects and without informing health professionals about their 
use.24,25 If probiotics are considered within the wider category of complementary and 
alternative medicine, and a significant number of people with inflammatory arthritis are 
using them, this highlights the perceived inadequacies or unacceptability of standard 
therapies for these conditions.26,27 
 
A survey from Australia indicated that 94.7% of a sample of 75 ankylosing spondylitis 
patients reported previous or current complementary therapy use.28 Clinicians may not 
appreciate the widespread use as research indicates that almost half are not reporting such 
use to their health care team. Whilst a full understanding of the rationale for such non-
disclosure is not currently known, studies by Rao and Robinson would indicate that the past 
experience, or anticipation of, a negative response from clinicians is part of the reason that 
complementary therapy use is hidden in formal healthcare interactions.29-31 
 
The reasons for complementary therapy use have been explored, and include a perception 
of lower risks/harms, alongside the value of being in control of their treatment choices.32  
The use of complementary therapies in ankylosing spondylitis has been identified as more 
likely in women with  higher levels of education, suggesting that use may be interpreted as 
an indicator of greater desire of autonomy, consistent with management principles for long-
term health conditions.28  Harnessing patients’ desire for involvement in their healthcare by 
understanding the evidence base for, and engaging in discussions about complementary 
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therapies, seems a more effective means of shared-decision making than the current  
situation of disguised use and non-disclosure. This thesis aims to help enable open 
discussion of the role of probiotics as an exemplar complementary therapy in rheumatology.  
1.6 Probiotics  
Probiotics have been defined as “live microorganisms which when administered in adequate 
amounts confer a health benefit on the host”. 33(p.507, Box.1) Probiotics are one of several 
potential ‘therapies’ that are being investigated regarding positive benefits for the 
gastrointestinal system. The GI system is home to most human microbiota, which confer 
significant benefit upon human hosts including contributing to an effective immune system 
that can tolerate safe commensal bacteria, whilst ensuring a rapid inflammatory response to 
pathogenic organisms.34,35 A bourgeoning literature base has investigated the effects of 
probiotics on the gastrointestinal system, theorizing that they address ‘dysbiosis’ or 
imbalance in the gut microbiome, and can down regulate the pro-inflammatory cytokine 
cycle implicated in triggering auto immune diseases, such as inflammatory arthritis.36-41 
 
The clinical benefits of probiotics on the microbiome have been most extensively studied in 
inflammatory bowel disease, where a systematic review and meta-analysis demonstrated 
that probiotics can induce remission and help prevent relapse.41 Furthermore, in animal 
studies probiotics were capable of down regulating the pro inflammatory cytokine cycle.42 
The interest in harnessing probiotics proven anti-inflammatory responses for managing 
inflammatory arthritis is growing with the emerging evidence highly relevant to researchers, 
clinicians, industry and patients.43 
 
However, alongside potential benefits there have also been potential risks identified.43 
Potential adverse health effects from probiotic use, such as systemic infection, deleterious 
metabolic activities, immune dysregulation and gene transfer, have been identified.44  A 
recent systematic review revealed the most common adverse effects were noted in 
immune-compromised patients and included sepsis, fungemia and GI ischemia.  Dangers 
should not be underestimated, as demonstrated where a multispecies probiotic was used 
enterally for individuals with acute pancreatitis. Mortality in the group which received the 
probiotics was 16%, significantly above that of the placebo group at 6%.45 Therefore, 
rheumatologists, general practitioners and pharmacists should be well informed and 
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capable of discussing the evidence-based risk benefit ratio of probiotics with their 
patients.46Therefore, a rigorous identification, appraisal and synthesis of the current 
evidence is urgently needed to inform practice and enable reliable, accurate information for 
health consumers. 
 
1.6.1 Historical context of probiotics 
The term probiotic is derived from the Latin preposition ‘pro’ which means ‘for’ and 
the Greek word ‘biotic’ meaning ‘bios’ or ‘life’.47 Its earliest documented scientific use was 
in the early 1950’s  to describe a range of supplements that had restorative properties for 
human health. The term was more tightly defined by an article in Science which attributed 
the benefits specifically to the work of bacteria.48,49 By 1974, it was suggested that a wide 
range of organisms beyond just bacteria could act as probiotics.47 The current definition of 
probiotics was formulated in 2001 by the Food and Agriculture Organization of the United 
Nations (FAO) and the World Health Organisations (WHO) as “live microorganisms which, 
when administered in an adequate amount, confers a health benefit to the host”.33(p.507) 
 
However, probiotics are not really such a recent phenomenon. Most of the world’s oldest 
cultures, including those of Asia, Africa and Australia, have practised forms of food 
fermentation using microbial cultures since 7,000 or more years BC, and these early 
fermented foods are the direct link to our modern probiotic products.48  Gogineni 49 
outlines how the understanding of probiotic mechanisms by the great French chemist 
Pasteur  in 1860 was followed by the work of Henry Tissier,  the first person to clinically 
apply lactic acid probiotics (LAB) by giving  isolated Bifidobacterium to infants with diarrhea.  
It is now known that LAB create an acidic local environment, which inhibits the growth of 
harmful bacteria, preventing food spoilage and protects humans from pathogenic bacteria 
in the gut.50  
 
Development of clinically validated commercial products has been more problematic as 
bacteria commonly used as yogurt starters (Lactobacillus bulgaricus and Streptococcus 
thermophilus)  were found to be incapable of colonizing the human intestine.51 
Whilst Dr Minoru Shirota is acknowledged as the first to develop a commercial probiotic 
product capable of surviving the gastrointestinal tract, the impact of the great depression, 
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the world wars and development of antibiotics, slowed much further research into 
probiotics until the 1980’s.50 The rise of antibiotic resistance alongside the capacity of 
modern microbiology techniques to identify mechanisms of actions in the human body 











Figure 1. Rapid growth in research in the microbiota and probiotic arena, as displayed by publications identified 
with key words in Pubmed 
 
Developments in health technology, such as microbiology molecular techniques, access to 
efficient large-scale genome sequencing and computer aided bioinformatics have 
revolutionised our understanding of the microbiota of the human GI system. Similarly, they 
have shed light on the far-reaching ways in which probiotics and their metabolites can 
impact human health, as will be discussed in greater detail in section 1.2.3.  Through 
applying metagenomic analysis, the Human Microbiome Project has identified >40 000 
species in the colon, however work to understand their complex actions, exquisitely tuned 
interactions and therapeutic potential has only just begun.53-55 
 
1.6.2 Taxonomy and classification of probiotics 
A clear understanding of classification becomes relevant when seeking to understand the 
mechanisms of action for probiotic formulations. Probiotics may include a variety of micro-
organisms living in and on the human body that confers a health benefit including 
eukaryotes, archaea, bacteria and viruses. However, the majority of organisms that have 
been researched, applied and evaluated are bacteria or yeast.55 There are still very few 
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despite increasing evidence of the link between reduced bacterial diversity and bacterial 
function with expansion of specific viruses in immune mediated disease, specifically Crohn’s 
disease.56,57  
 
This thesis will therefore focus on those organisms most commonly applied as probiotics 
currently: bacteria and yeast. Each organism will be referred to by its current brand name 
and nomenclature according to recognised taxonomic rules. It should be recognised, 
however, that there are significant challenges to the correct identification of probiotic 
strains, including a lack of a global standard. Some basic terms and concepts in bacterial 
taxonomy to understand throughout the thesis, are that ‘Classification’ is the process of 
clustering organisms into taxonomic groups (taxa) based on similarities or relationships. 
‘Nomenclature’ is the assignment of names to the taxonomic groups according to 
international rules.  
 
As genetic knowledge expands, classification can change resulting in the re naming of 
species. Whilst early classification was restricted to a limited number of organisms that 
could be cultured and grown ex vivo, the rise in genetic sequencing of in vivo samples has 
created complexity by generating several hundred thousand new species every year.58  The 
proliferation of  new species alongside increasingly precise genomic tools has created a 
shifting in taxonomy. Using genetic profiling to establish such relationships has created new 
phylogenetic trees that display the genetic (rather than morphological) relationships of 
organisms. (see Figure 2 below).  
 
Figure 2 is adapted from the interactive tree of life and displays the hypothesised 
phylogenetic tree and placing of the common probiotic genera.59-61   The four main genus of 















Figure 2. A highly resolved Tree Of Life, based on completely sequenced genomes [1]. The image was generated 
using iTOL: Interactive Tree Of Life[2], an online phylogenetic tree viewer and Tree Of Life resource.65 
   
 
Such phylogenetic schemes may require alignment with traditional classification schemes, 
requiring a combination of profiling and identification methods.  Where there have been 
changes in the naming and classification of probiotic species contained within studies, this 
has been flagged and discussed where required.The current three domain system groups 
organisms primarily based on differences in ribosomal RNA (rRNA) structure. Basically, all 
forms of life are classified into three domains and six kingdoms. 
 
. A clear understanding of classification becomes relevant when seeking to understand the 
mechanisms of action for probiotic formulations, to clarify species applied in trials or 
commercial products, and identify risks of negative side effects. As shown in Figure 3 most 
probiotic organisms belong to the gram-positive type bacteria within the domain of 
Bacteria, the kingdom of prokaryotic organisms and the phylum Firmicutes. Within the 
classification of Firmicutes, the two most common Genus applied as probiotics are the 
Lactobacillus and Bifidobacterium genera44 This is clarified within Figure 3 and it should be 
noted that throughout this thesis the terminology Bifidobacterium will be used to denote 
any probiotics that fall within the Bifidobacterium genus, and the term Lactobacillus will be 














Figure 3 Simplified classification diagram to represent basic taxonomy of common probiotics 
Classification at a species, or subspecies, level relies on 16S rRNA gene sequence 
technology. It has been determined that bacteria strains can be identified as belonging to 
the same species if they share 70% or more DNA relatedness (at the DNA–DNA hybridization 
or re-association level) and possess more than 97% 16S rRNA gene sequence identity.59 The 
genus Lactobacillus is the most extensively studied with the most validated species, but 
Bifidobacterium species are also well characterised.62,63 
 
Yeasts which have been applied as probiotic organisms are found within the kingdom of 
Eukaryotes. Yeasts are single-celled microorganisms classified as members of 
the fungus kingdom. They are a diverse group, and currently only organisms within the 
phylum of true yeasts, Ascomycota has been explored for commercial use as probiotics.64 
 
1.6.3 Mechanisms of action 
It has been a long-standing and commonly accepted paradigm that probiotics exhibit strain-
specific effects.64 This viewpoint would render a systematic review on different strains 
redundant, as treatment effects would not be able to be directly compared. However, 
advances in molecular technology are now revealing more complex and interwoven 
mechanisms of action, with shared actions within and across taxonomic groups for 
probiotics.64 Proposed mechanism of action relevant to the two main groups of probiotics 





The study of yeasts in dysbiosis is less developed than that of commensal bacteria, and 
primarily only the Saccharomyces cerevisiae has been studied in detail.65 A range of key 
mechanisms for the antimicrobial actions of yeast have been suggested as nutrient 
competition, pH change caused by their production of organic acids or ethanol  and 
secretion of antibacterial and anti-microbial compounds.66   
 
For decades, researchers have known that the production of secondary metabolites by 
yeast, known as killer toxins or ‘mycocins’ were a cause of the antimicrobial properties of 
foods and drinks fermented by yeast.67 Production of antibacterial compounds have been 
described across a range of yeast species, and are capable of inhibiting potentially 
pathogenic bacteria, for example, Candida intermedia can reduce Listeria monocytogenes.68 
They can also potentially alter the human commensal bacteria community, for example 
inhibition of Lactobacillus plantarum by yeasts has been reported.69 In addition many 
placebo controlled clinical trials have demonstrated an effect of Saccharomyces boulardii 
against antibiotic associated diarrhoea and Clostridium difficile associated diarrhoea.70 
Research has indicated that mechanisms of action are likely to be multifactorial, including 
releasing bacteriostatic or bactericidal substances, which inhibit pathogenic effects of 
bacterial toxins, have anti-secretory action, and show trophic, immune-stimulatory and anti-
inflammatory responses.67 Investigation into the application of yeast probiotics for 
inflammatory bowel disease has hypothesised that that anti-inflammatory benefits are 
gained by the yeast altering the migration of T cells, reducing levels of pro-inflammatory 
cytokines and therefore gut inflammation.71 
 
Bacteria  
It is important for the translational science of probiotics that common benefits via known 
mechanisms can be ascribed, since insufficient studies have been undertaken on identical 
strains to permit systematic reviews that adhere to a strain specific mechanism viewpoint. 
Whilst it appears that a comprehensive understanding of all mechanisms for all species and 
strains is not yet elucidated, there are some well-evidenced examples of modes of action 
that can be provided, specifically for the most studied genera of Lactobacillus and 
Bifidobacterium.69 Widely studied and well documented probiotic effects are discussed as 
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per Hill et al 201433 with more recent evidence supplied to substantiate specific mechanisms 
as relevant to this thesis. Probiotics have been shown to act in the gastrointestinal tract in 
different ways, which can be simplified and represented in four key areas (Figure 3).  
 
Each effect can be created through several mechanisms and an example of common shared 
mechanisms across genera, and more strain specific mechanisms is provided. This aims to 
provide a brief rationale for the capacity to undertake a systematic review in probiotics and 
a rationale for the sub-population analysis which occurs by genera due to the number of 
different mechanisms of action shown between the Bifidobacterium and Lactobacillus 
genera. A simplified diagram of shared and common mechanisms is shown in Figure 4. 
 
 
Figure 4 Diagrammatic representation of key probiotic mechanism of action with examples provided of  shared 
and strain specific mechanisms (SCFA, short chain fatty acids) 
Modulating the Gut microbiota: Lactic acid producing bacteria have been shown to 
demonstrate general anti-microbial resistance. This occurs through a common mechanism 
shared across many in the genus, since the production of lactic acid reduces gut pH locally, 
and is sufficient to reduce viability of potential pathogens.72,73 Targeted bacteriocins may 
also be secreted by specific probiotic strains which have a focused and narrow action, 
providing the probiotic with a competitive advantage in the gastrointestinal tract for 
example Bifidocin B, which is produced by Bifidobacterium bifidum NCFB 1454.74  
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Enhancement of gut epithelial barrier function by probiotics has been demonstrated in 
many ways. Inflammation of the gastrointestinal tract, as in Inflammatory bowel disease, 
has been linked to infiltration of pathogens/microbes, due to loss of barrier function. The 
epithelial integrity is mainly controlled by tight junctions, which are protein complexes 
found at the apex of the epithelial cell.  Most gram positive bacteria such as Lactobacillus 
and Bifidobacterium genera share cell surface molecules that enable them to adhere to the 
gastrointestinal epithelia, enhancing barrier function by facilitating competitive exclusion of 
other microbiota.75 Certain very strain-specific mechanisms have also been discovered, for 
example, Lactobacillus plantarum WCFS1 activates the Toll like receptors on the epithelial 
cells which up regulate the tight junctions, and therefore can enhance intestinal integrity.69  
 
Modulation of the immune system by probiotics supplied to the gastrointestinal tract has 
been demonstrated through in vivo and in vitro studies and is discussed extensively in 
Dwivedi et al. 2016.76 Immunodulation may be unsurprising considering approximately 70% 
of our body's immune system is located in the gut.77,78  Many different probiotic taxa share 
the ability to produce short chain fatty acids which directly affect levels of 
monocyte/macrophage and neutrophil recruitment and the production of anti-
inflammatory cytokines.  All Bifidobacteria share the same metabolic pathway to create 
short chain fatty acids (known as the ‘bifido shunt’) and a recent comparative genomic 
analysis of publicly available Bifidobacterium genomes reveals that all enzymes within the 
shunt pathway are found across all species of Bifidobacterium.64 Therefore, this anti-
inflammatory action working through the immune cytokines may be considered phylum 
generic. Specific short chain fatty acids have also been shown to enhance the release of 
specific anti-inflammatory cytokines, for example butyrate enhances the release of IL-10, 
and there are differences in the ability of strains of Lactobacillus plantarum to induce IL-10 
related to butyrate production.69   
 
Modulation of metabolic activities is complex and can occur across many aspects of 
metabolic function. For example, the capacity for Lactobacillus species to produce enzymes 
(lactase or beta galactosidase) that can degrade lactose in the gut. This capacity is so well 
proven that the specific health claim that probiotics may ‘improve the digestion of lactose’ 
is currently the only claim recognised in the European regulatory market.71 Another 
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potential probiotic metabolic activity is the hydrolysation of bile salts, which act to reduce 
the toxicity of bile to the probiotics cell membranes and therefore increases their intestinal 
survival and persistence. Bile salt hydrolase activity has been shown across the entire range 
of gram-positive bacteria.79 Therefore, such metabolic functions may be considered shared 
mechanisms across a broad range of probiotics.  
 
Probiotics also enable humans to obtain certain essential vitamins that they are unable to 
synthesis themselves. Vitamin synthesis capacity seems to be more strain specific, for 
example creation of folate requires two precursors, and genomic analysis of Bifidobacterium 
species suggests that only a few have the genes to code for both these precursors and could 
create folate in the gut of their host.80,81 As a mainstay of rheumatology continues to 
include the use of Methotrexate, a known folate antagonist, patients currently require 
folate supplementation to offset the adverse effects of folate depletion.82 The potential 
capacity of probiotics to create folate on demand in situ is an intriguing possibility for 
adjuvant therapy. 
 
Given the complexity and overlap between actions and mechanisms, in addition to the 
deficit in complete genome typing across all strains and species, this review will attempt to 
provide some broad background to the formula of probiotics employed in the included 
studies, and where possible, draw links between demonstrated effects in human 
populations and known mechanisms of probiotic action. 
 
1.6.4 Safety consideration of probiotics 
With increasing knowledge of the mechanisms of action of probiotics there has also been 
more clarity as to the potential side effects that may occur.43 Side effects have been 
suggested to occur for several reasons including, but not limited to : 
A. Translocation /transmigration of probiotics across the gut barrier resulting in 
invasive infection i.e. bacteraemia or endocarditis; 
B. Facilitation of transfer across gut membranes of pathogenic bacteria/species 
C. Toxic or metabolic effects on the gut, i.e.  ischaemia 
D. Alteration of immune system function in a deleterious manner,  
E. Transfer of antibiotic resistance between gut flora 
26 
 
A systematic review into the safety and side effects of probiotics published in 2013 
identified that opportunistic infection from ingested probiotics in immune compromised 
and hospitalised patients has rarely been observed, and led to clinical cases of sepsis, 
fungaemia and gut ischemia.44 As the majority of patients living with inflammatory arthritis 
are taking a range of immune supressing medications from traditional steroids through to 
biological disease modifying anti-rheumatic medications this indicates a higher degree of 
caution should be exercised when evaluating a risk: benefit ratio for probiotic use in this 
population. 
 
Safety profiles were found to vary across probiotics and study authors identified that most 
bacteraemia cases were associated with the delivery of Lactobacillus rhamnoses and the 
most fungaemia cases associated with Saccharomyces boulardii.44 The majority of evidence 
at this time suggests that serious adverse effects remain rare (based on epidemiologic data) 
and that there is little increase risks based on usage. However, there is a lack of trials that 
have aimed to investigate adverse events directly or establish any important dose 
dependant relationships that may exist. The risk of human infectious disease due to 
Lactobacillus is considered to be less than one case per million individuals.83 There are two 
accepted safety status labels applied to probiotics in the food industry: Qualified 
Presumption of Safety (QPS) by the European Food Safety Authority (EFSA) and Generally 
Recognised as Safe (GRAS) by the United States-Food and Drug Administration ( US-FDA).84 
 
The potential for translocation depends partially on the adhesive qualities of the bacteria 
for the gut epithelium. However greater adhesive qualities, do not necessary equate to 
greater risk of harm as this preferential adhesion can also exclude other pathogenic 
organisms.83 Direct toxic effects on the gut, due to metabolites produced by bacteria, can 
also occur. Such metabolite toxicity was identified in the PROPATRIA trial and resulted in 
significant increases in mortality in the group of advanced pancreatitis patients receiving 
probiotics.45 There is no universal system currently in place to categorise the safety of 
microorganisms such as probiotics, however a four-level Risk Group system is commonly 
used to categorise the risk that any microorganisms may pose to humans. For example, see 





Figure 5. Modified diagrammatic representation of World Health Organization four-level Risk Group system 
adapted from WHO laboratory safety manual 85 
 
A cautious approach to probiotic administration remains advisable, as specific strains may 
be exceptions to the rule in relation to risk assigned to their phylum. For example, whilst 
most lactic acid bacteria may be considered safe, the enterococcus genus includes strains 
that can also be opportunistic pathogens and which can lead to bacteraemia and 
infections.86 Therefore, active surveillance for adverse effects should be a core activity 
whenever clinical trials employ probiotics.87 
 
Known strains of probiotic organisms have been shown to harbor resistance to antibiotics. 
There is a natural evolutionary occurrence of antibacterial resistance within certain bacterial 
species, which has long been part of their survival mechanisms. However, there is also the 
capacity for specific antibiotic resistance to be transferred between bacteria allowing 
bacteria pathogenic to humans to develop new forms of antibacterial resistance.87As 
antibiotic resistance continues to present a major global health concern, this side effect 
whilst currently theoretical, requires close consideration. A wide range of antibiotic 
resistance genes have been found in the gut biota of healthy populations across the world, 
creating potential for administered probiotics to facilitate the passage of these antibiotic 
resistance genes to pathogenic bacteria through horizontal gene transfer.88 Such horizontal 
gene transfer is more likely when bacteria contain mobile genetic elements such as plasmids 




Whilst surveys on rheumatology patients views on the risks of probiotics are lacking a 
review of patients living with Inflammatory bowel disease concluded that “Patients viewed 
probiotics as an appealing alternative to pharmaceutical drugs and understood probiotics as 
a more natural, low-risk therapeutic option”.89 (p. 138) This view should be evidence based and 
therefore this review will aim to extract data relating specifically to safety and side effects in 
the rheumatology population. 
 
1.7 Measuring outcomes in rheumatology   
In general, medicine and therapeutic interventions aim to make a significant difference to 
the lives of patients in a manner that is meaningful to them. Historically, patient-centred 
outcomes have not necessarily predominated, as they are often not as easy to measure as 
biological markers. The international consortium known as OMERACT (Outcome Measures 
in Rheumatoid Arthritis Clinical Trials) has worked to place priorities of patients at the 
forefront of rheumatology research. They have done this by embedding patients as 
stakeholders and using evidence-based assessments of measurement tools in the 
development of a core set of outcomes.90  
 
This thesis has included and categorised outcomes in a modified OMERACT manner, as 
appropriate to probiotics research as shown in Figure 6 below. OMERACT identifies four 
core areas, death, pathophysiological manifestations, life impact, and resource utilisation.94 
The domain of pathophysiological mechanisms captures disease activity and therefore 
includes systemic inflammation, both at the joints and within the body as a whole. Separate 
domains have been developed for individual inflammatory forms of arthritis , for the basis 
of this thesis the RA OMERACT  guidelines provided a starting point for identifying outcomes 
relevant to both the condition and the intervention of probiotics.91  
 
For the purposes of this thesis, all aspects related to adverse events whether considered 
minor reported outcomes, such as gastrointestinal upset or flatulence, or major reported 
outcomes, such as sepsis, interaction with concurrent standard care/medication or 





Figure 6 Modified representation of OMERACT core measures and domains as they relate to probiotic 
research. 
 
1.7.1 Adverse events 
Adverse events may be defined in variable ways, but for the purpose of this thesis they are 
described as an unexpected medical problem that happens during treatment with a drug or 
other therapy. Adverse events may be mild, moderate, or severe, and may be caused by 
something other than the drug or therapy being given.92 Occurrence of an adverse event 
does not necessarily attribute causality or mean that the medicine/intervention was the 
cause of the event. Adverse events may include side effects, which are the known 
unintended effects of a medicine or treatment, adverse drug reactions, or drug interactions. 
There is the potential that reported adverse effects may be additional symptoms of the 
underlying concurrent condition for which the medicine is being taken. 
 
Improving reporting in rheumatology trials has been part of the OMERACT focus as 
acquisition of adverse event data in clinical trials has been described as ‘highly variable’ and 
that formal assessment of safety and tolerability lags far behind that for efficacy.93 
 
In this thesis, the Common Terminology Criteria for Adverse Events (CTCAE) as shown in 
Table 1 will be utilised as a way of grading the reported events reported in primary studies, 
where appropriate.92 
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Table 1 Common Terminology Criteria for Adverse Events (CTCAE) Version 4.02 96 
Classification Symptom severity Modification of treatment 
Grade 1 Asymptomatic or mild Observation only 
Grade 2 Moderate Minimal non-invasive intervention or limitations of ADL 
Grade 3 Severe Requires hospitalisation and   disabling  
Grade 4 Life threatening Urgent intervention required 
Grade 5 Death  
 
 
A key outcome measure when research affects the gut microbiota is identifying effects upon 
gut function, which may be related to change in microbial community, change in metabolic 
function, gut integrity or epithelial function. Adverse effects on the gastrointestinal system 
will be considered separately to bowel outcomes, although there is clearly overlap and 
debate as to whether change in bowel function would be considered an adverse effect, 
adverse reaction, expected or unexpected.  
 
 
1.7.2 Systemic Inflammation  
When considering ‘what matters’ to patients, aspects that relate to pathophysiological 
mechanisms such as markers of systemic inflammation, are often rated poorly.94 The 
outcomes desired from a patient perspective include functional improvement and the 
ability to live well with their condition experiencing meaningful and productive lives. 
However, with a plethora of new medicines being used to intervene and achieve early 
disease control or ‘remission’ – there remains a need for relatively quick, inexpensive and 
easy-to-interpret ways for health practitioners to monitor disease activity and response to 
intervention. Acute phase reactants, such as the erythrocyte sedimentation rate  and C 
reactive protein, are commonly used as a measure of inflammation in rheumatology, 
therefore they are specified within the core set of disease measures for RA by the American 
College of Rheumatology and European Union League Against Rheumatism.95 Acute phase 
reactants may be considered descriptive biomarkers, as they reflect disease state but are 
not specific to any given rheumatic condition and may be raised in other inflammatory and 
/or infectious conditions.95 They are discussed below. 
 
1.7.3. Erythrocyte Sedimentation Rate (ESR) 





Table 2 Characteristics of the outcome measure Erythrocyte Sedimentation Rate.  
OMERACT 
core area 













likelihood of false positives.96 
Slow response to the acute phase 
reaction so    likelihood of early 








count (p < 0.001) 
and correlated to 
CRP.98  
*CRP (C reactive Protein) ESR (erythrocyte sedimentation rate) 
As a simple validated disease assessment measure its use may be appropriate in probiotic 
trials as it may reflect inflammation in the gastrointestinal system and joints, as long as 
careful interpretation of the impact of the trials population demographics (age, gender and 
body mass index) on baseline values also occurs.97 
 
1.7.4 C-Reactive Protein (CRP) 
C-reactive protein is an acute phase reactive protein directly involved in early inflammation. 
Refer to Table 3 for details. 
 
Table 3. Characteristics of the outcome measure C-Reactive Protein  
OMERACT 
core area 










proteins so levels 
fall rapidly once the 
inflammatory 
cascade stops.96 
Still non- specific to 
the disease-causing 
inflammation so 






 (BMI) 97 
Direct comparison 
showed ESR and CRP are 
significantly correlated 
with each other, swollen 
joint counts, and 
common composite 
measures.99 
*CRP (C reactive Protein) ESR (erythrocyte sedimentation rate) 
 
Many studies tend to favour C-reactive protein over erythrocyte sedimentation rate when 
assessing RA inflammation, because of its more rapid response time. As change in gut 
microbiome and inflammatory bowel function may be occurring as quickly as 3 days after 
dietary change this makes it a more suitable marker for probiotic studies.100 
 
1.7.5 Immunological markers 
Elevation of specific cytokines has been identified in RA and other immune modulated 
musculoskeletal diseases, leading to the development of medications that block these 
specific cytokines. Such cytokine blocking therapies have revolutionised the management of 
rheumatic conditions. Cytokine levels and expression are being explored as outcome 
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measures in rheumatology.101,102 Similarly to probiotics, a true understanding of their 
complex systems, which contain considerable synergy and redundancy, currently limit the 
interpretation of cytokines used as biomarkers in clinical research for all areas including that 
of probiotics.102 Therefore, studies that only utilise biomarkers as outcomes were not 
included. Brief details of their utility and application are provided in Table 4. 
 
Table 4 Characteristics of cytokines as an outcome measure  
OMERACT core 
area 
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inflammation and 
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in RA and AS. New 
105,106 
*AS (Ankylosing spondylitis) RA (rheumatoid arthritis) 
1.7.6 Composite measures 
Given the complexities of chronic inflammatory forms of arthritis and the impact they can 
have upon an individual’s life, composite outcome measures or disease indices, that 
incorporate core concepts from OMERACT alongside biomarkers have been developed 
which aim to provide coverage of a wider number of outcome domains. As such measures 
cut across core components and domains, and individual data contributing to subjective and 
objective elements of the score cannot routinely be disaggregated, composite scores will be 
analysed and discussed separately. Whether individual or composite outcome measures are 
utilised, there remains the challenge of identifying recognizable endpoints and determining 
whether statistically significant changes in scores are clinically important, and meaningful to 
the patient.96 
 
 Validated minimal clinical differences that result in meaningful change for patients and 
identify response to treatment for each outcome measure will be discussed in greater detail 
in the results section. A range of commonly applied disease indices are discussed in Table 5. 
Joint count assessment are components of all the indices above, they are undertaken by the 
clinician and are widely used in clinical trials, research, and day-to-day practice. It is a 
practical low cost traditional method of identifying clinical synovitis, that is still used despite 
the development of more advanced imaging techniques such as magnetic resonance 
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imaging.107 It remains an important monitoring component, as ongoing joint swelling in 
patients in remission is known to correlate to radiographic progression.  Joint counts may be 
considered as a semi-objective clinical measure. 
 
Table 5 Characteristics of common disease indices in Rheumatology  
core area Disease activity score 
(DAS) 
Simplified Disease 
activity index (SDAI) 
 
Clinical disease activity 











marker ESR or CRP CRP None 
Patient 
scale 
General health scale  
(0-10) 
Physician Global 
assessment of disease 
activity 
Patient global assessment 
of disease activity 
Physician Global 
assessment of disease 
activity 
Patient global assessment 
of disease activity 
Scoring Based on an equation that 
incorporates weighted values 
of the 
Richie Articular Index and 
scores for other elements. 
The individual components 
are not weighted but a 
simple sum  
Ranges from 0 to 600, a 
score of 150 is defined as 
the threshold between 
remission and active 
disease 
Reliability Composite reliability 0.85 and 
0.86 for the DAS28-ESR and 
DAS28-CRP, respectively 110,111  
0.88112  0.89110 
Test retest When looking at individual elements the swollen jointcount has been found to have the 
lowest reliability.110 Test–retest reliability of patient-reported measures was satisfactory .111 
Internal Consistency  
Cronbach’s alpha  
Whilst reliability has been demonstrated – may view Cronbach’s Alpha as  an inappropriate 
internal consistency measure with an index measure.110 
Criterion validity DAS28 correlates well to 
SADAI and CDAI. 117 
correlated well with the 
ACR response criteria HAQ, 
and DAS28 (r > 0.8).116 
Correlated to both DAS28 
and HAQ 117  
Development  Developed for Inflammatory 
Arthritis from ACR response 
criteria, 
Derived from the Disease 
Activity Index for Reactive 
Arthritis 
Derived from the SDAI 
versions The modified DAS28 
compares favourably with the 
44-joint version in early RA.113 
One version only One version only 
Limitations/comments DAS may be performed using 
an ESR or CRP as a serum 
marker. DAS28-CRP and 
DAS28-ESR are 
interchangeable according to 
recent research.113 
Do not follow a normal 
distribution, 
 discrepancy between the 
SDAI and DAS28 in patients 
with low levels of disease 
activity113 
More stringent measure 
compared to the DAS28 
when classifying patients in 
remission or with a minimal 
residual disease activity. 121  
*AS (Ankylosing spondylitis) CRP (C reactive Protein) ESR (erythrocyte sedimentation rate) RA (rheumatoid arthritis) ACR (American 
College Rheumatology) 
 
A recent systematic review identified that whilst intra-observer reliability was good, inter 
observer reliability was poor especially in the swollen joint count.108 This difference was 
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suggested to occur because of a higher dependency of the swollen joint assessment on 
factors like the assessors' levels of training and experience, a lack of standardization in 
examination methods, unclear definitions of swelling, or the degree of joint deformity. 109 
Whether the administration of probiotics can meaningfully affect the swelling in synovial 
joints within the timeframe of most clinical trials is unknown, however as key rheumatology 
outcomes embedded within current practice they have been included for this thesis. 
 
 
1.7.7 Life impact 
Patients’ perspective on the impact of their conditions, and its medical management, has 
become a recommended aspect of outcome assessment in clinical trials. Not only is 
including patient-driven outcomes desirable but research has suggested they can be as 
effective as traditional composite outcomes.114 This efficacy extends to both identifying 
short term change in disease activity and predicting long term outcomes.  
 
There are a wide range of health-related quality of life instruments to measure life impact of 
rheumatology conditions, although this doesn’t guarantee that these tools prioritise aspects 
specifically rated as important by patients. Evidence suggests there remains disparity 
between clinician and patient viewpoints.115  
 
Relevant outcomes listed within the core OMERACT domain of life impact includes: pain, 
morning stiffness, fatigue, sleep disturbance, patient’s global rating of function and/or 
wellbeing, physical functioning as described through activities of daily living such as the 
Health Assessment Questionnaire (HAQ), mental health and wellbeing (for example anxiety, 
depression) and health-related quality of life. Life impact outcomes likely included within 




The International Association for the Study of Pain defines pain as an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage.116 Pain is not 
just a physical sensation. It is influenced by attitudes, beliefs, personality and social factors. 
Pain can affect emotional and mental wellbeing. Traditionally, acute pain is seen as a short-
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term experience (lasting less than three months) which relates only to the timeframe within 
which tissues are healing and nociceptive signals are being triggered by tissue damage. After 
this time, an ongoing experience of pain has been termed chronic or persistent pain, as it 
lasts beyond the time expected for healing, has become an independent entity and is 
characterised by changes within the central nervous system.  
 
Pain in Inflammatory arthritis 
In rheumatological conditions, a simple paradigm existed for many years with all joint pain 
being determined nociceptive pain, due to the stimulation of nerve endings by joint 
inflammatory processes. This is partly true, for at the outset of an inflammatory condition 
acute pain will be driven by inflammatory molecules within joints. These inflammatory 
messengers fire signals along the somatosensory neuron, via the dorsal horn, to the spinal 
cord and finally to the brain, where the pain is registered in our consciousness. The 
inflammatory cascade releases further chemicals locally which lower the firing threshold for 
nerves, so that normal movement and sensation can also be interpreted as painful. In a 
situation of chronic and intermittent inflammation, as in many rheumatic diseases, pain 
becomes more complex.117 Ongoing sensitisation of the peripheral and central nervous 
system can ensue, creating joints continually sensitive to normal ranges and pressures 
despite the absence of inflammatory chemicals. Descending pathways from the central 
nervous system can facilitate the maintenance of pain states, and neuroplasticity can ensue, 
both responding to and creating the pain experience of any given individual.  
 
Mechanisms for alteration of pain by probiotics 
There is some evidence that probiotics may have the capacity to influence pain via a variety 
of mechanisms. A systematic review concluded that the weight of evidence from 77 studies 
indicates that probiotics are able to “modulate the immune system, down regulate the 
inflammatory factors of immune system, reduce proliferation of T-Cells, and reduce  
proinflammatory cytokines”.118 (p.6)  Murine studies support this showing the capacity of 
supplementation with the probiotic Lactobacillus rhamnosus to increase the acute pain 
threshold in mice, the authors indicating that preferential stimulation of anti-inflammatory 
cytokines, such as IL2, may be the mechanisms by which the pain sensitivity was changed.119  
Alternatively, a broader explanation has been explored looking at communication between 
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the central nervous system and the enteric nervous system, termed the gut- brain axis. It 
has long been known that there are neural (via the vagus nerve and autonomic nervous 
system) and hormonal (via adrenocorticotrophic hormone  and cortisol) methods of 
communication that enable the brain to influence intestinal function and immune cells.120 
New knowledge suggests a more bi-directional communication along the gut-brain axis, 
which may be modulated by the resident microbiota or applied probiotics. Studies have 
confirmed that microbiota may affect anxiety via brain neurochemistry and that a change in 




Given the new insights into the pain picture in rheumatic diseases, it has been recognised 
that managing pain requires a multimodal approach and that innovative pharmacological 
approaches should be considered.123 Simple direct patients’ reports of pain using a visual 
analogue scale (VAS) are commonly used in rheumatology and there are a number of 
important elements to consider when looking at a change in VAS. Firstly, it is important to 
identify the minimal clinically important difference or MCID. MCID has been defined as the 
“smallest difference in score in the domain of interest which patients perceive as beneficial 
and which would mandate…a change in the patient’s management”.124 (p.408) Defining a 
MCID for any given scale requires a reference standard or anchor against which to 
benchmark the scale, in rheumatology the patient global assessment (PGA) is often used as 
the relevant anchor. Where improvement is the required outcome, the term minimal 
clinically important improvement (MCII) may be used as a specific reference.125 
VAS may be represented in different orientations and with different end of scale 
annotations. It has been assessed to be a valid measure of pain intensity in rheumatology 
patients.126,127 Whilst some cut-off points have been recommended: no pain (0–4 mm), mild 
pain(5-44 mm), moderate pain (45–74 mm), and severe pain (75–100 mm), they have been 
formulated in acute pain post-surgical environments that may differ from the complex pain 
experience of rheumatology patients.128 The approach taken to combine statistical and 
meaningful clinical difference, with standardised wording, for this thesis will follow that 
suggested by the American Academy of Orthopaedic Surgeons, (Table 6).128 
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Table 6 Level of efficacy used in Osteoarthritis  treatment guidelines depending on the statistical and minimal 
clinically important improvement (MCII) of the treatment effect From American Association Orthopaedic 
Surgeons 2013128 
 
Descriptive term Condition of use Rationale 
Clinically significant Statistically significant lower limit of CI > MCII 
Possibly clinically significant Statistically significant CI contains the MCII 
Not clinically significant Statistically significant upper limit of CI < MCII 
True negative finding Not statistically significant upper limit of CI < MCII 
Inconclusive finding Not statistically significant CI contains the MCII 
*CI (Confidence interval) MCII (minimal clinically important improvement) 
 
1.7.9   Fatigue 
Fatigue is defined by the dictionary as “a state of extreme tiredness, typically resulting from 
mental or physical exertion or illness”.129 It is a common symptom and a recent online 
survey identified it as a prevalent problem affecting 50% of adult patients across 30 
different rheumatic diseases.130 Rates of fatigue were found to vary across conditions with 
prevalence reported as 41% in RA, 45% in ankylosing spondylitis and highest at 57% in 
psoriatic arthritis.130 A clear consensus definition of fatigue in rheumatology is currently 
lacking, however Aaronson expands the definition to “a subjective, unpleasant symptom 
which incorporates total body feelings, ranging from tiredness to extreme exhaustion, 
creating an unrelenting overall condition which interferes with an individual’s ability to 
function to their normal capacity”.131 (p.527) As fatigue is common across the rheumatic 
conditions and has major consequences on patients’ lives, there is now international 
consensus that fatigue should be evaluated in clinical trials for inflammatory arthritis.132-134 
Table 7 provides detail on measures used in this review.  
 
Whilst there are many hypotheses about the stimulation and sustenance of fatigue in auto 
immune inflammatory conditions, the causes of fatigue are currently considered 
multifactorial, and have not been proven to be correlated with severity of disease state or 
systemic inflammation.135,142-144 There are many instruments that assess fatigue that have 
been used in research, and an in depth review of all available fatigue measures is provided 
by Hewlett et al.145  There is no gold standard fatigue instrument for rheumatologic 
conditions and  some of the commonly used measures are discussed briefly below in Table 
7. Investigating the potential effects of probiotics on the specific symptom of fatigue is 
important as it is already known that even in those patients who respond well and achieve 
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remission with DMARDS, only approximately a third achieve resolution of their fatigue 
symptoms.136 
Table 7 Characteristics of two common fatigue indices used in Rheumatology  
OMERACT core area Multi-dimensional 
assessment  
of fatigue (MAF) 
Visual analogue fatigue scale (VAS 
Fatigue) Life Impact- Fatigue 
 16 item scale with  four 
dimensions: degree and 
severity, distress that it causes, 
timing of fatigue), and its 
impact on  of daily living.135 
unidimensional scales and can be used for 
scoring the discrete components of 
severity, duration, or intensity 
Admin Self-administered. Higher scores indicate more fatigue. 
Scoring Total Score from zero (no 
fatigue) to 50 (severe fatigue).  
May be 0-10 or on a 100 mmm scale. 
Reliability 
  
Test retest Not found  coefficient of 0.70 in RA (23) 136 
Internal 
Consistency  
Cronbachs alpha 0.93 137 Cronbach’s alpha 0.91– 0.96 136 
Sensitivity Sensitivity to change was 
demonstrated  
 
VAS fatigue in RA is more strongly 
associated with clinical variables indicating 
it is more “sensitive to change performs as 
well as or better than longer. 135 (p.1896)  
Pop validity Developed for adults with RA Taken out of Bath Ankylosing spondylitis 




Healthy 17.0 (11.3)  No healthy norms  established , failure to 
differentiate fatigue and sleepiness 138 
RA 29.2 ( 9.9) in RA Median fatigue severity s 45 mm 138 
AS 32 (SD 20) in AS.135  Fatigue commonly observed (67% 
population n=639) with average 42.1 SD 
11.9 in those with fatigue.139 
 PsA Data not found Mean 3.79 (SD  3.09) 140 
Limitations/comments Easy-to-use with a low patient 
burden, good reliability and 
validity. However can 
underestimation of fatigue and 
its impact upon life.141 
VAS, MAF, and SF-36 vitality subscale in a 
large RA cohort scales correlated well with 
each other (r 0.71–0.8) and with clinical 
measures (r 0.5–0.63).141 
*AS (Ankylosing spondylitis) RA (rheumatoid arthritis) VAS (visual analogue scale) SF-26 (Short form 36) 
 
1.7.10 Bowel function 
A key outcome measure when researching gut microbiota is identifying effects upon gut 
function, which may be related to changing  microbial community, change in metabolic 
function, gut integrity or epithelial function.146 If, as hypothesised, the SpA share disease 
mechanisms with the inflammatory bowel disorders, then gut inflammation and changes in 
tolerance to commensal bacteria are a primary sign of all these diseases and may be 
expected to alter in response to the delivery of probiotics.146 It has also been suggested that 
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bowel symptoms should always be involved in monitoring disease activity in the SpA as 
clinically relevant bowel symptoms may be overlooked amongst.147 Tools designed 
specifically for rheumatology patients are not yet in use, therefore a brief review of 
common outcome measures currently used in trials is provided in Table 8. 
 
Table 8 Characteristics of three common patient reported outcomes for bowel symptoms  
OMERACT core area Dudley Inflammatory 
Bowel Symptom 
Questionnaire (DISQ) 
Visual analogue scale for 
bowel symptoms (VAS 
IBS) 
Gastrointestinal 
symptoms rating scale 
(GSRS) 
Adverse effects- GI 
Admin self-report measure, 
consisting of 15 questions 
Self-report measure on 7 
items- rated 0- 10  
interview-based rating 
scale of 15 items 
Scoring Original scored on a five-
point numerical rating 
scale (0 = none/never to 4 
= incapacitating). The 
score of the DISQ ranges 
from 0 -60. Higher scores 





perception of mental 
well-being, symptoms' 
effect on daily life.148 
 Items scored from 1 to 
7. then dividing by 15 
to obtain the final GSRS 
score between 1 - 7. 
The higher the 
overall score, the more 
severe the symptoms. 
MCID MCID that identifies bowel 
symptoms enough to 
affect QoL is 11 (out of a 
maximum of 60). 
FDA recommending that 
≥30% decrease of VAS IBS 
be considered a clinically 
significant endpoint. 160   
MCID of the GSRS total 
score was assumed to be 
0.33 score points.149 
reliability Test 
retest 
coefficient correlation for 
Spa 0.57147 
coefficient correlation 
ranges from 0.4 to 0.8 for 
different items 154 
coefficient correlation 
ranges from 0.36–
0.75.150   
Internal   0.79147 0.85 148 0.43–0.87 
Development for bowel symptoms of IBD for use in IBS for use in IBS 
Pop norms controls 2.6 (2.6),  
SpA 8.7 (6.1)132 
 
Clarifies symptoms rather 
than create a final score. 
Stats sig difference 
between controls and 
patients with IBS.148   
Normative scores have 
been set as less than 
2.149   
Criteria validity Reliable measure for 
SpA.133 Strong correlation 
shown with the CDAI 
(r = 0.98)147 
Correlation has been shown between the VAS IBS 
and the DISQ .148 
versions The SpA modification of 
the DISQ consists of 15 
questions scored similarly 
Caution as studies may 
only use certain 
components  
A paediatric version 
suitable for children 
with JIA (the GSRSK)151 
Limitations/comments Rheumatology Population have only been used to develop reliability, validity and 
population norms for the DISQ, therefore transferability to other rheumatology 
patients remains uncertain. 
*AS (Ankylosing spondylitis) CDAI(Clinical disease activity index) IBS( Irritable bowels syndrome) MCID(Minimal clinically important 
difference) QoL(Quality of life) RA (rheumatoid arthritis) SF-26 (Short form 36) SpA (Spondyloarthritis) VAS (visual analogue scale)  
 
Overall there is a of lack of validation of patient reported outcome measures in 
rheumatology and across SpA subtypes.152 However, the Food and Drug Administration has 
recommended ≥30% decrease on patient‐reported outcomes for abdominal pain be 
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considered clinically significant in clinical trials for adults, which provides some benchmark 
for clinical outcomes in this study. 
 
1.7.11 Stiffness  
Stiffness is an important indicator of inflammatory musculoskeletal diseases. Morning 
stiffness was included in the original American College of Rheumatology classification of RA 
and remains an indicator of inflammatory activity used by rheumatologists for crucial 
decision-making.153 Stiffness is thought to be directly related to circadian rhythmic increases 
over night of pro-inflammatory cytokines such as IL-6 .154 
 
Composite scores may contain sub elements relating to stiffness, which will be discussed 
later, such as the Bath Ankylosing Spondylitis Disease activity Index.154 When interviewed, 
patients have outlined the interaction of stiffness with pain, its contextual variability and the 
impact it has upon function, over and above the quantification of stiffness time in the 
morning, thus making stiffness a hard aspect to quantify.155  
 
The subjectivity and heterogeneity of the concept of stiffness may be why a ‘gold standard’ 
assessment that considers life impact of stiffness does not yet exist.156  A dedicated morning 
joint stiffness outcome measure has recently been developed and has shown reliability, 
validity, and responsiveness in the older RA cohort in measuring change in morning duration 
and severity, suitable for trial outcomes.157 This is an important area to consider, as out of a 
survey of 154 patients with RA who had retired, 64% identified RA-related morning stiffness 
as the key driver for leaving the workforce.158 
   
1.7.12 Overall wellbeing 
The contribution of disease management to overall wellbeing is assessed through quality of 
life measures, which are widely recognised as an important component of outcomes in 
rheumatic diseases.159 There are a wide variety of measures available, and those commonly 








Table 9 Characteristics of four common patient reported outcomes for quality of life.  
OMERACT 
 core area 
The Western Ontario and 
McMaster Universities 
Arthritis Index (WOMAC) 







Questionnaire (HAQ) Life impact 
Admin A self-administered 
questionnaire of 24 items, 
three subscales: (pain, 
stiffness and physical 
function) scored: None (0), 
Mild (1), Moderate (2), 
Severe(3) and Extreme(4).160 
Single question rated 
by the patient, on a 
scale of 0 -10cm or 
0-100 mm. Higher 
scores represent a 
higher level of 
disease activity 161 




activities, daily living, 









Scoring Scores for each subscale are 
summed to give a total. 
Higher scores indicate 
poorer health 
VAS format may vary 
from an unmarked 
line, divisional ticks 




Higher scores indicate 
greater disability.164 
A range of scoring 
methods used . 
MCID MCID ranged from 0.51 to 
1.33 points (scale 0 to 10) in 
post-surgical patients .163  
Unstated – may be 
considered similar to 




range from 0.36 
(small) to 0.8 (high).  
clinically important 
improvement in HAQ 






varies for the different 
subscales so should  
stipulate the rating and 
scoring methods applied.160 





a 2-week period 0.80.  
ranged from 0.87 to 
0.99 For the 
Dimension related to 
physical function.165 
Internal high internal consistency 
rating ( > 0.7).166 
 AIMS2. vary over the 
9 sections range from 
0.72 to 0.91.167  
internal consistency 
of 0.78–0.84 in 
patients with SpA.165  
Development Developed for the 
evaluation of hip and knee 
osteoarthritis. 
Originally designed 
for the assessment 
of pain in RA 
Developed for 
Osteoarthritis.162 
Developed in 1980 
for all forms of 
arthritis. 
Pop norms/ Population-based age- and 
gender-specific normative 
values are available.168  
 
Not stated but 
ACR/EULAR 
remission criteria 
use PtGA <1.169 
none 32% of an older 
population report 
some disability when 
assessed with HAQ,170 
Construct 
validity 
validity shown with other 
outcomes measure for 






fatigue are the 
strongest factors. 
171,172 
AIMS2 has internal 
consistency and 
moderate correlation 
with levels of disease 




correlated with other 
measures of self-
report.165,173 
versions Available in 5-point Likert, 
11-point numerical rating, 
100-mm visual analogue 
scale (VAS), digital and LOTE 
versions. 
Heterogeneity of 
wording creates a 
variety of informal 
versions. i.e. PtGA of 
disease activity.174 
AIMS2-SF assesses 
five components of 
health status AIMS2 
also includes arm 
function.175 
Different scoring 




Scale may be insensitive if 
the link between pain and 
function is weak, as may 
occur in more chronic 
conditions and confounded 
by physical disability.  
Lacks face validity 
when used alone. 
Poor correlation with 
DAS28,  Poor 
agreement with 
doctors rating.177-179 
A broad scope tool, 
so potential to be 
impacted by many 
other elements in 
longstanding disease.  
Clarity of version and 
scoring is essential 
for the interpretation 
of HAQ results 
*ACR (American College Rheumatology) AS (Ankylosing spondylitis)  IBS( Irritable bowels syndrome)ESR ( Erythrocyte sedimentation rate) 
EULAR(European Union League Against Rheumatism)  LOTE (language other than English) MCID(Minimal clinically important difference) 




Many measurement tools exist in varying versions which can impact administration and 
interpretation of results. There is a viewpoint that given the heterogeneous nature of 
inflammatory conditions, and unique symptoms affiliated with specific diagnoses, that 
generic measures are insufficiently sensitive to provide patient centred quality of life 
outcome data. Some condition specific patient reported outcome measures are briefly 
discussed below in Table 10. 
 
Table 10 Characteristics of three disease specific patient reported outcomes for quality of life. 
OMERACT core area 
Conditions specific  
Bath AS Functional 
Index BASFI 
Bath AS Disease 
Activity Index BASDAI 
Ankylosing Spondylitis 
Quality of Life AsQol 
Admin Self-administered 10 
questions, rated 0-10 
VAS or Numerical Rating 
scale (NRS) that focus 
upon functional capacity 
to for everyday tasks.180 
Six questions rated on 
a VAS or NRS scale 
from 0 (non-problem) 
through to 10 (worst 
problem).180 
18 dichotomous items 
forming a single scale. 
Includes  impact on sleep, 
mood, motivation, coping, 
activities of daily living, 
independence, relationships, 
and social life. 181 
Scoring Scores are summed and 
then divided by ten to 
give an average. Higher 
scores indicate greater 
the functional 
impairment. 
Two questions rate 
stiffness which are 
averaged before final 
score calculation. 
No scored zero, YES scored 1 
Total score is the sum of the 
individual scores. Higher 
scores reflecting greater 
impairment of health‐related 
quality of life. 
MCID MCII was 0.6 for the 
BASFI.182 
MCII was 1.1 for the 
BASDAI.182 




coefficient reported a 
0.89 to 0.92 181 
intraclass correlation 
coefficient of 0.87 183 
 
retest reliability (rs=0.92  
and rs=0.91181 
Internal  0.936 183 of 0.84–0.87 183 between 0.89–0.92 181,183 
Development Designed specifically for patients with AS. They 
include the Bath AS Metrology Index (BASMI), the 
Bath AS Functional Index (BASFI), the Bath AS 
Disease Activity Index (BASDAI) and the Bath AS 
Patient Global Score (BAS-G).184 
Developed to look at QoL 
from the AS patient’s 
perspective.181,185 
Criteria validity Been investigated for use in other spondyloarthritic 
conditions, with  preservation of content validity 
and measurement properties.184,186,187 Bath indices 
correlates well with other AS‐specific health 
outcome measures  and sensitive to change at all 
disease levels.188 
Correlates moderately well 
with other AS‐specific health 
outcome measures .183 




Validation studies positive but conducted some 
years ago, for patients in a steady state or 
remission.185 Bath Indices do not include any 
objective measures or clinician's perspective. 
Most frequently used disease‐
specific measure of health‐
related quality of life in AS 
studies 
* AS (Ankylosing spondylitis) ESR (Erythrocyte sedimentation rate) MCII (Minimal clinically important improvement) QoL (Quality of life) 
NRS (numerical rating scale) Nr.Ax. SpA (Non radiographic Spondyloarthritis) RA (rheumatoid arthritis) SF-26 (Short form 36) SpA 




1.7.13   Resource use/economic impact 
All the conditions included in this review are chronic conditions and are associated with the 
likelihood of progressive disability. Increasing disability may create a declining quality of  life 
and often incurs significant costs to both the individual and society. The costs of 
inflammatory forms of arthritis are significant. For example the estimated costs of biologics 
for RA, as a single disease entity, in the 2014-2015 financial year were approximately AUS 
$273 million in Australia according to the Counting the Costs report by Arthritis Australia, 
which represents a 104% increase from the costs reported in 2007.190 Taking into account 
the costs for biological disease modifying anti- rheumatic medications, healthcare costs for 
RA were estimated to be over AUS $550 million by 2030, representing a AUS $102 million 
increase from 2015 costs”.190 (p.24) Whilst the development of ‘biosimilar’ medications may 
reduce these estimates, the costs remain significant and do not include the wider costs, for 
example loss of earnings from reduction in work hours or early retirement due to the 
disease, disability payment costs, and other non-pharmaceutical interventions such as 
surgery, to name but a few. This may seem to make a clear case for the economic 
evaluation of alternative interventions. 
 
Economic evaluation often employs one of four methods: cost minimisation analysis, cost 
effectiveness analysis, cost utility analysis, and cost benefit analysis. These are scientifically 
based ways of allocating resources for health interventions and can only be employed when 
the benefits and efficacy of an intervention from a clinical perspective are well established. 
Therefore, it is required that the efficacy of specific probiotic strains and formulations is first 
established, prior to embarking on economic outcomes that may guide real world decision 
making and accessibility for patients. 
 
1.8 Current state of evidence, and justification for review 
1.8.1 Justification of approach 
This Master’s thesis has employed the application of a systematic review in order to provide 
guidance to clinicians and consumers regarding the efficacy of a specific health intervention 
to a specific population, that of probiotics for individuals living with an inflammatory 
arthritis. Evidence-based medicine involves the “explicit, conscious and judicious attempt to 
find the best available evidence to assist health professionals”.191(p.71) Whilst there is 
consensus that modern healthcare should be informed by the best available evidence in 
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order to maximise safety, quality and health outcomes for patients, keeping up to date with 
the rapid evolution of medical knowledge  and overwhelming volume of published articles is 
problematic. It has been estimated that more than 2 million articles per year, are published 
in over 20,000 journals.192 Therefore in reality, individuals may form opinions regarding the 
efficacy of interventions that are based on limited or biased sources of information, and 
therefore deliver misrepresentations of  estimates of benefits and harms.193 
 
Understanding what has already been studied in any given health field by undertaking a 
literature review has been an established manner of sourcing information. A literature 
review collates a range of papers in a current field, with discussion and judgement delivered 
in a narrative form by the authors. Whilst this helps readers to make decisions by drawing 
together relevant results and data in a single publication, literature reviews lack a 
systematic approach to the key processes of scoping, analysis, data synthesis and appraisal 
of bias. This deficit can create reviews with heterogenous studies, at risk of type I and type II 
errors as well as hidden bias. This Masters utilises a SR approach, conducted with the rigor 
expected of the studies contained within it.194 SR aim to address a specific question, using 
systematic and explicit methods to identify, select, and critically appraise relevant studies. 
Whilst an SR does collect and analyse data from included studies, it does not seek to create 
new knowledge but rather to synthesise and summarise existing knowledge.194(p55) The 
value of SRs is demonstrated by their place at the  top of the hierarchical pyramid of 
evidence. SR are conducted world-wide by a number of organisations  for example the 
Cochrane Collaboration -  an organisation mainly  focused on the effectiveness of  health 
interventions from randomised controlled trials and other groups such as the Joanna Briggs 
Institute (JBI) (http://joannabriggs.org) which include other study designs and types of 
evidence in their systematic reviews.195 
 
The key potential weakness of a systematic review process are outlined and include “ a lack 
of systematic and transparent conduct and reporting, …unrecognised and unaccounted 
statistical and clinical heterogeneity, data dredging in non-predefined statistical analyses, 
and a lack of assessment of the overall quality of evidence.”196 (p.518) To address such 
concerns this thesis applied JBI  methodology.197 The JBI is part of the Faculty of Health and 
Medical Sciences, University of Adelaide and has been working to develop and promote 
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evidence-based practice since 1996. They support the employment of rigorous review 
methodology including the utilisation of preferred reporting items for systematic reviews, 
known as PRISMA and the GRADE methodological approach for rating the quality of 
evidence within a review.198-200 This ensures a further rigor to the SR process by considering 
study design, risk of bias, precision, consistency, directness, publication bias and magnitude 
of effect in a transparent and standardised fashion.199,200The JBI has recently updated their 
evidence based model of healthcare, to recognise the role of evidence informing a more 
complex shared decision process between patients and clinical experts. This update of the 
JBI model recognises the contribution of systematic reviews and statistical facts but also the 
judicious use of expert knowledge, patient real-life priorities and the need for simple tools 
that outline risk and benefit to enable open dialogue between health professionals and 
patients. This thesis aims to deliver a SR that can be used within the wider paradigm of the 
Evidence Informing Healthcare Model.201  
 
1.8.2 Current research in the field 
A preliminary search of the Cochrane Library, JBI Database of Systematic Reviews and 
Implementation reports (JBISRIR), PubMed, CINAHL, and PROSPERO was conducted for 
existing systematic reviews related to this topic from Feb to April 2017. Four relevant 
systematic reviews were identified, which explored the benefits of probiotics for RA alone, 
in adults, with a range of outcomes examined.202-205 
 
Pan et al202 and Rudbane et al203 both focused on changes in systemic inflammation 
outcomes (Disease Activity score S28, C-Reactive protein and cytokine expression) including 
five  and six randomised controlled trials, respectively, with full overlap between reviews. All 
patients had a classification of RA. Pan et al202 concluded that whilst changes in systemic 
inflammatory outcomes were observed they did not meet the American College of 
Rheumatology criteria for 20% improvement and Rudbane et al203 concluded the statistically 
significant improvements seen may not reach clinical significance. Mohammed et al 2017204 
revised the inclusion criteria and found nine studies (randomised controlled trials and quasi-
experimental trials) for patients with RA, analysed similar systemic inflammation outcomes 
and came to similar conclusions. Whilst changes in cytokine biomarkers were identified their 
significance was undecided.204 The review by Dejoras et al 205 was lacking detail as published 
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in an abstract form, but used similar databases, population group and study inclusion 
criteria to the other reviews.205 Dejoras et al205 concluded again that potentially beneficial 
changes in systemic inflammation markers were seen in trials but that larger study sizes 
were required. 
 
A review by Mazidi et al206 concentrated on the changes in C-reactive protein alone, and 
included three studies of rheumatology patients amongst a total of 20 included studies. 
With a greater number of trials to analyse they concluded that probiotics may significantly 
reduce C-reactive protein, but not other biomarkers.206 
 
Whilst Didari et al44 have undertook a review on safety of probiotics, there were no studies 
on patients with rheumatic conditions were included. This systematic review aims to 
contribute to the growing literature of the potential effectiveness and safety of probiotics as 
a sole or adjuvant therapeutic intervention for individuals with inflammatory arthritis. 
Systematic reviews were not found which were solely focused on the Spondyloarthopathies, 
despite their arguably closer links with gut dysbiosis and pathology.  This systematic review 
aims to contribute to the growing literature of the potential effectiveness and safety of 
probiotics as a sole or adjuvant therapeutic intervention for individuals with inflammatory 
arthritic disease by including a wider range of conditions. This will allow for the 
heterogeneous overlapping nature of inflammatory disease and enable individuals with 
earlier disease states to be included, providing clearer guidance to clinicians in daily practice 
by increasing the transferability of findings. 
 
The outcomes of the systematic reviews discussed above, were divided across a range of 
outcome markers but primarily clinician reported outcomes and surrogate markers.  None 
of the systematic reviews noted investigated patient reported outcomes, fatigue, bowel 
symptoms or other outcomes that impact quality of life. Most of the reviews restricted 
inclusion to randomised controlled trails, thereby limiting evidence to studies with 
established disease states able to meet more stringent disease classification criteria. This 
potentially excludes the patient population most likely to engage with probiotics use and 
missing the early window of opportunity in which intervention may be most effective. It 
must be recognised that to direct clinical intervention and patient counselling regarding the 
use of probiotics, more data on risks and harms specific to rheumatology is required. This 
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review aims to add to the knowledge base by including adverse effects of probiotics as a 
primary outcome.  
 
Studies into clinician’s views on their patients using probiotics in rheumatology in Australia 
have not been formally undertaken. However, it is known from studies on other 
complementary medicines that knowledge of the therapy and level of scientific rigour 
applied to assessing it, are important factors that affect clinician’s willingness to consider 
alternative interventions.207,208 Therefore this review aims to inform clinicians and 
contribute to the rigorous evidence base around probiotics. 
 
Most importantly, none of the systematic reviews that include patients with rheumatic 
diseases provided subgroup analysis or discursive analysis on the preparations and 
compositions of probiotic supplied. Therefore, this review aims to match emerging science 
on strain-specific benefits to the specific formulations in each study along.  The review will 
also  apply strict definitions of probiotics and undertake greater consideration of important 
factors such as concentration, inclusion of prebiotics, and encapsulation methods that have 
been used within a wider variety of quantitative study designs. Whilst it is recognised that 
there are many challenges in undertaking a review with strain-specific analysis, it is 
increasingly recognised that this is paramount if clinicians are to prescribe probiotics 
appropriately.209 
 
Whilst research on probiotics for gastroenterology is more established than for 
rheumatology, it is only in 2018 that a systematic review by McFarland et al.209 has used a 
strain-specific approach to make recommendations on efficacy of probiotics for adult 
antibiotic associated diarrhoea.  This review discovered that certain strains of Lactobacillus 
were more effective than others in managing adult antibiotic associated diarrhoea and that 
past systematic reviews and meta-analyses were poorly placed to identify this.209,210 
Applying this strain-specific approach to the probiotic interventions used for rheumatology 
may provide the clarity required to identify probiotics with appropriate therapeutic 




CHAPTER TWO: Systematic review methodology 
 
2.1 Review objective 
The objective of this review was to identify the reported strain specific effectiveness and the 
strain specific adverse effects of probiotics when used as a therapeutic intervention for 
individuals living with inflammatory arthritis.  
 
2.2 Criteria for studies to be included 
2.2.1 Inclusion criteria: Types of participants/population of interest 
This review considered studies that include individuals (adult or child) of any gender living 
with the following specific forms of diagnosed inflammatory arthritis:  
• Rheumatoid arthritis 
• Adult spondyloarthritis (of any form) 
• Juvenile arthritis (of any form) 
Individuals with early, established or severe forms were included. Study participants should 
have been diagnosed for a minimum timeframe of three months.  Diagnosis was used rather 
than clinical classification as whist this may lower specificity it increases generalizability of 
study finding for real life clinical practice. 
 
2.2.2 Inclusion criteria: Types of intervention 
This review included studies that: 
• Supply probiotics that meet the definition of probiotics as defined in 2001 by the 
Food and Agriculture Organization of the United Nations (FAO) and the World Health 
Organizations (WHO)  “live microorganisms which, when administered in an 
adequate amount, confers a health benefit to the host”.33 
• Evaluate probiotics administered to the gut (either orally or via enteral feed). 
• Utilise any concentration of probiotics, measured in colony forming units. 
• Employ any strain or species, or combination of species. Probiotics may be 
administered with prebiotics (thereby termed a synbiotic). Products that do not 
require refrigeration utilise spore-forming bacteria are included as whilst the spores 
are dormant, there is evidence to suggest that these spores can germinate within 
the gut and exhibit benefits.211 
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This review excluded studies that: 
• Utilise prebiotics alone as these microbial cultures may deliver useful enzymes but 
have not been shown to proliferate and alter the microbial composition of the gut.33 
• Utilise probiotics within functional foods or fecal matter transplants as they include 
many microbial species in unknown and unstandardised quantities.37 
 
2.2.3 Inclusion criteria: Types of comparator(s) 
Studies that utilised probiotics as a sole or adjuvant therapeutic intervention to standard 
care, compared to standard care alone, are considered. 
2.2.4 Inclusion criteria: Types of outcome 
This review considered studies that include any outcomes specified in the core set of 
appropriate measures by the international consortium known as OMERACT (Outcome 
Measures in Rheumatoid Arthritis Clinical Trials).90,213 Primary outcomes included: 
 
A. Single measure patient reported outcomes, including but not limited to, Patient 
Global Assessment, Pain, Fatigue and Health Assessment Questionnaire. 
B. Composite measures of patient reported outcomes, for example; 
the short Health Assessment Questionnaire which is based on three patient centered 
dimensions: pain, patient global assessment and disability. 
C. Composite indices that include outcomes from patient, provider and a laboratory-
based score of inflammatory markers, for example, the Disease Activity Score. 
Composite indices that include surrogate lab markers for inflammation were included as a 
core part of all major guidelines and as accepted quality indicators for effective 
management. It is recognised that they may be affected by the weighting of specific 
elements that and this is considered in the results analysis. 
D. Safety and patient reported adverse effects were considered including 
minor reported outcomes, such as gastrointestinal upset or flatulence, and major 
reported outcomes, such as sepsis, interaction with concurrent standard 
care/medication or mortality. 
2.2.5 Inclusion criteria: Types of study 
A range of experimental and epidemiological study designs including randomised controlled 
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trials, non-randomised controlled trials, quasi-experimental studies, prospective and 
retrospective cohort studies, case control studies and analytical cross-sectional studies were 
eligible for inclusion in this review. Also, descriptive epidemiological study designs including 
case series, individual case reports and descriptive cross-sectional studies were eligible for 
inclusion. Studies that were published in English on humans were eligible for inclusion. 
 
Head to head studies, which compared interventions rather than use one intervention 
against control were included. The findings of head to head studies were treated with 
caution as extrapolating the comparison of two interventions whereby there is a current 
absence of firm data on the reliability and safety of either is not recommended.   
2.3 Method of the review  
This systematic review was carried out in accordance with the published protocol in the JBI 
Database of Systematic Reviews and Implementation reports and Prospero centre for 
Reviews and dissemination (CRD42019122116).212 
 
2.3.1 Search Strategy 
The search strategy aimed to find both published and unpublished studies. Studies 
published from 2000 were considered for inclusion in this review as probiotics were clearly 
defined at this time. A three-step search strategy was utilised in this review. Firstly, an initial 
limited search of MEDLINE and CINAHL was undertaken followed by an analysis of the text 
words contained in the title and abstract, and of the index terms used to describe the 
article.  For each database specified, the search terms and their related terms were 
expanded to cover relevant variations and database specific terminology or abbreviations in 
order to identify relevant search terms that reflected the studies inclusion criteria. The key 
word employed in this preliminary search therefore, identified the population with 
inflammatory arthritis, (rheumatoid arthritis, psoriatic arthritis, auto immune arthritis and 
juvenile arthritis), of any age, taking the intervention (probiotics, synbiotics) in clinical trials 
with any outcome. 
A second search using all identified keywords and index terms was then undertaken across 
all included databases. It included search terms specific and related to probiotics and the 
designated inflammatory arthritis conditions. Thirdly, the reference list of all identified 
reports and articles was searched for additional studies. Only studies published in English 
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were considered for inclusion in this review as this was the first language of the reviewers, 
due to resource constraints as relates to the provision of translation services and research 
indicates  no evidence of a systematic bias from the use of language restrictions in 
systematic review-based meta-analyses in conventional medicine.214 
Initial keywords 
Probiotics, Synbiotics, Rheumatology, Arthritis 
 
The databases searched included: Pubmed, CINAHL, EMBASE, SCOPUS 
The trial registers searched: 
• The Cochrane central register of controlled trials (CENTRAL) 
The World Health Organization clinical trials portal (ICTRP) 
• NIH clinical trials register Clinicaltrials.gov 
• Australian New Zealand Clinical trials register (ANZCTR). 
The search for unpublished studies included: 
• Pro dissertations and theses (PQDT) 
• Bielefeld Academic search engine (BASE) 
• System for Information on Grey Literature in Europe (OpenGrey) 
• Health Services Research Projects in Progress (HSRProj) 
• Mednar Deep web search technology database 
 
Due to the large volume of published literature in this field the retrieved articles were 
exported to a reference management system (Endnote) and screened in a three-step 
process. First by title, then by abstract and finally full text screening to ensure all articles 
met the inclusion criteria. For example, full text screening enabled the identification of 
studies that employed the application of bacterial cell wall components as opposed to live 
probiotics or utilised probiotics contained within functional foods in unspecified quantities. 
 
Pub Med Search terminology 
Condition Descriptors relevant to Inflammatory arthritis 
(Arthritis[mh] OR Arthritis[tw] OR JIA[tw] OR Enthesitis[tw] OR Polyarthritis[tw] OR 
Rheumatoid[tw] OR Psoriatic[tw] OR Rheumatoid Arthritis[mh] OR Rheumatoid arthritis[tw] 
OR Rheumatic disease[tw] OR Rheumatism[tw] OR Spondyloarthritis[mh] OR 
Spondyloarthropathies[mh] OR Spondyloarthr*[tw] OR Ankylosing Spondylitis[mh] OR 
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Ankylosing Spondylitis[tw]) OR enteropathic arthritis[tw] OR Arthralgia[mh] OR 
Arthralgia[tw])  
 
Intervention descriptors relevant to probiotics 
(Probiotics[mh] OR Probiotic*[tw] OR Synbiotics[mh] OR Synbiotic*[tw] OR 
Microbiota[mh:noexp] OR Microbiota[tw] OR Gastrointestinal microbiome[mh] OR 
Gastrointestinal microbiome[tw] OR Microbiome[tw] OR Gut microbiome[tw] OR 
Dysbiosis[mh] OR Dysbiosis[tw] OR Gut Flora[tw] OR Gut microflora[tw] OR Gastrointestinal 
flora[tw] OR Gastrointestinal microflora[tw] OR Lactobacillus[mh] OR Lactobacill*[tw] OR 
Bifidobacterium[mh] OR Bifidobacter*[tw] OR Saccharomyces[mh] OR Saccharomyces[tw] 
OR Escherichia[mh] OR Escherichia[tw] OR Bacillus[tw] OR Bacillus[mh] OR Dietary 
supplement[mh] OR Dietary supplement*[tw] OR Food supplement*[tw] OR Diet 
therap*[tw] OR Nutrition therapy[mh] OR Nutrition therap*[tw] OR Nutritional therap* OR 
Nutraceutical*[tw] OR Nutriceutical*[tw] OR Neutraceutical*[tw]) 
Table 11 Core search terminology applied regarding Population and Intervention 
Population Condition AND Intervention-  
(Arthritis[mh] OR 
Arthritis [tw] OR 
JIA[tw] OR 
Enthesitis [tw] OR 
Polyarthritis [tw] OR 
Rheumatoid [tw] OR 
Psoriatic [tw] OR 
Rheumatoid Arthritis[mh] OR 
Rheumatoid arthritis [tw]OR 
Rheumatic disease [tw] OR 
Rheumatism [tw]OR 
Spondyloarthritis [mh] OR 
Spondyloarthropathies [mh] OR 
Spondyloarthr*[tw] OR 
Reactive arthritis [tw] OR 
Enteropathic arthritis [tw] OR 
Inflammatory Bowel disease [mh] OR 
Inflammatory Bowel disease [tw] 
Arthralgia [tw] OR 
Ankylosing Spondylitis[mh] OR 
Ankylosing Spondylitis [tw]) 
 
 (Probiotics [mh] OR 
Probiotic*[tw] OR 
Synbiotics [mh] OR 
Synbiotic* [tw] OR 
Microbiota [mh:noexp] OR 
Microbiota [tw] OR 
Gastrointestinal microbiome [mh] OR 





Gut Flora [tw] OR 
Gut microflora [tw]OR 
Gastrointestinal flora[tw]OR 
Gastrointestinal microflora[tw] OR 




Saccharomyces [mh] OR 
Saccharomyces [tw] OR 
Escherichia [mh] OR 
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Escherichia [tw] OR 
Bacillus [tw] OR 
Bacillus[mh] OR 
Dietary supplement [mh] OR 
Dietary supplement* [tw] OR 
Food supplement* [tw] OR 
Diet therap* [tw] OR 
Nutrition therapy[mh] OR 
Nutrition therap*[tw] OR 
Nutritional therap* OR 





CINAHL Search Terminology 
((MH “Arthritis”) OR “Arthritis” OR “JIA” OR “Enthesitis” OR “Polyarthritis” OR 
“Rheumatoid” OR “Psoriatic” OR MH “Rheumatoid Arthritis” OR “Rheumatoid arthritis” OR 
“Rheumatic disease” OR “Rheumatism” OR MH”Spondyloarthritis” OR 
MH”Spondyloarthropathies” OR “Spondyloarthr*” OR MH”Ankylosing Spondylitis” OR 
“Ankylosing Spondylitis”) AND (MH "Probiotics") OR “probiotic” OR “ Synbiotic” OR (MH 
"Prebiotics") OR (MH "Lactobacillus") OR (MH "Lactobacillus Acidophilus") OR 
Saccharomyces[tw] OR (MH "Bacillus") OR (MH "Escherichia") OR (MH "Gram-Negative 
Bacteria") OR (MH "Bifidobacterium") OR "synbiotics" OR (MH "Microbiota") OR (MH "Gut 
Microbiota") OR "microbiome" OR (MH "Dietary Supplements") OR (MH "Dietary 
Supplementation") OR "nutraceutical" OR (MH "Enteral Nutrition")  
 
Embase Search terminology 
('arthritis':de,ti,ab OR 'jia':ti,ab OR 'juvenile idiopathic arthritis':ti,ab OR 'juvenile chronic 
arthritis':ti,ab OR 'reiter syndrome':ti,ab OR 'enthesitis':ti,ab OR 'polyarthritis':ti,ab OR 
'arthritis, rheumatoid':de,ti,ab OR 'rheumatic disease':ti,ab OR 'rheumatism':ti,ab OR 
'psoriatic arthritis':de,ti,ab OR 'reactive arthritis':ti,ab OR 'post-infectious arthritis':ti,ab OR 
'spondylarthropath*':de,ti,ab OR 'autoimmune arthritis':ti,ab) AND ('probiotic':de,ti,ab OR 
'synbiotic':ti,ab OR 'microbiota':de,ti,ab OR 'gastrointestinal microbiome':de,ti,ab OR 
'microbiome':ti,ab OR 'gut flora':ti,ab OR 'gastrointestinal flora':ti,ab OR 'gastrointestinal 
microflora':ti,ab OR 'lactobacillus':de,ti,ab OR 'bifidobacterium':de,ti,ab OR 
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'saccharomyces':de,ti,ab OR 'escherichia':de,ti,ab OR 'bacillus':de,ti,ab OR 'dietary 
supplement':de,ti,ab OR 'food supplement':de,ti,ab OR 'diet therapy':ti,ab OR 'nutrition 
therapy':de,ti,ab OR 'nutritional therapy':de,ti,ab OR 'nutraceutical':de,ti,ab OR 




(arthritis OR (“juvenile arthritis") OR (" reiter AND syndrome")  OR enthesitis 
OR  rheumatoid OR  ("rheumatic disease")  OR  rheumatism OR  ("psoriatic 
arthritis")  OR  ("reactive arthritis")  OR  spondyloarth* OR  ankylosing OR arthralgia) AND 
(probiotic OR  synbiotic  OR  microbiota OR  ("gut flora")  OR  ("Gut microflora") 
OR  lactobacill* OR  bifidobacteri*  OR  saccharomyces OR  escherichia  OR  bacill*   OR 
( "gastrointestinal microbiome")  OR  ("gastrointestinal flora")  OR  ("Dietary 
supplement*")  ("food supplement*")  OR  ("nutrition therapy") OR nutr?ceutical* OR ( "diet 
therap*") OR "nutrition* support")   
 
2.3.2 Assessment of methodological quality 
Papers selected for retrieval were assessed by two independent reviewers for 
methodological quality prior to inclusion in the review using standardised critical appraisal 
instruments from the JBI.207 Any disagreements that arise between the reviewers was 
resolved through discussion, or with a third reviewer. 
 
All articles were included within the review, and quality appraisal was included within the 
narrative discussion of results. No specific threshold for inclusion of studies was applied as 
risk of bias assessments are undertaken within the GRADE approach and accounted for 
before any clinical recommendation or systematic review conclusions are made. 
 
2.3.3 Data extraction 
Quantitative data was extracted from papers included in the review using the a tailored 
excel spread sheet that accommodated specific information relevant to the study of 
probiotic interventions. The extracted data included specific details about the interventions, 
populations, study methods and outcomes of significance to the review question and 
specific objectives. Detailed demographic data was mined from the studies as these factors 
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impact upon the probiotics mechanism and have been poorly considered previously when 
interpreting data and ensuring clinical transferability of study outcomes. Attention was 
specifically given to the nature of the probiotic formulation with respect to included 
bacteria, their taxonomic classification and dosage in colony forming units. Data was 
extracted wherever numerical results were reported. The authors of included studies were 
contacted where necessary to request any relevant data that was not available in the 
published articles. Due to the time constraints of this thesis 6 months response time was 
allowed. 
 
2.3.4 Data synthesis 
Data were grouped by outcome that matches the key OMERACT outcome domains, 
regarding adverse events (from minor to major), quality of life (patient reported outcomes 
with respect to pain, fatigue, general wellbeing and bowel symptoms) and markers of 
systemic inflammation (C-reactive protein and disease activity score). These outcomes were 
cross referenced to the demographic and probiotic formulation data extracted from the 
studies. A table was presented to summarise the study characteristics of included trials and 
is provided in chapter 4.  Results of all included studies across all included outcomes were 
synthesised in narrative form with the inclusion of tables and graphics to aid in data 
presentation. Meta-analysis was considered where enough studies employed similar 
outcomes such that a weighted mean difference or standardised mean difference would be 
appropriate. Where meta-analysis was inappropriate due to heterogeneity or incomparable 
data, a narrative review was undertaken. A standardised robust approach was taken to 
perform meta-analysis on the difference between post test scores in the experimental 
studies (as opposed to mean change) for most outcomes. This necessitated the calculation 
of post test data in studies where only baseline and change from baseline were reported.  
 
2.4 Statistical analysis 
2.4.1 Data conversions 
Where studies presented data as median and interquartile ranges, they were converted to 
mean using the formulas supplied in Weir et al.215  Where data was presented on the same 
outcome measure but on different scales (for example pain measured un VAS, or CRP 
measure in mg or g per L) the data was converted to the most common utilised scale. 
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2.4.2 Missing data  
Where missing or incomplete data was presented in studies, this was first resolved by 
communicating with the authors to request full raw data. Where this was not achieved and 
missing data values remained the approach of Weir et al215 was employed, as their 
Illustrative meta-analyses showed that “replacing a missing SD by approximation using the 
range minimised loss of precision and generally performed better than omitting trials.”215(p.1) 
Using the baseline values and mean change scores, estimates for post-test scores were 
achieved, however if the p value for post-test scores was not known the Cochrane 
handbook methodology was applied, whereby an average of the baseline standard 
deviation were taken as an approximate of post-test standard deviation.216 
 
2.4.3 Effect size calculations 
Effect sizes were expressed as relative risk (for categorical data) and weighted mean 
differences (for continuous data) and their 95% confidence intervals have been calculated 
for analysis in case of identical scales across studies; otherwise, standardised mean 
difference (SMD) was used. Effect size was calculated using the difference between post-
test scores, where no statistical difference in baseline values exist. 
 
2.4.4 Secondary outcome and incidental findings reporting 
Data concerning the outcomes of interest including adverse effects was mined from all 
studies irrespective of its status as a primary outcome measure. Whilst this may limit the 
rigor of the reporting, evidence of harm is a major consideration when communicating the 
risk/benefits of probiotics with patients and therefore this scrutiny is valid. 
 
2.5 Meta-analysis 
Any relevant quantitative data was, where possible, pooled in statistical meta-analysis. 
Meta-analysis performed using System for the Unified Management, Assessment and 
Review of Information (SUMARI) was be considered for all outcomes. Where more than five 
studies were available for meta-analysis a random effects approach was chosen as the 
variation in formulation of probiotics applied was hypothesised to be a key factor 
influencing outcomes above and beyond sampling error or chance.  As random models of 
calculation provide a more conservative model of effect size this was deemed more 
appropriate for the heterogeneity of studies included.  Where limited studies were included 
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a fixed approach was taken and, in all cases, the statistical heterogeneity was assessed using 
X2 and I2 test and statistics. Significant heterogeneity was considered when X2 test has a P 
value < 0.1 or an I2 test value > 50%.  
 
2.5.1 Subgroup analysis 
Results explored using subgroup analyses where appropriate. Where possible subgroup 
analysis based on condition, and on data for specific strains and combinations of probiotics 
was be employed. Where statistical pooling is not possible the findings were presented in 
narrative form including tables and figures to aid in data presentation where appropriate. 
 
2.5.2 Confidence in effect size 
A summary of findings table was generated in order to provide a concise outline of key 
findings for each of the outcomes and to provide an accessible format to outline the 
certainty of confidence in the effect estimates from the review. The review effect estimates 
were graded from very low (very little confidence in the effect estimate) up to high (very 
confident that the true effect lies close to that of the estimate of the effect) after 
considering the factors that may increase or decrease confidence for each included study. 
As per the grade methodology factors that may increase confidence included magnitude of 
effect, dose response gradients and plausible confounders. Factors that may reduce 
confidence for an individual study included Limitations in study design or execution (risk of 




CHAPTER THREE Results  
3.1 Study Selection  
A total of 6,316 articles were identified from searching the specified databases, and a 
further 1,842 were identified from grey literature searching including clinical trial databases, 
dissertation databases and online deep web searches. These article citations were exported 
into the reference manager software Endnote (Clarivate Analytics), and after removing 
duplicates, 5,876 records remained. These were screened for inclusion by title, and after 
removing 5,278 records deemed not to meet inclusion criteria, 598 records remained.  
These records were further screened by abstract providing 152 articles which were obtained 
in full form. Full texts of these 152 articles were retrieved and assessed against the exclusion 
noted as per appendix IV. Following screening of the reference lists, two further articles 
meeting inclusion criteria for the review were identified. Of the 154 articles that were 
reviewed, a final 12 studies met inclusion criteria and were obtained in full form.218-229 Of 
these, ten were randomised controlled trials of which nine employed a placebo control 
methodology and one compared to standard treatment. Two articles were quasi-
experimental and only one of these employed a placebo. There were no studies included 
which provided an active control of an alternative probiotic formulation. Two of the 
included 12 studies, Alipour et al218 and Vaghref -Mehrabany et al.227 were reporting 
different outcomes for the same trial, and therefore this was accounted for when analysing 
outcomes to prevent duplication of data. Four studies included a variety of 
Spondyloarthopathies .219,221,225,226 Eight studies focused on RA.218,220,222-224,227-229OF these 
the majority employed American College of Rheumatology criteria for RA. Probiotics were 
supplied for 56 to 84 days in 77% of studies. Overall, 17 different probiotics were supplied in 
colony forming units ranging from 1x 108 to 2.25 x 1011 per 24hrs . Lactobacillus was most 
commonly supplied (59%) then Bifidobacterium (20.8%). 
 
Search and study selection results were presented according to the PRISMA guidelines as 

















































Figure 7 Prisma flow diagram230 
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3.2 Methodological quality 
Of the included articles, ten studies were blinded randomised control trials and their quality 
was appraised using the JBI critical appraisal tool for randomised controlled trials (appendix 
Ia & Ib).  Two reviewers appraised the articles and any disagreements were resolved 
through discussion and the input of a third reviewer where necessary. The results are shown 
below in Table 12. Two studies were considered quasi-experimental and their appraisal was 
completed using the JBI appraisal checklist for quasi-experimental studies (appendix IIa and 
IIb) and results are shown in Table 13. From the quasi-experimental articles, Tomasello et 
al.226 compared probiotics to standard therapy, and Lee et al.222 provided the probiotic 
intervention without a control group. 
  
 
Table 12. Assessment of methodological quality of included randomised control trials. 
Study Question number 
1 2 3 4 5 6 7 8 9 10 11 12 13 
Alipour et al 
2014218 
Y U Y Y Y Y Y U U Y Y Y Y 
Brophy et al 
2008219 
Y Y Y U Y Y Y Y Y U N Y Y 
Hattaka et al 
2003220 
Y U Y Y U Y Y N N Y Y U Y 
Jenks et al 
2010221 
Y Y Y Y U Y Y Y Y Y Y Y Y 
Mandel et al 
2010223 
Y Y U Y Y Y Y Y N Y Y Y Y 
Pineda et al 
2011224 
Y U Y Y Y U Y Y Y Y Y Y Y 
Shukla et al 
2016225 
Y Y Y Y Y Y Y Y U Y Y Y Y 
Vaghref -
Mehrabany et al 
2014227 
U U Y Y Y Y Y Y N Y Y U Y 
Zamani et al 
2016228 
Y U Y Y Y Y Y U Y Y Y Y Y 
Zamani et al 
2017229 
Y U Y Y Y Y Y U Y Y Y Y Y 
 
Table 13 Assessment of methodological quality of included quasi-experimental studies 
Study Question number 
 1 2 3 4 5 6 7 8 9 
Lee et al 2010222 Y NA NA N Y Y NA Y Y 
Tomasello et al 
2015226 
Y U Y Y Y U Y Y U 
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True randomisation was clearly described and employed in nine out of ten studies. Only one 
study was unclear as to the exact methodology.227 As this study used alternative outcome 
data from the trial by Alipour et al.218  the lack of clarity may be a change in write-up style. 
Therefore, all included the randomised controlled trials had a secure method to equally 
distribute potentially confounding variables between study groups. 
 
Allocation of concealment to groups was poorly detailed in two thirds of randomised 
controlled trials potentially allowing studies to be affected by allocation bias.231 Whilst true 
randomisation should ensure baseline population comparability, the studies included in this 
review involved small populations and inconsistent levels of allocation concealment.  
Therefore, it was important that populations were consistently similar at baseline in all 
included studies as this enabled the use of post-test mean differences to estimate the 
effects size of the intervention. 
 
Unlike some complementary therapies the provision of probiotics can be easily concealed 
by providing sham capsules providing that all participants, providers of care and assessors 
are suitably blinded. Five of the nine studies scored the maximum for blinding across all 
areas, the other four studies did not clearly specify the blinding employed for one out of the 
three groups in question.  All studies ensured participants within the intervention and 
control/placebo groups were treated similarly. Where participants required any concurrent 
intervention, this was clearly stated, as the requirement for additional medications 
(whether steroids, anti-inflammatories or DMARDS) would clearly affect outcomes. 
 
Only half the included randomised controlled trials clearly described complete follow up and 
the application of intention to treat analysis. Outcome measures were applied consistently 
and reliably in most studies. Only the study by Brophy et al219 relied purely upon self-report 
as it was an online format. This provides a significant flaw in the study with the largest 
sample size. Whilst it was deemed that appropriate statistical tests were employed, there 
were a great variety of different statistical methods applied which further validates the 
choice of a consistent post-test analysis of effects size across all possible studies. All 
included randomised controlled trials were appraised to have followed appropriate trial 
design. Failure to analyse participants in the treatment group to which they were allocated 
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was the major weakness identified across the assessment of methodological quality for the 
included randomised controlled trials. 
 
Appraisal of methodological quality of the quasi-experimental studies revealed that all 
clearly identified cause and effect, and all employed multiple post intervention outcome 
assessments. Two studies provided a suitable control and ensured similar care between 
groups. Comparison is hard to achieve in quasi-experimental studies, due to heterogeneity 
of design. Lee et al.222 did not employ a control group, Shukla et al.225 compared to placebo 
and Tomasello et al.226 compared probiotic intervention to standard care. 
 
3.3 Study characteristics of included trials 
A full table outlining the study characteristics of included trials is found in the appendix III 
The studies were published from 2003 to 2017. A total number of 603 participants were 
enrolled to treatment and control groups in the eligible 12 studies. As the same population 
was utilised in two publications (Alipour et al.218 and Vaghef-Mehrabany et al.227), but 
different outcome measures were provided in each publication, this population of 
participants was only counted once when analysing participant numbers.   
 
3.4 Description of included studies  
3.4.1 Study demographics 
Robust clinical studies ensure a study population that is sufficiently homogenous to control 
known confounding variables but through this process may introduce limitations on the 
generalizability of results to the broader clinical population. By examining the study 
demographics carefully, confidence on the transferability of results can be assessed. There 
are many known variabilities that can affect the microbiome (such as gender, age, diet and 
concurrent medications) which have been poorly considered in past reviews. This may 
underly the different conclusions drawn regarding probiotic treatments efficacy in trials and 
potential effectiveness in clinical practice. Baseline demographic data as extracted from 






Table 14 Population demographics of included studies 










Probiotic  overall  Probiotic 
group 
Total N  
Control/Inter 
Compliance Drop out  Disease 
duration 
Yrs. 
Alipour et al 2014218 RA N=60 (30/30) 41.14 56 0:60 67.6% 23.33% 5.25 
(3.75,10)* 
Brophy et al 2008 SpA  N=147(76/71) 44.8 84 45:31 67.9% 34.69% 20.3 (± 13,2) 
Hattaka et al 2003220 RA N=26 (13/13) 50 365 4:5 ‘good’ 19.23% 8.3 (± 7.3) 
Jenks et al 2010221 AS N=63 (31/32) 45.5 84 19:13 92.5% 0.00% 9.8 (± 13) 




B. lactis 0% 
0.00% NS 
Mandel et al 2010223 RA N=45 (23/22) 62.9# 60 3:9 Not stated 2.22% 11.8 (± 5.4) 
Pineda Mde L et al 
2011224 
RA N=29 (14/15) 63.8 84 21:2 Not stated 10.34% 19 (± 12.4) 
Shukla et al 2016225 SpA  N=46(23/23) 16* 84 23:21 98.1% 13.04% 3 (1.5,5)* 
Tomasello et al 2015226 SpA N=59 (28/31) 43.4 365 NS NS NS NS 
Zamani et al (2016)228 RA N=54 (27/27) 49.3 56 22:3 >90% 7.41% 7.7 (± 6.1) 
Zamani et al 
(2017)229Popula 
RA N=60 (30/30) 52.2 56 22:4 >90% 26.67% 7 (± 5.7) 
*Median and IQR range provided # participant age not given for probiotic intervention alone  
 
3.4.2 Condition 
The impact of probiotics upon many types of  inflammatory arthritis remains unexplored. 
Eight of the included studies focused on individuals with RA and the remaining four studies 
included a range SpA ( including juvenile arthritis, ankylosing spondylitis and enteropathic 
arthritis) which are generically referred to throughout the results section as SpA.  
 
3.4.3 Age 
Immunosenescence may be a confounding factor affecting the impact of probiotic 
interventions in inflammatory conditions. As there were no significant differences in 
baseline age between intervention and control groups across studies data is being 
presented for the intervention group. Only Shukla et al.225, was conducted with children, the 
median age of this study was 16 yrs.  Excluding the paediatric trial data, the average age of 
participants (using a weighted average approach)  receiving probiotics in trials concerning 
SpA was still younger (45 yrs.) than for those concerning RA (51 yrs.). 
 
3.4.4 Disease duration 
Inflammatory conditions have a long prodromal periods and distinct phases of the condition 
may present differerent capacity for modulation by probiotics.There was a large range of 
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disease duration described in the populations provided with probiotics. All samples 
achieved a mean duration of greater than three years indicating established, not early 
disease status. Three studies included participants with disease duration greater than 10 
years. The average disease duration ( calculated by weighted mean) of all recipients 
receiving probiotics was 11.7 years, however, when analysed by condition those with RA 
had a lower average disease duration of 9 years and those with any form of SpA an average 
of 14.5 years. Excluding the paediatric trial the average disease duration of those with a SpA 
form of arthritis in the study rose to 17.04 years. 
 
3.4.5 Duration of intervention 
The median duration of probiotic delivery across studies was 60 days (just over eight 
weeks). Only one study utilised a short time frame of seven days, and only one study used a 
long-time frame of a year. Therefore, the most frequently employed delivery time (mode) 
was 56 days (eight weeks). When reviewed by condition (RA versus SpA) a difference was 
identified. Studies utilising participants with RA had a shorter median duration of 56 days (8 
weeks) compared to SpA median of 84 days ( twelve weeks).  When considering participant 
numbers (rather than trials), most individuals (93%) received probiotics for 56-84 days. 
Where intervention stated as three months without reference to days used, taken as 
standard 12-week intervention (84 days). 
 
3.4.6 Gender 
Gender and hormonal influences may affect the microbiome and response to probiotics. 
There was significance difference in gender balance in population samples across studies. 
One study population, discussed in two papers only used females.218,227 Whereas in three 
studies the population was predominately males.224,228,229 Not all studies described the 
gender balance of their sample groups.226 
 
3.4.7 Patient adherence 
Patient adherence is the level of compliance a patient has with taking their medication as 
prescribed. This should be considered alongside patient retention as both may affect the 
population size receiving the identified study intervention in the correct dose/ duration. 
65 
 
Most studies used tablet count or weight as a measure of compliance. Exceptions were self-
report Brophy et al,219 and faecal assay to assess probiotic levels in Lee et al.222 
 
3.4.8 Patient retention  
Patient retention may also be known as dropout. Average dropout rates across all clinical 
trials has been estimated at 30%.232 Placebo-controlled trials may be more vulnerable to 
retention issues if individuals become concerned that their condition is not being well 
managed. Two included studies showed drop out above 30%. The highest overall drop-out 
was in the study by Brophy et al.219,220 Drop out between intervention and control groups 
was similar in 7 out of the 10 studies that explicitly identified patient retention. Differential 
drop out with greater loss affecting  intervention participants was seen in two studies, 
Hattaka et al.220 (38% in intervention versus none in control) and Vaghref et al.227 (26% in 
intervention versus 20% in control). Differential drop with greater loss of control 
participants was seen in two studies Pineda et al.224 (21.43% in control versus none in 
intervention) and Shukla et al.225(17% in control versus 8% in intervention).  
 
3.4.9 Population exclusions 
A wide variety of factors have been shown, or suggested, to affect the microbiota of the gut 
and alter the function of ingested probiotics and/or their capacity to colonise the gut. 
Therefore, the characteristics of participants that were excluded from the study trials were 
extracted. Whilst in clinical practice all factors may be considered by the medical 
practitioner before commencing a given form of intervention, this review employed a 
simple grouping of exclusion criteria aimed to clarify the transferability of outcomes to real 
world situations. The most commonly stated exclusions were current use of other 
supplements, recent use of antibiotics individuals with IBD, kidney disease and pregnant or 
breastfeeding women. The most commonly applied exclusion criteria were use of biologic 
disease modifying anti-rheumatic medications. 
 
3.4.10 Probiotic formulations:  
Organisms that may act as probiotics include viruses, fungi and bacteria. A simple outline of 
relevant classification was provided in Chapter 1, Figure 2 and 3. A key focus of this study is 
to identify any change in outcome with respect to specific probiotics supplied, therefore a 
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Probiotics species  
From the 12 included studies only one study, involving 31 participants utilised a yeast 
(Saccharomyces boullardii) and the rest of the studies employed bacteria. The specific 
probiotic species and the concentration in which it was supplied, where known, has been 
provided for each study in Table 15 above. The studies included a variety of bacterial 
organisms, classified within three different orders. There were 17 different bacteria species 
delivered with the formula of the 12 studies. The numbers of individual participants 
receiving specific species are represented in Figure 8 below and have been colour coded to 
identify their shared phylum. The order and genus of bacteria delivered to the most 
participants across the studies was that of Lactobacillus.   
 
 
Figure 8 Total number of participants receiving each species of probiotic. 
 
Probiotic combinations 
The formulation and number of bacterial species within the probiotic intervention was 
varied, from those containing single species to formulations with up to eight different 
species. A combination of three or four types of probiotic was commonly employed and 
given to the majority number of participants. Only one study by Zamani et al.229 included 
specific prebiotics in the form of 800mg of inulin.  





















Probiotic concentrations  
Concentration of a probiotic formula is measured in colony forming units. For comparability 
data is taken as the CFU in 108. Probiotic formulations were delivered heterogeneously 
across studies, in single daily or twice daily doses. Therefore, the actual amount of the 
probiotic received per 24 hours was calculated.  As demonstrated in Figure 9 Shukla et al.225 
provided the greatest concentration of probiotics to participants. Alipour et al.218 (and 
therefore Vaghref-Mehrabany et al.227) supplied the lowest concentration. Due to 
duplication of study participants and intervention, any graphs or tables relating to 
duplicated information display that related to Alipour et al.222 
 
 
Figure 9 Total concentration measured in Colony Forming Units (CFU) of probiotics supplied in 24 hours by each 
study.(RA represented in Blue, SpA represented in orange) 
  
3.5 Outcomes 
3.5.1 Life Impact 
Quality of life and patient reported well-being 
Five studies employed patient reported wellbeing scores on a visual analogue scale from 0-
10. Details are provided in Table 16. Two studies also assessed a broader quality of life 
measure the health assessment questionnaire. Heterogeneity of study participants was 
apparent with Brophy et al.219 having a significantly longer disease duration, Jenks et al.221 
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69 
 
oldest population. Only one study employed a high concentration formula.219 Two studies 
employed single species formulation, Lactobacillus caseii in Alipour et al.218 and Bacillus 
coagulans in Mandel et al.223 All studies except Mandel et al. 223 incorporated probiotics 
within the Lactobacillus family. Effect scores calculated by the authors indicated a 
statistically significant trend towards improvement in quality of life. When post test scores 
were analysed to create a standardised mean difference  a statistically significant benefit of 
probiotic administration was found, effect size -0.37 (95%CI -0.59,-0.15) see Figure 10. Data 
conversion was used as per the methodology protocol and as decribed in the Cochrane 
handbook.216 The application of an average standard deviation may underlie the different 
findings between original authors and this review.  
 
Table 16  Outcome of administered probiotic in included studies on patient wellbeing as measured with a 
variety of scoring systems. 
Study Measure Probiotic 
Mean Post-
test and SD 
Placebo Mean 
Post-test and SD 
SMD and 95% CI 
Alipour et al 2014218 Global Health Score 20.92 (±27.94) 35 (±40.98) -0.40 (-0.91,0.11) 
Brophy et al  2008219 BAS-G 2.9 (±2.3) 3.7(±3.3) -0.28 (-0.64, 0.05) 
Jenks et al 2010221 PtGa wellbeing 2.7(±2) 3.3 (±2.4) -0.27 (-0.76,0.22) 
Mandel et al 2010223 PtGa   Raw Data unavailable 
Pineda Mde L et al 2011224 PtGa Disease activity 2.71 (±1.75)* 4.69 (±1.75)* -1.1 (-1.88,-0.32) 
Hattaka et al 2003220 HAQ 0.5 (±0.4) 0.7 (±0.7) -0.34  (-1.11, 0.43) 
Pineda Mde L et al 2011224 HAQ    n/a 
*Data conversion applied CI ( confidence interval) SMD (standardised mean difference)  




Figure 10 Forest plot displaying the meta-analysis of five individual studies of probiotic effect upon patient 
reported general wellbeing and quality of life, measure with patient general assessment (Pt GA) and Health 
assessment questionnaire (HAQ). 
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A sensitivity analysis was undertaken, see Figure 11,  by removing the study where data was 
converted.224  A random model was used as whilst the number of studies investigated was 
below the threshold of five recommended for random effects models by the JBI reviewers 
handbook, it enables a comparable forest plot to examine the effect of leaving one study 
out of the meta-analysis. The result remained a positive statistical benefit of probiotics upon 
patient wellbeing. p=0.009. 
 
 
Figure 11 Forest plot displaying sensitivity analysis for  4 individual studies of probiotic effect upon patient 
reported general wellbeing and quality of life. 
 
Subgroup analysis was conducted to investigate the specific effect of different probiotic 
formulation. Studies that employed only Lactobacillus forms of probiotic were compared to 
those that contained both Lactobacillus and Bifidobacterium genera. 
 
The subgroup analysis as shown in Figure 12 a and b, revealed a stronger effect from the use 
of Lactobacillus compared to combination Lactobacillus and Bifidobacterium products.  
Identifying further differences from the Lactobacillus and Bifidobacterium mixtures relevant 
to specific species is not possible. However, within the Lactobacillus only sub-group there 
did appear to be differences within formulations. For example, formulations containing 
Lactobacillus rhamnosus had greater effects size than  Lactobacillus caseii alone.  It should 
be noted that confounding effects of differing concentrations of formulation may be 














Figure 12a & b  Forest plot displaying subgroup analysis  of two individual studies sub-grouped by probiotic 
formulation upon Patient reported general wellbeing and quality of life 
 
Fatigue 
Two studies measured fatigue after a 12 week probiotic intervention, Pineda et al.224 
utilised a visual analogue scale to score fatigue on a uni-dimensional scale with RA patients 
and Jenks et al.221 employed a fully validated multidimensional tool with SpA patients.  
Results are shown below in Table 17.  Whilst both studies provided a relatively low once 
daily dose of probiotics, the formulation of probiotic varied. Pineda et al.224 used a 
combination of two probiotics within the Lactobacillus family whereas Jenks et al.221 used a 
combination of three probiotics, two Lactobacillus and one Streptococcus species however 
all three remain with the broader Lactobacillus genera.  
 
Significant heterogeneity in sample population demographics was seen between studies. 
The trial population was predominately female (93%) older (mean age 63 yrs.) and long 
disease duration (mean 19 years ± 12.4 years) in the study by Pineda et al.224  Jenks et al. 221 
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included a predominately male population of younger age (mean 45.5 years) and  shorter 
disease duration (mean duration 9.8 yrs.). The probiotic was supplied once daily in a dose of 
2x 109 colony forming units per strain. In both studies baseline fatigue levels were greater 
than for established healthy population norms but below the norms established for 
individuals with RA or SpA respectively. 140,233 Mean clinically important differences were 
not achieved in either study.  
 
Table 17 Outcome of administered probiotics on fatigue measured on two different scales, Visual Analogue 
Scale for fatigue (VAS-f)  and the multi-dimensional assessment of Fatigue Scale (MAFS). 
Study Measure  
at 12 weeks 
Probiotic Post-test 
mean and SD 
Control Post-test 
mean and SD 
SMD and 95% CI 
Jenks et al221 MAFS 21.9 (±10.2) 23.9 (±11.1) -0.19 (-0.68,0.31) 
Pineda et al224 VAS 2.88 (±2.00) 5.7 (±2.00) -1.73 (-2.18,-0.56) 
* Calculated using mean changes in patients from baseline to final visit CI ( confidence interval) SMD (standardised mean difference)  
MAFS (Multidimensional Assessment of Fatigue Scale) VAS ( Visual Analogue Scale) 
 
Using identical method on both data, post-test effects size was calculated, and a forest plot 
generated as shown in Figure 13. When calculating effects size from post test scores alone, 
a small benefit for the administration of probiotics was seen for both studies and whilst 
combination suggests a statistically significant effect when combined the fixed effects forest 
plot revealed a very high level of heterogeneity (I2=83) indicating that it is inappropriate to 
combine the results of these two studies and that further data is required to assess the 





Figure 13 Forest plot representing the meta-analysis of two studies investigating the effect of probiotics upon 




Two studies measured change in bowel symptoms after a 12-week probiotic intervention 
for individuals with SpA. Brophy et al.223 utilised a portion of the visual analogue scale for 
Irritable bowel syndrome (including diarrhoea, stomach pain and blood in stool) on a scale 
of  0 to10 whereas Jenks et al.225 used a fully validated multidimensional tool the Dudley 
Inflammatory Bowel symptom questionnaire. On both scales a reduction in score is seen as 
an improvement in symptoms.  
 
Patient demographics were similar in each group being predominately male of similar age, 
however the disease duration was significantly longer in the study by Brophy et al. 223  
Results are shown below in Table 26.  
 
Brophy et al.223 provided a combination of four different probiotics, two Lactobacillus and 
two Bifidobacterium , supplying a total of 10 x 109 colony forming units per 24 hrs. Jenks et 
al. 225 provided a  lower concentration product 9 x 10 8 containing three different families of 
probiotic (Bifidobacterium lactis, Streptococcus salivarius and Lactobacillus acidophilus) but 
supplied twice a day, therefore providing a total of 1.8 x 109 over 24 hours. Baseline bowel 
symptoms varied between studies. Whilst both had symptoms above healthy baseline 
norms the baseline bowels symptom levels as measured with the Dudley questionnaire 
were below the threshold at which symptoms should affect quality of life. The authors 
outcomes are provided in Table 18 and neither identified a statistically or clinically 
significant benefit from probiotic administration.  
 
Table 18. Outcome of administered probiotics in included studies on Bowel symptoms 
Study measure Probiotic at 12 weeks 
Post-test mean and SD 
Placebo at 12 weeks  
Post-test mean and SD 
SMD and 95% CI 
Brophy et al 223 VAS (IBS) 1.4 (±2.3) 1.0 (±1.7) 0.48  (0.16,0.81) 
Jenks et al225   DISQ 6.6 (±5.1) 8.8 (±8.0) -0.33 (-0.82,0.16) 
CI ( confidence interval) DISQ (Dudley Inflammatory Bowel Symptom Questionnaire) VAS ( Visual Analogue Scale) IBS (Irritable Bowel 
Syndrome) SMD (standardised mean difference)  
 
When calculating effects size from post-test scores alone, no benefit for the administration 
of probiotics was seen, effect size 0.04, which would not be considered statistically 
significant (95%CI -0.23 to 0.31). When calculating effects size from post-test scores without 
adjustment the same conclusion was reached as seen in Figure 14. A fixed model for meta-
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analysis was employed as the number of studies investigated was below the threshold of 
five recommended for random effects models by the JBI reviewers handbook. As both study 
lines cross the line of null effect, the plot does not illustrate a statistically significant result 
and high heterogeneity (I2=66) indicates it is inappropriate to combine these results, and 
further studies are required.  
 
Figure 14 Forest plot displaying the meta-analysis of two studies investigating probiotics on bowel symptoms. 
 
Pain 
Data from five studies provided direct outcomes of pain as measured with a visual analogue 
scale, see Table 19. Two studies individually concluded no significant difference in pain 
scores after the application of mixed formula probiotics in low concentration for patients 
with SpA and RA.221,224 Three further studies using change from baseline, identified a 
statistically significant reduction in pain in the intervention groups. These studies included 
two with a high concentration multi-formula probiotic (Zamani et al.228,229) and one with a 
single species low concentration formula (Vaghef-Mehrabany et al.227). All studies which 
identified probiotic benefits were conducted on individuals with RA.   Heterogeneity in 
visual analogue scale occurred so all results were converted to the 100 point scale as 
recommended by Busse et al.234  and mean difference was then employed. 
 
Table 19 Outcome of probiotic administration on pain using Visual Analogue Scale ( VAS) as outcome. 




from baseline   






Effect size SMD 
95% CI 
Jenks et al221 27 (± 25) -6.90% 26 (±22) -13.33% 1.00 (-10.62,12.62) 
Pineda Mde L et al224 34.8 (±21.5) -6.76% 52.2 (±21.5)    0.2 -17.7(-33.36,-2.04) 
Zamani et al228   22 (±27) -52.96% 38 (±26.2) -24.26% -8.90 (-20.60,2.80) 
Zamani et al229 27(± 15.6) -43.15% 35.9 (±26.8) -23.54% -16.0 (-29.46,-2.54) 
Vaghef-Mehrabany et al227  -43.90%  -5.99% N/A 
*CI ( confidence interval) SMD (standardised mean difference)  
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When re analysed using post-test statistical analysis the effects size, as shown in Figure 15. 
indicates a small positive and statistically significant effect of probiotic administration on 
patient reported pain in RA. Fixed model analysis was employed due to the low number of 
studies and heterogeneity was moderately high but below the 50% threshold for 
considering meta-analysis suitable. 
 
Figure 15 Forest plot displaying the meta-analysis of four studies investigating effect of probiotics upon  patient 
reported pain using Visual Analogue Scale ( VAS) 
 
A minimal clinically  important difference for the visual analogue scale is often stated as 1.0 
(10 on a 100 point scale), in which case this was only achieved in two studies. It been 
suggested that this may not be meaningful to patients and that the greater difference of 20 
point change  on a 100 scale is employed.235 Using this alternative approach would suggest 
that there was no clinically meaningful change in pain scores in any of the studies 
included.234 Assessing the impact of pain on individuals is not simple and it is known that the 
starting value may affects the magnitude of the  change from a patients perspective. An 
alternative approach has been suggested to use the percentage change from baseline. Using 
this approach, higher changes as a percentage from baseline were reported in the groups 
receiving probiotics and therefore it cannot be assumed that patients will not gain 
important benefits from this intervention.  
As only one study employed a purely Lactobacillus formulation, a sensitivity analysis was 
performed to identify if any change in effect size was identified when only studies 
employing a mix of Lactobacillus and Bifidobacterium formulations were included in the 




Figure 16 Forest plot displaying the meta-analysis of three studies investigating effect of mixed probiotics 
formulations upon patient reported pain (VAS). 
 
The removal of the only study employing purely Lactobaccillus reduced the size of the effect 
score, but it remained. statistically significant. Whilst visual analogue pain scores were only 
reported by five studies, tender joint scores were reported by eight studies therefore this 
was mined as an alternative pain outcome measure as shown in Table 20. 
 
Table 20 Outcome of probiotic on tender joint score. 
Study Probiotic outcome Control 
outcome 
Effect size, Mean 
Difference and 95%CI 
(post test scores) 
Hatakka et al220 2.5 (±1.7) 2.6 (± 2.4) -0.05 (-0.82,0.72) 
Jenks et al221 3.1 (± 3.9) 5.4 (± 8.8) -0.34 (-0.83,0.16) 
Mandel et al223 Raw Data Not available N/A 
Pineda Mde L et al224 12.87 (11.89) -8.97 (4.4) 0.55 (-0.19,1.30) 
Shukla et al225 2.33 (± 2.175) 0.5 (± 2.175) 0.83 (0.22,1.43) 
Zamani et al228 4.8  (± 2.2) 4.7 (± 2.4) 0.04 (-0.46,0.55) 
BAS-G(Bath Ankylosing Spondylitis Patient General score) HAQ ( Health Assessment Questionnaire)   
 
A meta-analysis, as shown in Figure 17, was conducted with five studies where raw tender 
joint score data was available.  No significant benefit of probiotics upon tender joint scores 
was found. Formal joint counts have been described with the evaluation of anywhere 
between 28 to 80 joints, as the specific number of joints assessed was not detailed in all 
studies standardise mean difference was used for the met analysis. Data presented as 






Figure 17 Forest plot for the meta -analysis of probiotic administration on tender joint score 
 
3.5.2 Adverse events 
Adverse effects were reported in 11 of the 12 studies included in this review are displayed 
below in Table 21.  
 
Table 21 Outcome of administered probiotics on adverse effects. 
Study Probiotic Control RR and CI  P NNT 
harm 
Pop Adverse effect Pop Adverse effect ANY event   
N= Major Minor N= Major Minor   
Alipour et al218   30 0 0 30 0 0 -   
Brophy et al219 76 0 6 71 0 5 1.12 (0.36,3.51) 0.86 135 
Hatakka et al220 13 0 0 13 0 0 -   
Jenks et al221 32 0 14 31 0 12 1.09 (1.56,2.08) 0.8 40 
Lee et al222 12 0 4 - - - -   
Mandel et al223 22 0 4 23 0 3 1.33 (0.33,5.37) 0.69 26 
Pineda Mde L et al224 15 0 0 15 0 0 -   
Shukla et al225 23 1 9 23 1 11 0.88 (0.44,1.76) 0.73 25 
Tomasello et al226 28 0 0 31 0 0 -   
Zamani et al228 30 0 0 30 0 0 -   
Zamani et al229 27 0 0 27 0 0 -   
CI ( confidence interval) RR ( relative risk) NNT ( number needed to treat) 
 
Only Tomasello et al.226 did not state any information regarding side effects or adverse 
events in their study. Overall there was a lack of clarity regarding the definitions of 
mild/minor as opposed to serious adverse events. If including studies where adverse effects 
were not reported, and those where zero occurrences were reported, 50% of studies did 
not identify any effects from the administration of probiotics. This is reassuring but may also 
indicate a lack of standardised reporting in place. A forest plot of the meta-analysis of 
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relative risk of side effects is provided in Figure 18.  No increase risk as a result of taking 
probiotics was identified, relative risk 1.02.  
 
Figure 18 Forest plot representing the meta-analysis of 9 studies investigating the relative risk of minor adverse 
effects after the use of probiotics. 
 
Table 22 places these reported effects into the Common Terminology Criteria for Adverse 
Events  and identifies equivalent rates of adverse effects between intervention and 
control/placebo groups.  
 
Table 22. Common Terminology Criteria for Adverse Events (CTAE) categorisation of reported adverse effects by 
included studies. 








Grade 2 Moderate Minimal non-invasive intervention or 





Grade 3 Severe Requires hospitalisation and   disabling  0 0 
Grade 4 Life threatening Urgent intervention required 0 0 
Grade 5 Death  0 0 
 
Only Shukla et al.225 reported any serious adverse events. It should be noted that the serious 
side effects experienced were due to severe diarrhea in the placebo group and pulmonary 
tuberculosis in the probiotic group, with neither likely attributable to the intervention. The 
risk of a minor adverse effect from each study, calculated taking an intention to treat 
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approach, varied from 0.88 to 1.33 which indicates approximately the same number of 
events being reported by individuals in the control group as in the intervention group. 
 
Zero event trials were included in the meta-analysis as recommended.236 The study by Lee 
et al.222 did not include a control group and administration of probiotics in the intervention 
group resulted in 33% of participants experiencing a minor adverse event. A trend, as shown 
in Figure 19, was observed that more studies on individuals with SpA reported adverse 
effects. However, subpopulation analysis applied to the studies to compare SpA versus RA 




Figure 19 Percentage of individuals that reported side effects in intervention groups across included studies. 
  
Data from two studies provided a more detailed breakdown of specific types of adverse 
events. Increased flatulence was the most common adverse events which gave a relative 
risk of 2.03 (95%CI 0.45,9.5 p=0.36 Shukla et al.225 ) and 2.03 (95%CI 0.57,7.25 p=0.27 Jenks 
et al.221). Whilst this result was not statistically significant, and flatulence is a minor side 
effect it indicates a Number needed to treat (harm) of ten for both studies. It should be 
noted that there was no use of validated adverse events scales and that many relied on end 
point self-report to investigators. A wide range of other minor adverse effects were also 
noted with nausea the next most commonly reported symptom, the authors indicated that 
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3.5.3 Markers of systemic inflammation 
C-Reactive Protein 
Nine studies included C-reactive protein measured in mg/L as an outcome of interest. 
Despite significant heterogeneity in population demographics, probiotic interventions and 
formulations all studies indicated a negative effect size, indicating a possible reduction in 
inflammation due to the intervention of probiotics. Access to full data enabled seven of 
these studies to be used in a meta-analysis. The confidence interval crossed the midline in 
all studies except Zamani et al.229 as shown in Table 23. 
 
Table 23 . Outcome of administered probiotics for included studies on C-Reactive Protein (CRP) in mg/L 
Study Probiotic Post-test 
and SD 
Control Post-test and 
SD 
MD CRP mg/L  
95% CI 
Alipour et al218   2.8 (±4.79) 3.5 (±7.43) -0.70 (-3.86,2.46) 
Hatakka et al220 2.6 (± 3.3) 7.4 (±8.7) -4.80 (-9.86,0.26) 
Jenks et al221 6.7 (± 6.3) 11.3 (±11.2) -4.6 (-9.11,-0.09) 
Lee et al222 9.5 (±9.9) N/A N/A 
Mandel et al223 Data Not avail Data not available N/A 
Pineda Mde L et al224 5.6 (± 6)* 8.6 (± 6)* -3.00 (-7.37,1.37) 
Shukla et al225 2.96 (± 4.39)* 1.5 (±4.39)* 1.46 (-1.23,4.15) 
Zamani et al228 6.61(±6.03) 9.09 (±7.46) -2.48 (-5.91,0.95) 
Zamani et al229 4.61(±2.71) 8.47 (±6.83) -4.39 (-7.12,-1.66) 
* Data conversion applied  ^ standardised AUC values analysed. CI ( confidence interval) CRP (C-reactive Protein) 
MD (mean difference) SD (standard deviation) 
 
A meta-analysis revealed a statistically significant benefit of probiotics on C-reactive protein, 
see Figure 20. The size and significance of this effect may reasonably be expected to 
increase if the additional data from the other positive studies was included. 
 
Figure 20 Forest plot representing the meta-analysis of seven studies investigating the effects of probiotics on 
C-Reactive Protein (CRP).mg/L 
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As prior reviews have consistently concluded that probiotic intervention can lower C-
reactive protein in individuals with RA, a subpopulation analysis was performed as shown in 
Figure 21a,b. This aimed to identify  population specific effects between individuals living 
with SpA compared to RA.  
 
A) Rheumatoid Arthritis  patient demographic only 
 
 




Figure 21a and b. Forest plot representing the sub population meta-analysis of 5 studies investigating the effects of 
probiotics on C-Reactive Protein (CRP mg/L) on individuals with rheumatoid arthritis(RA)  compared to Spondyloarthritis 
(SpA) 
 
Looking at the sub population of SpA did not reveal a benefit of probiotics on C-reactive 
protein, and there was high heterogeneity as shown by I2=83 indicating that meta-analysis 
not appropriate for these studies. 
A sub-population analysis was performed as shown in Figure 22 a and b. This aimed to 
identify  formulation specific effects between probiotic that include both genera and those 
that used only Lactobacillus.  
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A) Lactobacillus  
 
 
B) Lactobacillus and Bifidobacterium 
 
 
Figure 22a and b. Forest plot representing the sub population meta-analysis of 7 studies investigating the effects of 
probiotics on  C-Reactive Protein (CRP mg/L) on individuals according to probiotic formulation. 
 
Individual study results indicate a trend in favour of the ability of probiotics to reduce C-
reactive protein, and when combines in a meta-analysis a statistically significant effect size 
is observed with low heterogeneity. Sub population analysis revealed a statistically 
significant decrease was only seen in studies for individuals with RA.  
 
Sub population analysis targeting studies which provided different formulations of 
probiotics revealed a statistically significant benefit was only obtained by the mixture of 
probiotics (Lactobacillus and Bifidobacterium) compared with Lactobacillus alone. It should 
be noted that raw data from three studies which describe statistically significant reductions 
in c- reactive protein after the application of probiotics (two based on patients with RA and 
one based on patients with SpA) were not available for the meta-analysis raw data but 




Composite disease activity score  DAS28 
Four studies provided available data on DAS28 for a meta-analysis as detailed in Table 24. 
Whilst a further study by Hatakka et al.220 provided data on the composite elements, it was 
not statistically appropriate to reconstruct mean DAS28.  The study by Lee et al.222  provided 
only baseline DAS28 data. All studies concerned patients with RA and similar demographics. 
All indicated a beneficial outcome for groups receiving active probiotic intervention. Meta-
analysis, as shown in the forest plot in Figure 23, revealed a statistically significant benefit 
(effect size -0.28) of probiotics on disease activity score p=0.016. 
Clinically significant reductions in disease activity score using C-reactive protein, are 
estimated as a one point drop overall, therefore the combined effects size did not reach 
clinical significance. Moving between accepted disease categorisation groups may also be 
meaningful with respect to change in medical management. None of the studies included 
individual with high baseline scores, but drops from moderate to low disease state were 
seen in Zamani et al. 229 and sufficient to meet remission criteria occurred in Pineda et al. 224 
 
Table 24 Outcome of administered probiotic in included studies on Disease Activity Score (DAS28) 
Study Disease Activity Score (DAS28) 
Probiotic outcome Control outcome SMD and CI 
Alipour et al218   2.07 (±0.82) 2.23 (±0.86) -0.16 CI(-0.59,0.27) 
Pineda Mde L et al224 2.08 (± 0.98) 1.93 (±0.98) 0.15 CI(-0.56,0.86) 
Zamani et al228 3.7 (± 0.7) 4 (± 0.7) -0.30 CI( -0.65,0.05) 
Zamani et al229 2.6 (± 0.7) 3.2 (±1.1) -0.60 CI(-1.09,-0.11) 





Figure 23 Forest plot representing the meta-analysis on 4 studies investigating the effects of probiotics upon Disease 
Activity Score (DAS28) score. 
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Sub population analysis revealed that studies using a combined formulation was statistically 
significant at reducing DAS28, effect size -0.4 (p=0.006)  compared to Lactobacillus alone, 
effect size -0.08 (p=0.666), see Figure 24 a,b. 
 
A) Lactobacillus  
 
B) Lactobacillus and Bifidobacterium 
 
Figure 24a and b Forest plot representing the sub-group analysis to investigate the effect of probiotic formulation upon 
Disease Activity Score (DAS28). 
 
A single study into patients with SpA by Tomasello et al.226 assessed the composite score 
after employing  two separate applications of four separate species in a high strength 
formulation. Analysing the average score obtained over the entire period of observation the 
score was significantly lower for the group receiving probiotics (p<0.05). However, during 
the first week of treatment, patients were given a mixture of Enterococcus faecium and 
Saccharomyces boulardii and in the second week they were given a mixture of Lactobacillus 
salivarius and Lactobacillus acidophilus. This unique intervention makes it harder to 





Disease specific composite outcome measures 
Jenks et al.221 employed aspects of the Bath Ankylosing Spondylitis disease activity index 
measures for individuals with longstanding ankylosing spondylitis after the intervention of a 
low concentration multispecies formula of three bacteria, (Bifidobacterium lactis, 
Streptococcus salivarius and Lactobacillus acidophilus). Whilst the calculated effect size in 
for both outcomes favoured probiotics  (-0.1 and -0.6 respectively) both the confidence 
intervals crossed the midline therefore the effect is not significant. A similar result was 
provided when outcomes were measured using the ankylosing spondylitis quality of life 
measure, with an effects size reported as -0.5 (95% CI -2, 1.1). 
Shukla et al.225 employed a juvenile arthritis specific scale, in two formats using both the 
erythrocyte sedimentation rate  and C-reactive protein. When comparing median changes 
after 12 weeks using the Mann Whitney U test , neither changes in  score  were statistically 




Chapter Four Discussion 
4.1 Introduction to the discussion 
The use of probiotics for general health and wellbeing and the scientific appraisal of their 
effects has occurred for more than one hundred years. Recent advances in genomics and 
immunology has allowed a more nuanced appraisal of the relative benefits and risks of 
probiotics. Understanding their influence on the gut microbial communities, immune 
function and human health has indicated a possible role for probiotics in controlling 
inflammation in a range of auto-immune inflammatory conditions.  
 
Prior systematic reviews have examined probiotics for rheumatoid arthritis. Pan et al.202 and 
Rudbane et al.203, both focused on changes in systemic inflammation outcomes (disease 
activity scores, C-reactive protein and cytokine expression), demonstrated an overlap in 
primary sources and both concluded that the statistically significant changes in systemic 
inflammatory outcomes may not reach clinical significance. 
Mohammed et al.204 revised the inclusion criteria and found nine studies for patients with 
RA, which when analysed, provided similar systemic inflammation outcomes and 
conclusions. The changes in cytokine biomarkers noted by Mohammed et al.204 could not 
provide clinical conclusions. A further review by Dejoras et al.205 was lacking detail as it was 
only published only in abstract form, however it used the same databases, population 
group, inclusion criteria and reached similar conclusions proposing that larger study sizes 
were required.  
 
This review aimed to broaden the scope to include a wider range of inflammatory auto 
immune arthritis conditions. It also aimed to investigate in greater detail the formulations 
used in the clinical trials, in order to provide clearer pragmatic guidance to clinicians when 
discussing probiotics with patients. Whilst the medical community may be undecided on the 
validity of probiotic claims, patients are taking them in record numbers. Therefore, a sound 
understanding of the current state of evidence for their actions remains appropriate for 
rheumatologists.  The systematic review was successful in finding 12 studies which could 




4.1.1 Structure of the discussion 
The discussion starts with the summary of findings, see Table 25, followed by discussion 
relevant to each OMERACT outcome domain: life impact, disease manifestations and 
adverse events. This includes discussion of effect size, level of clinical and statistical 
significance. Sub-population analysis is reviewed, and space devoted to study demographics 
as recognizing sub-populations is the key to enabling risk/benefit stratification. Where 
appropriate, the effect of specific probiotic formulations are discussed including dosage, 
species number, species mix and prebiotic inclusions. The discussion concludes by reviewing 
the practical significance findings for future research and clinical practice. 
 
4.2 Summary of findings 
Table 25 Summary of Findings  













371 (6 studies) 





(CI -0.59, -1.5) 
 P=0.001  
 
Subgroup analysis revealed that 
sole Lactobacillus formulations 
more effective than combined.  
Fatigue VAS 
MAFS 









Did not reach MCID. 















Did not reach MCID. Significant 
heterogeneity limits the ability to 
draw any further conclusions. 





















Did not reach MCID. 
Sub population analysis revealed 
that a combined formulation was 
statistically significant at reducing 
DAS28 than Lactobacillus alone. 
Systemic 
markers 









Did not reach MCID. Sub 
population analysis revealed a 
statistically significant decrease in 
CRP only seen in RA, and that  a 
combined formulation was more 
effective at reducing CRP  
Adverse 
effects  









Many studies did not formally 
assess. 
Subpopulation analysis did not find 
any statistical difference between 
outcomes in RA and SpA. 
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative 
effect of the intervention (and its 95% CI). MD: mean difference; SMD: standardised mean difference, MCID: minimally clinically significant 
difference, RCT: Randomised controlled trial GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but 
there is a possibility that it is substantially different 
Low certainty: confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect 
Explanations a. small sample size ,b. varying estimates across studies, c. I2>50%,d. sig risk of bias, e. Indirect comparison 
PtGa Patient General assessment,  HAQ (Health assessment questionnaire) Visual Analogue Scale, Multi-dimensional assessment of fatigue 
( MAFS) Disease activity score (DAS28) C reactive protein ( CRP) Dudley inflammatory bowel symptoms Questionnaire ( DISQ). Minimal 




4.3.1 Life impact  
Quality of life  
Effect scores calculated by the authors indicated a trend towards the improvement of 
patient reported quality of life, but this did not reach statistical significance in any individual 
study. Meta-analysis indicated a small but statistically significant benefit of probiotic 
administration. Statistically significant changes in quality of life, were not expected as most 
individuals in the included studies had a long disease duration prior to inclusion in the 
clinical trials. Therefore, they were likely to experience the consequences of longstanding 
disease, such as bony erosions, which may be contributing factors to disability but be 
considered relatively unamenable to change. 
 
There have been other systematic reviews completed regarding the effects of probiotics on 
quality of life. A review on individuals with RA by Mohammed et al.204 assessed the mean 
difference between two studies that employed the Health Assessment Questionnaire as an 
outcome. Due to high heterogeneity a random effects model was applied, and a statistically 
significant effect was not found, p= 0.081. The difference in findings between the 
Mohammed et a.l204  and this review, may be related to the number of studies involved but 
also the greater proportion of unidimensional outcomes used in this review.  Whereas 
Mohammed et al.204 used a more complex domain questionnaire that includes a broader 
disability index. Whilst the disability index used by Mohammed et al.204 aims to measure 
discrete physical limitation of daily activity– it is difficult to disengage physical limitations 
from the emotional impact of health conditions (such as helplessness), the impact of 
comorbid conditions and restriction in participation due to external environmental aspects. 
For all these reasons poor associations have been reported between calculated change in 
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disability and patient perceptions of disability and may underlie why a statistically significant 
difference was not found in the review by Mohammed et al.204 
 
The author of this review suggests that probiotics may be moderating perceived quality of 
life indirectly through perception and mood, as some recent studies have shown decreased 
central responses to stress and negative stimuli after the application of probiotics and 
resulting changes in  anxiety and low mood.237-239  This research may provide a further step 
in clarifying how probiotics not only change brain activity but also human behaviours such 
as engaging in activities of daily living and perception of quality of life. 
 
It is important that small statistically significant benefits are evaluated to determine the real 
clinical significance.  Whilst a MCID has not been clearly stated for the many differently 
worded versions of the patient general assessment , the minimal clinical difference in 
rheumatology measures as identified by the OMERACT Rasch group, is 11 points on a 100 
point scale .240 Alternatively  using two points as a minimal clinical difference would 
correlate to the recommended American College of Rheumatology response of 20% which 
identifies individuals as a responder to intervention. The second most commonly used 
outcome the Health assessment questionnaire has a stated minimal clinical difference of 
0.22.164 Examining the forest plot indicates that only Jenks et al.221 and Hattaka et al.220 
provided a confidence interval that includes the minimal clinical difference for the scale 
used. Therefore, whilst probiotics can create a statistically significant change in quality of 
life measures, this remains only a possibly clinically significant finding. 
 
The sub-group analysis of quality of life revealed a greater effect size from the use of 
Lactobacillus compared to combination Lactobacillus and Bifidobacterium. This may be an 
artefact of small study sizes as a recent review has found that many different formulations 
of probiotics (including combined Lactobacillus and Bifidobacterium) can be  associated with 
a significant reduction in depression.241  Underlying mechanisms have been hypothesised as 
the probiotics capacity to generate serotonergic precursor or serotonin type chemicals.242 
However the Lactobacillus only sub group displayed that the formulation of  Lactobacillus 
rhamnosus and Lactobacillus reuteri appears more effective than Lactobacillus rhamnosus 
alone , and any combination of Lactobacillus rhamnosus is more effective than  Lactobacillus 
caseii alone. A hypothesis to explain the lower effect suggested for  Lactobacillus caseii may 
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relate to its absence of surface layer adhesion proteins, which reduce its  capacity to attach 
in the gut and therefore its immunomodulatory capacity.243 
 
Fatigue 
Fatigue in rheumatology patients has been described as a “multidimensional, persistent 
symptom with far-reaching consequences”.140 (p.1) Despite international consensus that 
fatigue should be evaluated in clinical trials for inflammatory arthritis only two studies 
included in this systematic review employed fatigue as an outcome. In both studies the 
post-intervention fatigue scores reduced. Calculating effects size from post test scores a 
small statistically benefit for the administration of probiotics was seen, effect size -0.51 
p=0.018. However significant heterogeneity is shown by an I2 of 83 indicating that the true 
size of effect is unknown, and that more data is required to clarify the impact of probiotics 
on fatigue.  GRADE analysis also revealed a low confidence in the effects identified due to 
high risk of bias in studies. Due to low numbers of studies and heterogeneity any subgroup 
analysis to investigate differences between formulations was not appropriate.  
The cause of rheumatological related fatigue remains debated and complex. For example, 
even in those patients who respond well and achieve remission with disease modifying anti 
rheumatic medications, only approximately a third achieve resolution of their fatigue 
symptoms.136  A systematic review into the causality of fatigue by Nikolaus et al.143 indicates 
strong relationships between fatigue and both pain and depression. Such links may provide 
a hypothesis for the amelioration of fatigue via the psychobiotic effect of probiotics on the 
gut-brain axis.  Specifically, that probiotics can create a benefit in positive mental health.244 
The research underpinning this hypothesis has been largely based on animal studies, after 
the finding that germ free mice were found to have an exaggerated central nervous system 
response to stress, which could be altered by intervention with 
specific Bifidobacterium species.245 Many subsequent studies have clarified that microbiota 
changes affect anxiety related behaviour in mice, for a deeper review see Foster et al.246 
Limitations apply when generalising results from murine studies, so further research is 




 Bowel symptoms 
Two studies investigated the effect of probiotics supplementation on bowel symptoms, both 
were addressing SpA. When calculating effects size from post-test scores without 
adjustment both study lines cross the line of null effect, therefore the plot does not 
illustrate a statistically significant result and significant heterogeneity limits the ability to 
draw any further conclusions. Both studies were undertaken on populations with long-
standing Spondyloarthropathy. Gut inflammation in the SpA has been categorised into two 
main forms, an acute gut inflammation and a chronic form.247 The chronic form has been 
associated with significant tissue changes, similar to that seen in Crohn’s disease, that alter 
the normal function of the gut.  Changes include detachment of epithelial layers, villi 
vacuoles and haemorrhagic extravasation.247 Systematic reviews into the effect of probiotics 
in inflammatory bowel disease have shown a differential response between ulcerative colitis 
and Crohn’s whereby probiotics have not been assessed as effective in adult Crohn’s.248,249 
Therefore, it may be extrapolated that Crohn’s like changes in long standing SpA would also 
be unamenable to impact by probiotics. Whilst subclinical gut inflammation has been 
described in up to 60% of patients with SpA  the level and extent of damage to the gut in the 
populations included within this review remain an unknown confounding factor.250  Future 
studies would require earlier intervention and more nuanced methods of assessing baseline 
gut inflammation.  
 
Pain 
Evidence has been provided, that gut microbiota can modulate key pathways that affect the 
pain experience.  Meta-analysis indicated a positive and statistically significant effect of 
probiotic administration on patient reported pain using a visual analogue scale in RA. 
However, a meta-analysis using tender joint score indicated no significant benefit of 
probiotics. This latter result agrees with the recent review of Mohammed et al.204  who 
looked at the data from five studies on RA who had included tender joint scores.  
 
Identifying exact levels of clinically significant changes in visual analogue scale pain has been 
much debated. The smallest detectable difference on a measurement scale is the smallest 
change that can be reliably distinguished from random error. The smallest detectable 
difference reported in three randomised controlled trials of rheumatoid arthritis, given as 
negative change or improvement, was from−18.6, to −20.0. 136 Therefore the effect size in 
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this meta-analysis (-8.97) did not reach a level at which could be distinguishable from 
random error. 
 
Minimal clinically important difference may also be used and  should be appreciated as 
context-specific, for example a small change in very severe pain may be more significant to a 
patient than a larger change in low levels of discomfort.235  As minimal clinically important 
difference is context specific, cautious  interpretation and  judicious application are 
required. Applying the latter part of Jaeschke’s definition of minimal clinically important 
difference, it is important to consider what level of change in pain would “mandate a 
change in patients management”.124 (p.260)  At less than ten mm change on a 100 mm scale, it 
would be unlikely this would mandate management change and confirms it is not a clinically 
significant result. Furthermore if, as Graham et al.251 suggests,  a minimal clinically 
important difference cannot easily be converted between 10 and 100 point visual analogue 
scales, then applying it to this meta-analysis may be misguided. The effect size of all the 
studies included in the meta-analysis did not exceed the minimal clinically important 
difference of 10mm,  therefore it would not be termed a clinically significant result. 
Assessing the impact of pain on individuals is not simple, an alternative approach has been 
suggested to use the percentage change from baseline. Using this approach, it is seen that 
wide variation in change as a percentage from baseline were reported. In summary whilst 
the interpretation of the significance of the result upon pain is complex and depends upon 
the methodology applied, the small statistically significant  difference did not reach clinical 
significance in any of the methodologies applied. 
 
4.3.2  Adverse events 
There are many characteristics required of effective probiotics, for example the capacity to 
survive passage of the upper gastrointestinal tract, to persist and to interact with the 
mucosal layers that create immunological responses. However, most importantly they 
should be safe, which includes being non-pathogenic, not capable of transferring antibiotic 
resistance and demonstrated not to cause any other harms. Serious side effects were 
uncommon in this review. A prior systematic review into the safety of probiotics by Didari et 
al.44 focused on major side effects and identified bacterial sepsis, as the main issue in high-
risk groups such as the immune-compromised patient. Despite many patients in this review 
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taking systemic steroids and/or disease modifying anti-rheumatic diseases and being 
considered clinically immune compromised  higher risk of adverse events was not 
demonstrated. 
 
The risk of a minor adverse effect from each study, calculated taking an intention to treat 
approach, varied from 1 to 1.28 which indicates approximately the same number of events 
being reported by individuals in the control group as in the intervention group. 
 
Table 26 Side effects as categorised according to WHO85 
Classification Symptom severity Modification of treatment total probiotics Total 
control 
Grade 1 Asymptomatic or 
mild 




Grade 2 Moderate Minimal non-invasive intervention or 





Grade 3 Severe Requires hospitalisation and   disabling  0 0 
Grade 4 Life threatening Urgent intervention required 0 0 
Grade 5 death  0 0 
 
There was a trend that more studies reporting minor adverse effects concerned individual 
with SpA. Sub-population analysis did not reveal a statistically significant difference, but this 
trend is a new finding. It may represent an increased sensitivity of the gastrointestinal tract 
to administered probiotics in SpA conditions or better assessment and reporting of bowel 
related side effects in spondyloarthritis as opposed to rheumatoid arthritis. Consequently, 
number needed to treat (harm) concerning minor side effects was higher in the trials 
concerning SpA patients. 
 
There are many problems when attempting to include adverse events in meta-analysis, 
when the original trials concerned have not used these as a primary endpoint. Issues include 
incomplete reporting, inconsistent definitions and an unknown level of vigilance regarding 
adverse events.252  The number of trials with brief information or lacking a discussion of 
adverse events in this review provide a high index of suspicion of low vigilance.  
The wide variation in trial time spans for the studies in this review (from 7-365 days) may 
also be problematic if, as stated, that “the hazard of an adverse event is not constant over 
time… then percentages reported from trials with varying follow-up periods may  generate a 
misleading estimate of the adverse event”.252 (p.107) Whilst the failure to include zero events 
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in relative risk meta-analysis is common, the approach taken to avoid this pitfall in this 
thesis was to assign a very low numerical value to zero event trials equally to intervention 
and control arms. This allowed the software SUMARI (System for the Unified Management, 
Assessment and Review of Information) to calculate a forest plot for relative risk. It should 
be noted that there were significant population exclusions employed in all the included 
trials that may underestimate the true risk of probiotics being applied in the wider 
rheumatological population, for example almost all studies excluded individuals with renal 
or liver disease. An intention-to-treat concept including the sample numbers originally 
recruited  was used in this review , as whilst it does not reflect actual probiotic exposure, 
making it harder to attribute adverse events to  relevant underlying biological mechanisms 
an ‘as treated’ concept would have reduced randomization and small sample sizes even 
further.253   
 
Whilst serious adverse effects related to the ingestion of the probiotics intervention were 
not widely reported it should be noted that both genera have known antibiotic resistance, 
Lactobacillus, most notably, to vancomycin and Bifidobacterium, most notably, to mupirocin 
and both have the capacity to share this resistance in the gut.254  Commercial product 
screening for antibiotic resistance has occurred in some jurisdictions .255 Such safety 
screening is advised if larger scale trials be considered. The results of this review agree with 
recent research that “Harms reporting in published reports of randomised controlled trials 
assessing probiotics, prebiotics, and synbiotics is often lacking or inadequate” and hopes 
that by raising the profile of this issue in this review, future work can be improved.256 (p.240)  
Taking all these factors into account the results from this study may be interpreted as 
highlighting a potential subgroup (spondyloarthropathy) with a different adverse effects 
profile to RA, and that further exploration is warranted.  
 
4.3.3 Markers of systemic inflammation 
C-Reactive Protein  
Seven studies were included in the meta-analysis of effects of probiotics on C-reactive 
protein. Individual study results indicated a trend for probiotics to reduce C-reactive protein 
and, when combined in a meta-analysis, a statistically significant effect size is observed with 
low heterogeneity. This agrees with two recent systematic reviews and meta-analysis on the 
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effect of probiotics on C-reactive protein for rheumatoid arthritis.  Pan et al.202 included four 
studies on rheumatoid arthritis populations,  identifying a  statistically significant reduction 
in the levels of C-reactive protein (p= 0.007) and  Mohammed et al.204 also identified a  
statistically  significant reduction (p=0.001). 
 
Investigating SpA sub-populations did not reveal a benefit of probiotics on C-reactive 
protein levels, and there was high heterogeneity as shown by I2=83 indicating that meta-
analysis is not appropriate for these studies.  Whilst interpretation of these results from 
limited studies should be cautious it does suggest a differential response between RA and 
SpA to common probiotic formulations may exist. 
 
Sub-population analysis targeting different formulations of probiotics revealed a statistically 
significant benefit was only obtained by the mixture of probiotics (Lactobacillus and 
Bifidobacterium) compared to Lactobacillus alone. There is some research which may 
contribute a hypothesis for this finding. Lactobacillus rhamnosus GG has been shown to 
raise key elements in the inflammatory pathways, specifically  interleukin 10, also known as 
human cytokine synthesis inhibitory factor, when assessed in murine studies.257 This key 
regulatory cytokine is a complex player in innate and adaptive immunes responses. 
Interleukin 10 may be produced by many different types of cells and they can interact in 
feedforward and feedback pathways determining not only the volume of circulating 
cytokine but also what function it performs.  Research has suggested that all three 
elements, the feedback loops, the source and timing of secretion of interleukin 10 is  vital in 
determining an anti-inflammatory outcome and  long-term immune regulation.257,258  It is 
this complex and contradictory action of interleukin 10 that has made it hard to harness as a 
pharmaceutical intervention and the result of this study could suggest the interplay of other 
microbiota may also be a determining factor in the capacity of interleukin 10 to down 
regulate (not up regulate ) the inflammatory pathways. 
 
Caution interpreting the results of this systematic review on C-reactive protein are advised 
as the significance of changes may be conditional on the baseline from which the change 
occurs. When patients with baseline low levels of C-reactive protein are included ,such as in 
this review, it is difficult to estimate whether a small change in score remains more or less 
significant to the individual. It is also hard to evaluate the benefit of probiotics for patients 
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with low levels of systemic inflammatory markers, as this may not reflect the stages at 
which patients may consider using probiotics. There were no eligible studies which included 
patients with C-reactive protein in the moderate or high range at baseline. In fact, two of the 
included studies had baseline values within normal range, this was seen in the probiotic 
group in Hattaka et al.220 and control group of Shukla et al.225 Considering this low baseline, 
the author of this review suggests that a potential role exists for probiotics in maintaining 
remission via C-reactive protein maintenance, or reduction, as no evidence exists for 
probiotics roles in acute and high inflammatory C-reactive protein states. It is known that  
“remission rates, particularly off-therapy, remain low, and a long-term cure, or 
re-establishment of immune homeostasis, is elusive for all but a minority.”259(p.63) Therefore 
enabling patients who are in ‘off medication’ remission to access appropriate probiotic 
regimes could be an interesting and ethical approach to gauge the contribution of probiotics 
to long term suppression of inflammation and overall disease management. Significant 
variance exists in the definition of remission and estimates of successful remission between 
different conditions and across different age groups. As there are no current studies which 
have specifically investigated any role of probiotics in remission it remains a fertile area for 
further investigation.  
 
Cytokine profiles were not included in this review, for they are not yet core OMERACT 
outcome measures and a complete understanding of specific cytokines in inflammatory 
arthritis has not been achieved. There is appreciation that the method of profiling can exert 
considerable effect on outcomes, in research settings, and that their role as reliable 
biomarkers remains unclear due to the confounding effects of age and gender.104   Defining 
the exact nature of condition specific cytokine changes or pathological microbial signatures 
remains a work in progress.260   
 
Composite Disease activity Score DAS28 
Meta-analysis revealed a statistically significant effect of probiotics on disease activity score. 
However, as clinically significant reductions in this score when using C-reactive protein, are 
estimated at a drop of 1 point overall, the combined effects size did not reach clinical 
significance. This agrees with prior reviews as discussed in the introduction.206,208  Disease 
activity scores are calculated using a formula which weights the different individual 
elements. It is worth examining how each weighted element can affect the final score in 
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order to identify any factors that may have affected disease activity scores calculation for 
the studies within this review. Firstly, variation in wording within the patient general 
assessment component can create meaningful differences of up to 0.63 in final score, 
however as study populations included in this review had small changes in patient general 
assessment scores minimal impact of wording variations is expected.174 Secondly measures 
of systemic inflammation (such as C-reactive protein) are expressed as a log function, 
therefore small changes can provide a large change on the final composite score. As the 
studies included within this review generally displayed small changes from a low base of 
both C-reactive protein and tender joint scores, this could cause a proportionally higher 
impact on final score. It should be noted that some studies could not be incorporated into 
the meta-analysis because of a lack of raw data, but as these studies were included in the 
reviews by Pan et al. and Mohammed et al., it is unlikely to change the agreement between 
all three reviews.202,204 
Sub-population analysis of the available studies, with appropriate data, revealed that a 
combined formulation of Lactobacillus and Bifidobacterium created greater effect sizes  
than Lactobacillus alone. This is discussed further in section 4.5.1. 
 
4.4 Heterogeneity of included studies 
The inclusion and exclusion criteria for studies were pre-specified, as per the systematic 
review protocol. However, significant levels of heterogeneity remained in population 
demographics (for example age, disease duration, and applied exclusion criteria) and 
intervention (for example probiotic formulation, strength and dosage). These elements and 
their potential influence on the outcomes are discussed below. 
 
4.4.1 Confounding factors 
Condition 
Results indicate some condition specific responses, specifically the greater likelihood of 
adverse events and reduced anti-inflammatory capacity of probiotics as measured via 
reduction in C-reactive protein. As subclinical intestinal inflammation occurs in a significant 
number of patients living with SpA and “it has been demonstrated that up to 10% of those 
patients displaying chronic gut inflammation will develop over the time a clinically overt CD” 
this may  explains the differential findings between RA and SpA patients.247(p.2,) The 
98 
 
timelines for a transition from acute to chronic changes in the bowel have not been 
determined, but it would be logical to expect that the individual with longstanding disease 
duration may be more likely to experience such changes and therefore may also have  
altered interaction with probiotic formulations. Using biopsy specimens along the gut may 
create a more nuanced picture of dysbiosis for individuals with SpA however, as this 
invasive action is unjustified, this review would indicate that both patients and health 
professionals should be aware that individual with SpA taking probiotics may experience 




There is significant interpersonal variation in the microbiome, however  healthy young 
adults have been demonstrated to have a relatively stable personal composition of gut 
microbiota.261-263 in comparison older adults (over 65) have more interpersonal microbiota 
variability, lower overall levels of diversity and recognised to experience 
’immunoscenescence’. This is when the immune system is compromised leading to a 
chronic low grade inflammatory state.264  Studies have shown that elderly patients often 
specifically lack Bifidobacterium species and that supplementation with these can increase 
the size and diversity of Bifidobacterium populations.265 Therefore studies that include a 
greater proportion of older patients may show a different response to formulations with 
Bifidobacterium. Interestingly the two studies with the oldest age populations, Mandel et 
al.223  average age 62.9 yrs. and Pineda et al.224 , average age of 63.8 years only supplied  
Lactobacillus formulations.   
 
Only one study involved patients under the aged of 16.225  Studies have indicated that the 
juvenile arthritis microbiome similarly shows a relative lack of the family of firmicutes 
bacteria (including, but not limited to Bifidobacterium).266 The study included in this review 
provided a variety of Firmicutes species in a mixture known as VSL#3 . VSL#3 is a high-
concentrated probiotic of eight different bacterium that has demonstrated efficacy in the 
control of inflammation in other conditions, for example extending the remission in 
inflammatory bowel disease249. Future results will be interesting and large international 





Inflammatory arthritis has a long prodromal period, and the earlier that diagnosis and 
intervention can occur, the better the likelihood of disease remission and symptom 
reduction.268 This has led to the concept of a ‘window’ of opportunity for intervention, in 
the first three years post diagnosis.  All study populations had a mean duration of greater 
than three years, indicating established disease status beyond the window of intervention. 
Three studies included participants with a mean disease duration of greater than ten years. 
Therefore longstanding changes in multiple systems, including but not limited to structural 
joint damage and changes in central processing of pain may be expected. Research in RA has 
discovered that both the type of cytokines involved in generating auto immune dysfunction 
in early RA and their mechanism of action seem to be different from those that are involved 
in persistence of the disease long term.259 Synovitis established for more than six months is 
harder ro resolve and supports the theory of a switch from cytokines initiated from gut 
immunity challenges to cytokines created from fibroblasts in and around the joints. 
Consequently, it may be hypothesised that probiotics have a different capacity to influence 
established auto immune disease. 
 
Relatively little is known about when Australian patients access complementary treatment 
in their arthritis journey. A study into the complementary therapy use of American patients 
with RA discovered that therapies were frequently used in the early stages of disease 
alongside conventional treatments.269 However this is contrary to the disease period in 
which clinical trials of probiotics have been conducted. The average disease duration was 
significantly longer in the studies of patients with SpA than compared to  RA. This is 
significant as early use of anti‐TNF treatment in peripheral spondyloarthritis (pSpA) has 
demonstrated  more than 50% of patients  can achieve sustained drug-free clinical 
remission  and suggests that later disease is marked by loss of tolerance, epigenetic 
modifications, or irreparably impaired immunoregulatory pathways.270   
 
In summary, the current research is conducted mainly on patients with extended disease 
duration, missing the window of opportunity for immunological change via the gut and  





Four studies excluded individuals on any type of formal ‘diet’ but only two excluded 
individuals with a body mass index that placed them in the morbidly obese category (score 
>40). Therefore, by default, overweight or obese individuals were included within all 
studies. Conflicting results surround the influence of obesity on the microbial community, 
but it has been characterised as showing reduced diversity and altered 
Firmicutes:Bacteroides ratio.271,272  Zmora et al.273 have reviewed the role of obesity in the 
pathogenesis of RA and identified that body mass index becomes significantly associated 
with inflammatory markers and is relevant to the  inflammatory state as the disease 
progresses. Therefore including patients with a long disease duration and obese status adds 
another confounding factor to the included studies. 
 
Whilst meta-analysis has shown probiotic administration can provide a small effect size for 
weight loss in otherwise healthy individuals, the question of how an individuals body mass 
index may affect probiotic intake has not been so thoroughly examined274.  Relationships 
between obesity and inflammation, are yet to be fully clarified but the evidence of a 
persistent, low-grade, inflammatory response in overweight and obese individuals may 
suggest sub population specific responses to probiotic intervention dependant on their 
baseline weight. Whilst this review did not find any relevant probiotic studies applied to 
patients with psoriatic arthritis there is a known relationship whereby obese people with 
psoritaic arthritis are 48% less likely than their normal-weight counterparts to reach, after a 
year, a point of ‘minimal disease activity’, and the heavier the individual the less likely they 
were to respond to pharmaceutical management.275  Therefore the affects of probiotics for  
patients of different body weights with inflammatory arthritis cannot be presumed. Recent 
surveys from the United Kingdom have identified that the most significant change in 
individuals presenting with RA is the comorbid burden of obesity, with obesity prevalence in 
newly diagnosed individuals rising from 13.3% in 1990 to 33.6% in 2010.276 Therefore 
considering the affect of obesiogenic inflammation will become an increasing priority for 
clinicians and future probiotic trials should better account for body mass index. 
Diet 
Research indicates that dietary influence can be an even greater influence on the gut 
microbiome than body mass index,  in RA.277  Higher levels of Bacteroidetes phylum are 
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associated with a highly processed food diet, higher levels of firmicutes are associated with 
a greater fresh food intake and high longterm carbohydrate intake is associated with 
prevotella bacteria.273,277  The impact of different culture and diet therefore may be a 
confounding factor when assessing probiotic intervention. The studies within  this review 
came from different socio economic and cultural regions see Figure 26,  therefore 
heterogenous  dietary patterns are likely 
 
Study Country 
Alipour et al218   Iran 
Brophy et al UK 
Hatakka et al220 Finland 
Jenks et al221 New Zealand 
Lee et al222 New Zealand 
Mandel et al223 New Zealand 
Pineda Mde L et al224 Canada 
Shukla et al 225 India 
Tomasello et al 226 Italy 
Zamani et al228 Iran 
Zamani et al229 Iran 
 
Figure 25 Geographic location of studies incorporated within the review, with marked numbers of studies per location. 
 
In conclusion tighter demographic control or capacity for sub-population analysis is required 
to pull out the confounding factors of diet and body weight. As simple food-frequency 
questionnaires, strongly associate with core microbiome status, future studies may reduce 
the confounding factors of diet by incorporating their use.278 
 
Concurrent Medications 
Probiotics were supplied as adjunct medications in all the included studies. Gut commensal 
bacteria actively participate in the metabolism of many chemical compounds, thereby 
potentially impacting drug availability, levels, and toxicity.  Conversely medications, may 
impact upon the presence, function and viability of gut microbiota. The most commonly 





Non-steroidal anti-inflammatories  were stated as available for participants  in the majority 
of studies, and  formally excluded in two studies.227,236  Non-steroidal anti-inflammatories 
can reduce symptoms of joint pain and swelling and their use may confound overall 
outcomes. Only Brophy et al.219  identified statistically different percentages of this 
medication use at baseline between groups ,with 85% of  probiotic intervention group and 
in 65% of the control group using non-steroidal anti-inflammatories. Murine research has 
identified that probiotics can have a complex relationship with non-steroidal anti-
inflammatories.279 Dependant on the diversity and ratios of bacteria present, the microbiota 
can ameliorate the adverse enteropathic affects associated with this medications use, but 
can also alter drug metabolism such that  medication efficacy is also changed.280,281 Where 
Non-steroidal anti-inflammatories usage was employed as a formal outcome measure, no 
reduction in the usage or difference between control and intervention was observed.225 The 
lack of personalised microbial analysis within the sample populations of the included studies 
precludes the ability to understand how all these complex links may have changed study 
outcomes.  However, the possible confounding influences should be acknowledged in 
studies where recent antibiotic use and current non-steroidal anti-inflammatories use is 
occuring.   
 
Antibiotics. It is generally accepted that the short term effect of antibiotics is a significant 
loss of microbial diversity and  16S rRNA gene sequencing techniques have shown that 
broad-spectrum antibiotics also change  the bacteroidetes:firmicutes ratio.282 Greater detail 
is provided in a recent review by Mikkelsen et al.283  Therefore, it is relevant that five of the 
studies included in this review did not state recent use of antibiotics as an exclusion criteria 
and this may be a confounding factor. 
 
Steroids. Participants taking oral corticosteroids were excluded in the study by Shukla et 
al.225 not  stated in four and as allowed in the other studies. Corticosteroid medications are 
anti-inflammatory immune suppressants and  as such can reduce the symptoms associated 
with Inflammatory arthritis. They are quick acting and could be a confounding factor in the 
change in symptoms noted over the course of the trial however it was stipulated that 
medication use should be stable and there was no statistical significant difference in 
precentages taken between control and intervention groups. 
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Intra-articular steroids can provide rapid relief of discrete joint pain and swelling. These 
were only stated as allowed in two studies,  Jenks et al.221 and Hatakka et al.220 Double the 
number of  participants in the probiotic group received steroid injections in Jenks et al.221 
compared to the control group raising the likelihood of this being a confounding factor.  
 
Disease modifying anti rheumatic drugs (DMARDS) Traditional diseae modifying ant 
rheuamtic medications, which include methotrexate, leflunomide, hydroxychloroquine, and 
sulfasalazine reduce the immune responses that contribute to pain and inflammation in a 
broad manner. Several known mechanisms exist by which the intestinal microbiota can 
either directly, or indirectly, change the bioavailability and/or efficacy of such drugs. It is 
known that there is considerable  individual variation in response to drug treatments, for 
example,  methotrexate has highly variable response rates suggested to relate to gut 
microbiota.282 As methotrexate, as similar medications,were allowed in eight of the included 
studies it may be considered a confounding factor. The study by Lee et al.222  looked 
specifically at the effect of probiotics upon patients taking the anti-rheumatic medication 
Sulfasalazine, which requires specific intestinal microbiota to convert it in to its active form 
in animal studies.284  Short-term treatment of RA patients with a multi-strain probiotic was 
not found to statistically  influence Sulfasalazine in this study although the authors 
identified a large interpersonal variation in drug metabolism at baseline which would 
obscure any small effects from this short study.222 
 
In conclusion heterogenity of concurrent medications and paucity of considerations of their 
affect on the micorbiome and ingested probiotics is a limiting factor in this review.There 
were no studies in which the newer generation biological or small molecule diseae 
modifying anot-rheumatic medications were  taken alongside probiotics, therefore the 
findings of this review with regards to tolerability, safety and efficacy of probiotics cannot 
be generalised to individuals on these next generation medications. 
 
Duration of intervention  
The median duration of delivery of probiotic interventions was 84 days. Little is known 
about the required duration for probiotics in rheumatology or the persistence of any effects 
when their administration is ceased. Studies from other areas of investigation can provide 
some guidance. Murine studies have indicated that the protective effects of probiotics 
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against non-steroidal anti-inflammatories enteropathy require a minimum of a weeks 
duration of probiotic supply prior to medication use.285  The optimal duration of supply is 
likely to depend upon the mechanism of effect. If proposing that probiotics are only working 
through competitive exclusion of more pathogenic or pro inflammatory bacteria, this 
presupposes that mucosal attachment, long term persistence and colonisation within the 
relevant part of the gastrointestinal tract is required to maintain the benefit. Considering 
that individual probiotics may have limited persistence in the gut then ongoing ingestion 
would be required to maintain benefits. Persistence studies have been carried out for 
specific strains of Lactobacillus and Bifidobacterium, and demonstrated diverse resistance to 
bile, antbiotics, and variable adhesive properties.243 The combined properties of multi-
species probiotics have not been as fully investigated but it may be that broader range 
formulations have a potential for more diverse range of persistence and adhesive qualities 
of the probiotics included.286 It should be noted that faecal recovery studies have been 
traditionally used to assess probiotic survival and persistence.  
 
Alternatively if immune modulation, through the innate and acquired immune system, are 
the primary mechamisms it remains possible that, similar to disease modifying anti 
rheumatic medications, long term benefit can be achieved with a correctly timed 
intervention and that benefits may be maintained without ongoing administration. 
 
When considering the alternative hypothesis, it is unfortunate that the studies in this review 
are not well placed to inform knowledge on persistence, due to the variation in probiotic 
intervention timelines and because just one study, Lee et al.222,  provided re analysis of 
outcomes after a three week wash out period. The results of Lee et al.222 indicated no 
change after intervention or wash out in faecal species which may be interpreted in various 
ways. It may indicate an intrinsically stable intestinal microbiota, or insufficient probiotic 
formulations or instability of the faecal analysis to identify probiotic effect. A recent study 
by Zmora et al.287  informs this discussion, as it supplied eleven bacterial species and all 
dropped to insignificant faecal levels after cessation of supplementation yet submucosal 
samples showed nine of the eleven had enriched the mucosal layers. The study reported 
that ‘permissive’ host microbiome features (for example HLAB27) could be used to estimate 
individual host susceptibility to probiotics modification but that invasive mucosal sampling is 
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the most accurate method of determining probiotic persistence. Therefore this review 
recommends that future studies  work to identify further characteristics of permissive 




Concentration The definition of probiotics states that organisms should be supplied in an 
adequate number to provide health benefits. The exact concentration required, however 
remains under debate.  It has been estimated to be somewhere between 107 and 109.288 A 
clear dose dependant relationship has not been demonstrated for probiotics. Establishing 
suitable concentrations for multi strain formulations has been even less investigated than 
for single strain formulations, however a study concerning a four strain probiotic by 
Taverniti et al.289 reported that the higher concentration 70 billion dose, compared to seven  
billion dose,  did result in earlier, larger and longer durations of viable bacteria being found 
using faecal monitoring. This suggests that a healthier number of bacteria surviving the 
stomach and entering the intestines will provide higher benefits to the individual. However, 
using faecal bacterial load may be misrepresentative of the microbe’s ability to deliver 
health benefits, as bacteria may be transient passengers in the gut lumen with greater 
faecal shed relating only to higher ingestion rates, not to replication, persistence or 
immunomodulation. Historically work has focused on determining probiotic concentrations 
required to survive stomach and intestinal passage, as opposed to concentrations required 
to ensure optimal mucosal contact and immunomodulation. Significant differences in the 
concentration of probiotic formula, as measured by colony forming units, were found across 
the included studies. Interestingly, murine studies into the optimal therapeutic dosage of 
Lactobacillus acidophilus for ileal colitis identified 106 as providing better outcomes than 
stronger 108 dosages.290 Therefore it cannot be assumed that higher concentrations will 
provide higher benefits. Recent research by Zmora et al.287 has identified a significant 
inverse correlation between initial levels of a given probiotics species in a specific area of 
the  gastrointestinal tract and its fold change. That means that low abundant species were 
more likely to expand than those already present in high loads. This may indicate a loading 
ceiling of capacity in the mucosal fold beyond which further probiotic supplementation will 
not change the composition, and therefore reinforces the concept that higher 
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concentrations may not always yield greater benefits. A probiotics monograph for industry 
stakeholders in the food industry, developed by Health Canada, lists a variety of 
recommended dosages for different species from 1x 107 to 3 x 108 in food.88 However, the 
stipulation of specific concentrations for multi-species probiotic has not been established 
for healthy individuals or individuals with inflammatory arthritis. Therefore, it is hard to 
interpret the significance of the varying concentrations used within this review or provide 
practical guidance for a recommended concentration, in colony forming units, to clinicians 
or patients. 
 
Viability The presence of live specific probiotic species and viability of these organisms in a 
given probiotic product is affected by many possible elements within the manufacturing 
process and thereafter during storage by the consumer.291 Only  the studies by Shukla et 
al.225  and Brophy et al.219 provided consumer instructions for refridgeration and product 
care, however there was no verification of this or checks made on the ongoing viability of 
the products they were supplied. Changes in viability to probiotics, due to failure of 
appropriate storage at multiple stages of the supply chain, and lack of verification of viability 
is a considerable source of error. 
 
Species Verification There was no stated verification of  the probiotic products supplied in 
the papers, except where the name of the commercial product was supplied. The integrity 
of commercial probiotic products cannot be assumed. Verification of commercial products 
by Goldstein et al.292 identified that most products were correctly labelled however a larger 
review revealed a significant disparity in both content and concentration with up to a third 
of products containing insufficient viable cells to obtain any health benefit.293,294  Lewis et 
al.295 investigated  16 commercial  Bifidobacterium products and found frequent differences 
between label and content which included misclassification of species, inclusion of 
additional species, variation in species between product batches and even within capsules 
within batches. 
 
Classification Bacterial classification remains complex and changeable as discussed 
previously in chapter 1.  This shifting taxonomy of probiotics creates unintentional 
disparities, for example, as identified by Mill et al.296  the strain of Bifidobacterium infantis in 
the product VSL#3 has been more recently been reclassified to Bifidobcaterium lactis.296 A 
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further example, within Tomasello et al.226 identified the probiotic as Saccharomyces 
boulardii. Modern Srna technology has recently reclassified  Saccharomyces boulardii as  a 
variant of Saccharomyces cerevisiae.297 It is recognised that accurate and proper 
nomenclature and strain specification is desirable for safety, repeatability and reliability but 
as detail was lacking in many studies a pragmatic approach of of investigating the the two 
main genera of probiotics was applied. It is recommended that future studies should be 
better designed to provide accurate detail on strains and therefore their proven 
mechanisms of action. 
 
Availability for consumers Two commercial products were used within some studies in the 
review, VSL#3 made by Actial Farmaceutica and a BLIS technologies oral tablet. Only the 
VSL#3 remains available as BLIS have moved in to the development and marketing of oral 
probiotic prducts (lozenges, mouthwash and toothpaste) specifically for the paediatric 
market. The literature on the oral BLIS products was not included in this review as it was 
targeted to the prevention of Streptococcus throat infections, otitis and halitosis and did 
not target individuals with any forms of inflammatory arthritis.298,299 However individuals 
with inflammatory arthritis display higher levels of  periodontal disease there is 
considerable scope for further investigation of oral probiotic products in rheumatology 
patients.300,301 
 
4.5 Study limitations 
4.5.1 Strain specific mechanisms of action 
Systematic reviews of probiotics face unique issues, as studies often utitlise a combination 
of probiotic formulations, in the absence of a rigorous evidence base for the underlying 
mechanisms of action of any given single component.210  This may create heterogenous 
interventions inappropiate for systematic review or meta-analysis. Experts in the field have 
expressed the opinion that combining results on multi probiotic blends can occur if any of 
the following criteria are established: evidence that outlines some similarity in the blends 
mechanisms of action,   a common physiological effect previously proven by at least one 
human study of quality,  recognition of common structural basis, common secreted 
products or the capacity to grouped into logical subsets, including by genera.210 (p. 5) 
Prior systematic reviews in this areas have largely avoided the consideration of  limitations 
related to the content of the probiotic formula. This thesis has taken a pragmatic approach 
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based on the evidence for shared mechanisms and differences that may be relevant to the 
two broad genera of Lactobacillus and Bifidobacterium as outlined by Sanders et al. 64 
Whilst they are taxonomically distinct groups, with the genus Lactobacillus  sitting in the 
phylum Firmicutes and the genus Bifidobacterium in the phylum Actinobacteria they are 
both non-spore-forming, gram-positive, bacteria. Both genera are mucin binding bacteria 
which provides a shared capacity for them to attach to the mucosal lining of the gut, provide 
competitive exclusion to other pathogenic bacteria  and interact with the host immune 
system, as opposed to being transitory members of the microbial community in the gut 
lumen.  However, again they differ in the manner of this attachment with Lactobacillus 
displaying specific surface layer adhesion proteins that tend to create specific 
immunomodulatory affects. Both genera can stimulate the synthesis of key cytokines in the 
inflammatory pathway however usually via different mechanisms as they differ in the end 
product of their metabolic process which is lactic acid  for Lactobacilllus  and short chain 
fatty acids (SCFA) via a process known as the bif shunt for Bifidobacterium.302  The resulting  
SCFA  end products, affect synthesis of specific inflammatory cytokines, including inhibiting 
the  synthesis of  pro-inflammatory cytokines as well as promoting the production of the 
regulatory cytokine interleukin 10, as summarised in the review by Vlasova et al 2016.303 
Comparative genomic analysis has identified that the  Bif Shunt pathway is shared across all 
species of Bifidobacterium, providing a rationale for grouping Bifidobacterium in 
subpopulation analysis. 
 
Both genera of probiotics have been found to generate beneficial substances for humans 
such as vitamin B12 and folate, essential substances for mental health and wellbeing.81 
Studies suggest that low folate and low vitamin B12 are found in depressed patients, and 
there is “an association between depression and low levels of these two vitamins in studies 
of the general population”.304(p.59),305 Supplementation of B12 and folate has been suggested 
to combat this deficiency, therefore providing probiotics capable of generating these 
substances in vitro may provide similar benefits in elevating mood, reducing anxiety and 
alleviating depression. This provides a rationale for grouping genera together when 




The author of this review believes that the conditions for undertaking a systeamtic review 
are met due to identified shared mechanisms identified. Sanders et al.64 recommend that 
where substantial differences are seen in study effects, specifically  when study effects are 
shown in opposing directions,  then sub grouping logically by the nature of the probiotic 
supplied should be considered. The author of this review considers that the conditions for 
meta-analysis specifically regarding the creation of logical subsets have been met  and were 
justifified given that many outcomes  displayed substantial differences in effect size and 
direction across included studies.  
 
Whilst the  limitations imposed by the hetereogenity and mixed mechanism of probiotic 
formulations may reduce confidence in findings from this review, the author believes that 
investigating probiotics with some leeway to account for mechanisms of action is currently 
justified given the volume and frequency of usage by patients and emerging knowledge 
base on mecahnisms of action. Whilst the combined interaction of multi strain and multi 
species probiotic products is not yet understood and may be critiqued for adding extra 
complexity into the known mechanisms of action,  there is also an opinion that providing  
mixtures of probiotics maximises the different unique properties from each strain and 
provides a greater range of benefits to the individual.    
 
4.5.2 Drop out  
Drop out rates above average and evidence of differential attrition between experimental 
and control groups were identified in some studies. Whether differential or equal, 
identifying the rationale behind drop out remains vital when considering bias. For example 
Alipour et al.218  counted patients as ‘drop out ‘when excluded for not precisely following 
the protocol, which would be an example of missing in a non-random fashion, that may 
potentially affect outcome and be a source of bias.  Alternatively, Brophy et al.219 included 
‘drop out’ that occurred early, prior to starting the intervention, for example, due to 
individuals moving overseas. This can be described as missing completely at random, as 
systematic differences between such drop outs and the patients who remained in the study 
are unlikely.306 When using this taxonomy of missingness five of the included studies 
included drop outs  missing in a non-random fashion, two as a mixture and only one as 
purely missing completely at random. Therefore, despite the overall equality in attrition, the 
potential for bias remains.  
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4.5.3 Adherence and compliance 
Adherence rates across the studies varied substantially. Judging adherence and compliance 
can be complex. Only the internet based study by Brophy et al.219 replied purely on self 
report. Tablet count was used by the majority of studies, but this remains open to patient 
based manipulation. Two studies used faecal count as a surrogate marker for probiotic 
adherence. The study by Hattaka et al.220 identified an increase of Lactobacillus group 
bacteria in the intervention group from 25% at baseline to 83% post intervention, whereas 
the control group dropped from 23% to zero. The study by Lee et al.222 did not identify 
faecal Bifidobacterium lactis after intervention. Traditional interpretation of these results 
may indicate that Bifidobacterium lactis did not survive passage, or colonised the gut. This 
may lead to an assumption that the patient would only benefit from those bateria found in 
faecal analysis. Recent research has suggested interpretation errors if relying on faecal 
analysis.287 By comparing faecal count to lumen bacterial levels and intestinal biopsy  Zmora 
et al.287 confirmed that  gut mucosal microbiome only partially correlates with stool as 
humans exhibit very specific patterns of ‘permission’or ‘resistance’ to probiotic 
colonisation.287 The authors concluded that faecal presence cannot determine if faecal 
presence of bacteria represents active colonisation or a passive ‘wash out’ of luminal 
bacterial contents. This may explain why systematic reviews have disagreed on the 
alteration in fecal microbiome. If it is only species bound in the mucosal layers and 
interacting closely with the epithelial surface that can engage in active immunomodulation 
then only  gut  biopsies can provide acurate microbiotia information and identify patient 
adherence to intervention.287  
 
In conclusion, significant heterogeneity of the studies involved in this review provide 
numerous limitations regarding the population with respect to gender, condition, age and  
disease duration and heterogenity regarding the intervention with respect to probiotic 
dosage, formulation and application. Study probiotics were administered across a wide 
variety of time frames and in conjunction with a variety of medications. Sample sizes across 
the included studies were generally small, and therefore determining the clinical meaning of 
outcome measures that have not been validated for use in these patient groups is difficult, 
for example the use of the visual analogue scale for irritable bowel syndrome which has not 
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been validated in rheumatology patients.  Lastly, there remains resonable doubt about the 
probiotic formulations supplied due to the lack of product batch verification. 
 
4.6 Limitations of the review process 
Only studies in English were included in this review, which introduces a potential source of 
bias and the risk of invalid conclusions should important studies be excluded. However as 
seen from Figure 26 included studies were undertaken across a range of English and non 
English speaking countries. Whilst all quality appraisal was undertaken by two reviewers and 
utilised a third when necessary to resolve differences, the initial study screening for 
inclusion and exclusion was undertaken by a sole reviewer, and the final data extraction was 
undertaken by a sole reviewer introducing the risk of human based error. The most 
significant limiting factor for this study was the variation in data and the presence of 
missing/ incomplete data that was unable to be obtained  despite requests to authors. 
 
4.6.1 Sources of Bias 
Publication bias is present when research is published that does not represent the total 
body of research conducted. Funnel plots may be used to help identify potential publication 
bias. As a funnel plot is used for 10 or more studies, it was not possible to generate one for 
this review but the suspiscion exists that studies with negative outcomes were not accepted 
for publication. As the majrity of studies in this review reported positive or neutral 
conclusions despite small populations samples and  questions over the clinical relevance of 
changes found.  It is important to note that inspection and analysis of funnel plots should 
not be the only method of identifying publication and reporting bias. By following the clear 
JBI systematic review process this review has minimised the likelihood of bias by thoroughly 
and systematically searching available information sources.307 The source of funding for 
publications may also introduce bias.  Two  studies using commercially available 
preparations acknowledged funding from the companies associated with the products. It  is 
recognised that industry funded research can increase pressure for favourable reporting of 
outcomes.  However the likelihood of funding bias applying to probiotic research for acute 




4.7 Looking forward 
4.7.1 The future of probiotics 
As the knowledge base underlying microbial interactions grows, there is the development of 
next generation ‘bioengineered’ probiotics which can be tailored create more precise, 
consistent and desired effect on the human immune system. For example, genetically  
engineered Lactococcus lactis strains have been designed to secrete the anti inflammatory 
cytkine interleukin-35, and have been shown to effectively reduce the incidence and disease 
severity of collagen induced arthritis in mice.309  Much research remains at an early stage, in 
murine trials and benefits identified in animal studies are not always replicated in human 
trials.310  However, it does provide the possibility of more targeted approaches for probiotics 
in the future. Whilst essential research is ongoing, members of the public continue to use 
the many commercially available brands of probiotics, in 2015 McFarland et al.51 identified  
>100 different probiotic products available globally. Therefore, clinicians still require the 
capacity to discuss the general benefits and harms of current products  in a transparent 
manner with their patients 
 
4.7.2 Key features for future work on probiotics in IA. 
Secondary research, the analysis of existing data, may no longer be appropriate as it has 
been conducted several times and the existing literature has  too many limitations to yield 
further findings.  Given the rate of development of new knowledge regarding specific 
strains, new technology to interpret the gut microbiome and new insights into individual 
microbial determinants further rigorous primary research  to creating better data is the 
suggested course of action. There remain many recommendations for primary research 
which would aim to address the limitations of the current body of evidence by: 
1. Addressing sample populations that carefully address population based confounding 
factors such as age, gender, disease duration,diet and body weight.   
2. Investigating the ethical application of probiotics at specific windows of opportunity for 
reducing  inflammation. This may be targeting individuals ‘at risk’ of inflammatory arthritis  
or investigating the role, if any, of probiotics in maintaining  remission. 
2.Employing patient stratification according to new information on permissive phenotypes 




3.Examining emotional and cognitive affects of probiotic consumption in rheumatology  
patients in order to  clarify the mechanisms of effect upon quality of life and pain.   
4.Repeating studies using rigorously identified probiotics species in order to identify any 
dose dependant responses and to allow stratification of patients by treatment 
responsiveness and susceptibility to adverse effects. 
5. Employing validation and verification of probiotic products at multiple stages of the 
clinical trial through product batch and lot testing. This may be recommeded to include 
screening for antibiotic resistant genes. 
6. Broadening research to include the application of probiotics to oral mucosal surfaces as 
oral mucosa are more accessible for sampling and intervention. 
 
It has been suggested that probiotic research is fundamentally unsuited to an randomised 
controlled trial approach, because this pre supposes population uniformity and intervention 
homogeneity which, as we learn more about the interaction of  genetics, lifestyle, diet and 
medications becomes more difficult to control through clinical trial exclusion criteria. 
Therefore, appropriate primary research may not be large scale randomised control trials 
but targeted small scale experimental trials which aim to match personal microbiomes and 
dysbiosis to specifically bioengineered formulations. Whilst the core OMERACT domains 
include the development of economic studies, robust evidence of the clinical benefit of the 
intervention is required before proceeding to cost benefit analysis therefore this has not 
been included as a key research recommendation. 
 
4.8 Implications for clinical practice 
There have been five systematic reviews now conducted investigating  the outcome of 
probiotic supplementation for individuals with rheumatological conditions. Determining 
what level of evidence is sufficient to support the use, promotion or even discussion of 
supplements such as probiotics which are not subject to the same level of rigour in trials 
compared to  medications continues to be debated. Knowledge continues to evolve and this 
will shape the strength of recommendations possible. Current international collaborations 
are expanding the metagenomics database for the gastrointestinal tract. This will aid the 
precision and accuracy of metagenomic analyses that are required to understand the 
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marked difference in personal microbiome and facilitate the development of personalised 
and predictive medicine. In the future, the individual microbiome signature for patients may  
be matched to probiotic regimes facilitating specific and predictable outcomes for bacterial 
mechanisms of action.  This may then enable targeted mechanistic research and shorter 
translation pipelines back to clinical practise than the isolated study of every possible 
probiotics strain and every condition. 
 
Despite the potential of further breakthroughs in microbiome understanding and patient 
stratification,  the author of this thesis would still suggest that the results of this systematic 
review can be applied to inform patient clinician interactions and communication about the 
current use of probiotics in rheumatology in plain English as follows: 
Current research has mainly been undertaken on older individuals, with low markers of 
inflammation and longstanding RA.  Few studies have focused on SpA. Probiotics appear 
safe for this type of patient, when taken alongside most traditional medications but this has 
not been demonstrated alongside the newer biological DMARDS.  The specific formulations, 
doses or durations of probiotics cannot yet be specified, and minor side effects can still 
occur. The studies found some small benefits that improved quality of life, reduced pain 
(specifically for formulations of lactobacillus for reducing pain) and lowered/maintained 
inflammation (specifically for mixed formulations). These small benefits may not be clinically 
meaningful and do not justify the use of probiotics as sole interventions for IA. In summary, 
there is little robust evidence to support their use for managing RA and SpA,  but if you 
choose to consider probiotics they should be discussed with your specialist to prevent any 
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Appendix Ib Modified version of JBI Critical appraisal tool for randomised control trials 
 
Study:        
1. Was true randomisation used for assignment of participants to treatment groups? 
Yes Method by which randomisation to intervention or control group described eg random 
allocation using number generator, stratified block randomisation scheme 
No Method other than randomisation used to allocate patients to groups (quasi 
randomisation/stratification) 
Unclear Terms like ‘random’ and ‘randomisation’ used but method not described 
              Comment/detail: ____________________________________________________________________ 
 
2. Was allocation to treatment groups concealed? 
Yes The researcher responsible for allocating participants to compared groups is unaware of 
the allocation order. An appropriate allocation concealment method was used, such as 
central randomisation; sequentially numbered opaque sealed envelopes used? 
No Person responsible for allocation to groups able to determine which group the participant 
was being allocated.  
Unclear Unable to determine how allocation to treatment groups occurred.  
Comment:  _____________________________________________________________________ 
 
3. Were treatment groups similar at the baseline? 
Yes Recorded minimum base line data including: 
- Age 
- Gender ratio 
- Duration of disease ( time since diagnosis) 
- Severity of disease ( i.e. mild, moderate or severe) 
- Baseline measurements for individual intended measurable outcomes 
Additional information can include 
- Weight 
- diet 
- concurrent medication use ( i.e. oral steroids , intra artic steroids, NSAIDS or 
DMARDS) 
- Genetic or serum disease markers ( HLAB27, Rheumatoid factor,  ACCP ore 
presence of enthesitis) 
No Baseline data between groups is clearly not comparable (statistical differences between 
groups at baseline that may affect the outcome of results eg differences in sex, age, SES 
on effectiveness of intervention/uptake)  
Unclear Inadequately described. No or minimal reporting of baseline data i.e. only age, sex. No 




4. Were participants blind to treatment assignment? 
Yes Participants unaware that they have been allocated to either intervention or control group 
and methods for ensuring participant blinding to treatment assignment indicated.  
*(provision of placebo pills in same format  is necessary to ensure blinding) 
No Participants aware of which group they have been allocated 
Unclear Inadequately described 
Comment: _____________________________________________________________________ 
 
5. Were those delivering the treatment blind to treatment assignment? 
Yes Doctors/nurses/health workers implementing the intervention are unaware if they are 
providing intervention to control or intervention/treatment group 
135 
 
No Doctors/nurses/health workers implementing the intervention are aware they are 
providing the intervention to the treatment group 
Provide explanation  for lack of blinding 
Unclear Inadequately described 
Comment: _____________________________________________________________________ 
 
6. Were outcomes assessors blind to treatment assignment? 
Yes Data collectors were blinded for outcomes assessment (eg conducting interview) 
No Data collectors were aware of the group in which the participant belonged  
Unclear Inadequately described 
Comment: _____________________________________________________________________ 
 
7. Were treatment groups treated identically other than the intervention of interest? 
Yes Participants in both the intervention and control groups were treated identically for all 
other aspects other than intervention of interest , eg access to ongoing medication as 
required, exercise and usual diet. 
 
Study includes active control group. Any intervention provided to control group described 
in detail, e.g. control group received daily placebo tablet if the intervention received daily 
probiotic tablet 
No Wait listed control groups where control intervention not provided, or intervention 
provided clearly not matched for attention, giving control participants an indication that 
they may be in the control group. 
Participants receiving concurrent intervention outside intervention of interest that may 
impact on results, eg allowed to take other supplements, to use antibiotics or start 
medication such as Biological class DMARDS 
Unclear Control intervention inadequately described 
Comment: _____________________________________________________________________ 
 
8. Was follow up complete and if not, were differences between groups in terms of their follow up 
adequately described and analysed? 
Yes Complete follow up 
Withdrawn participants/losses to follow up reported and reasons for the withdrawal 
described.  
All participants included in final calculations including withdrawn participants, regardless 
of whether their final outcomes were measured.  
No No explanation of withdrawn participants/losses to follow up, or the significance of these 
withdrawals.  
Withdrawn participants not analysed in the groups to which they were allocated 
Unclear Withdrawn participants inadequately described 
Numbers of included/withdrawn participants do not match result figures, inadequately 
described 
Comment:  _____________________________________________________________________ 
9. Were participants analysed in the groups to which they were randomised? 
Yes Withdrawn participants analysed in the groups to which they were originally allocated 
(Intention to treat analysis, ITT) 
No Missing participant data not reported or accounted for 
Unclear Inadequately described 
              Comment: _____________________________________________________________________ 
 
10. Were outcomes measured in the same way for treatment groups? 
Yes Outcome data was measured and collected consistently in all groups 
No Outcome data was measured and collected differently for each group 
Unclear Inadequately described 




11. Were outcomes measured in a reliable way? 
Yes Outcomes (Pain, serum markers of inflammation such as CRP or ESR, clinical outcomes 
such as DAS28 or immunological markers) measured using standardised methods 
- Authors identify tool adequately- for example Composite scores may be 
created with ESR or CRP values – have they identified which were used? 
- Authors state the reliability and or validity of the measures used (incl 
appropriately trained clinical data collectors) or piloted within the trial. 
- Demonstrates/indicates test-retest reliability ( for example Global scores 
undertaken by the clinician alone have very poor inter-rater reliability ) 
- Are clear about when subjective measures such as pain ( VAS) are being 
assessed ( as a point measurement at a single clinical visit? Or by recall for a 
past period) 
No Self-reported/subjective outcomes, reliant on participant recall  
- VAS over past days/week or months 
- Patient self-report of compliance with taking the probiotic/placebo tablets 
No reporting on the reliability and or validity of the methods used  
No indication of outcomes tools being employed by individuals trained in their use. 
Unclear Inadequately described 
               Comment: ____________________________________________________________________ 
 
12. Was appropriate statistical analysis used? 
Yes Appropriate statistical methods used, described and reported 
For example, Paired or nonnon-paired data tests 
Mean difference reported for comparison between intervention and active control 
No Statistical methods  inappropriate 
Unclear Inadequately described 
              Comment: ____________________________________________________________________ 
 
13. Was the trial design appropriate and any deviations from the standard RCT design (individual 
randomisation, parallel groups) accounted for in the conduct and analysis of the trial? 
Yes Described study methods in detail and any deviation from standard RCT design 
accounted for with explanation  
No Inappropriate study design/no explanation of deviation from standard RCT 
Unclear Inadequately described, lack of detail 









Appendix IIb Modified version of JBI Critical appraisal tool quasi experimental (non-
randomised controlled) trials 
 
Study:        
14. Is it clear in the study what is cause and what is effect? 
Yes It is clear that the ‘cause’ – ie provision of probiotics was manipulated before the 
occurrence of the ‘effect’? ( taken to be the patient reported outcomes) 
No It is NOT clear that the ‘cause’ – ie provision of probiotics was manipulated before the 
occurrence of the ‘effect’? ( taken to be the patient reported outcomes) 
Unclear There is lack of clarity about the timelines for intervention and measuring outcomes. 
Comment/detail:_____________________________________________________________________ 
 
15. Were the participants included in the comparison similar? 
Yes Recorded minimum base line data shows similarity including: 
- Age 
- Gender ratio 
- Duration of disease ( time since diagnosis) 
- Severity of disease ( i.e. mild, moderate or severe) 
- Baseline measurements for individual intended measurable outcomes 
Additional information can include 
- Weight 
- diet 
- concurrent medication use ( i.e. steroid ( oral or injected) NSAIDS or DMARDS) 
Genetic or serum disease markers ( HLAB27, Rheumatoid factor,  etc 
No Baseline data between groups is clearly not comparable (statistical differences between 
groups at baseline that may affect the outcome of results eg differences in sex, age, SES 
on effectiveness of intervention/uptake)  
Unclear Inadequately described. No or minimal reporting of baseline data i.e. only age, sex. No 
mention of statistical differences in baseline data between groups. 
Comment:__________________________________________________________________________ 
 
16. Were the participants included in any comparisons receiving the similar treatment or care to other 
than the exposure or intervention of interest ? 
Yes Participants in both the intervention and control groups were treated identically for all 
other aspects other than intervention of interest , eg access to ongoing medication as 
required, exercise and usual diet. 
Study includes active control group. Any intervention provided to control group described 
in detail, e.g. control group received daily placebo tablet if the intervention received daily 
probiotic tablet 
No Wait listed control groups where control intervention not provided, or intervention 
provided clearly not matched for attention, giving control participants an indication that 
they may be in the control group. 
Participants receiving concurrent intervention outside intervention of interest that may 
impact on results, eg allowed to take other supplements, to use antibiotics or start 
medication such as Biological class DMARDS 
Unclear Control intervention inadequately described 
Comment: _____________________________________________________________________ 
 
17. Was there a control group? 
Yes An independent control group was used 
No NO an independent control was not used 
Unclear Note that The control group should be an independent, separate control group, not the 





18. Were there multiple measurements of the outcome both pre and post intervention? 
Yes multiple measurements of the outcome both pre and post intervention 
No No measures pre or post were lacking 
Unclear Inadequately described 
              Comment: _____________________________________________________________________ 
 
19. Was follow up complete and if not, were differences between groups in terms of their follow up 
adequately described and analysed? 
Yes Complete follow up 
Withdrawn participants/losses to follow up reported and reasons for the withdrawal 
described.  
All participants included in final calculations including withdrawn participants, regardless 
of whether their final outcomes were measured.  
No No explanation of withdrawn participants/losses to follow up, or the significance of these 
withdrawals.  
Withdrawn participants not analysed in the groups to which they were allocated 
Unclear Withdrawn participants inadequately described. Numbers of included/withdrawn 
participants do not match result figures, inadequately described 
Comment:  _____________________________________________________________________ 
 
20. Were outcomes of participants included in any comparison measured in the same way? 
Yes Outcome data was measured and collected consistently in all groups 
No Outcome data was measured and collected differently for each group 
Unclear Inadequately described 
               Comment: _____________________________________________________________________ 
 
21. Were outcomes measured in a reliable way? 
Yes Outcomes (Pain, serum markers of inflammation such as CRP or ESR, clinical outcomes 
such as DAS28 or immunological markers) measured using standardised methods 
- Authors identify tool adequately- for example Composite scores may be created 
with ESR or CRP values – have they identified which were used? 
- Authors state the reliability and or validity of the measures used (incl appropriately 
trained clinical data collectors) or piloted within the trial. 
- Demonstrates/indicates test-retest reliability ( for example Global scores 
undertaken by the clinician alone have very poor inter-rater reliability ) 
- Are clear about when subjective measures such as pain ( VAS) are being assessed ( 
as a point measurement at a single clinical visit? Or by recall for a past period) 
No Self-reported/subjective outcomes, reliant on participant recall  
- VAS over past days/week or months 
- Patient self-report of compliance with taking the probiotic/placebo tablets 
No reporting on the reliability and or validity of the methods used  
No indication of outcomes tools being employed by individuals trained in their use. 
Unclear Inadequately described 
               Comment: ____________________________________________________________________ 
 
22. Was appropriate statistical analysis used? 
Yes Appropriate statistical methods used, described and reported 
For example, Paired or non-paired data tests 
Mean difference reported for comparison between intervention and active control 
No Statistical methods  inappropriate 
Unclear Inadequately described 
                Comment__________________________________________________________________________  
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Start N finish N Drop out%  
  probiotic control Probiotic control probiotic control Total 
Alipour et al  60 30 30 22 24 26 20 23 




Study AGE -mean Yrs. (SD) Disease duration 
mean YRS (SD) 
Gender ratio M:F % HLAB27  other 
 probiotic control Probiotic control probiotic control probiotic control  
Alipour 






 (SD 1.81) 
5.88 
(SD1.7) 
0:30 0:30 N/A N/A  
          
 
Probiotic intervention 
Probiotic Avg CFU over 







MIN CFU MAX 
CFU 
 Alipour B,  
et al   
 
Saccharomyces boulardii N/A 31 31 
   
 
Bifidobacterium lactis  8 312 44 
   
 
Bifidobacterium breve N/A 
 
23 
   
 
Bifidobacterium Longum N/A 
 
23 
   
 
Bifidobacterium infantis 12.5 
 
94 
   
 
Bifidobacterium bifidum 16.25 
 
128 12.5x 108 20 x 108 
 
 
Lactobacillus acidophilus  N/A 515 155 4 x 108 2x 109 
 
 
Lactobacillus salivarius  N/A 
 
102 
   
 
 Lactobacillus rhamnosus  210 
 
27 10x108 400x108 
 
 
 Lactobacillus plantarum 14 
 
23 
   
 
 Lactobacillus paracasei 6.25 
 
94 
   
 
 Lactobacillus delbrueckii N/A 
 
23 
   
 
 Lactobacillus caseii N/A 
 
77 1 x 108 20 x 108 1x 108  
 Lactobacillus reuterii 12.5 
 
14 
   
 
Streptococcus thermophilus N/A 97 23 
   
 
Streptococcus salivarius  13.6 
 
74 1 x 108 8 x 108 
 
 
Enterococcus faecium 20 31 31 
   
 
Bacillus coagulans 150 22 22 
   
 
Delivery      Once daily  
Total per study in CFU       1x 108  
Total per study CFU 108      1x 108  
*N/A CFU not supplied for all studies so all study average not calculable 





Study AGE -mean Yrs. (SD) Disease duration 
mean YRS ( SD) 
Gender ratio M:F HLAB27 as percentage 
 probiotic control Probiotic control probiotic control probiotic control 
Alipour 







 (SD 1.81) 
5.88 
(SD1.7) 
0:30 0:30 Not 
measured 
Not measured 









diet smoker obese Pregnant 
lactating 
Thyroid IBD Kidney Liver DM 
Alipour 
et al  
X X X X X X X X X X X 
            
 
 
Study Medications  
 antibiotics NSAIDS Oral steroids DMARDS bDMARDS Other (i.e. HFT) 
Alipour 
et al  
X X Not stated Not stated X X 
       
 
 
OUTCOME – Life impact – Bowel symptom 










et al  
DISQ diarrhoea 1.8 (SD1.6) 1.4(SD2.3) 1.9(SD2.7) 1(SD1.7) 0.24 (-0.36, 0.83) 
 
         
*Repeated for Pain, Blood in stools 
 
 
OUTCOME – Life impact – PAIN 
Study Tool Pain  mean(SD) Probiotic  Pain Mean ( SD) Control Stats 
  baseline end baseline end Effect size Range 
 
Jenks et al  VAS 29 (SD23) 27 (SD25) 30 (SD26) 26 (SD22) 0.0424 (-0.45, 0.54) 
        
 
OUTCOME – Life impact – FATIGUE 
Study Tool Outcome Probiotic Outcome Control Stats 





MAFS 24.3 (SD11.7) 21.9 (SD10.2) 25.8 (SD11.4) 23.9 (SD11.1) -0.19  (-0.68,0.31) 






OUTCOME – Life impact – quality of life 
Study Tool Score probiotic  
mean (SD) 
Score Control  
mean (SD) 
Stats 
  baseline end baseline end Effect size Range 
Brophy 
et al   
BAS-G  3.2 (SD 0.2) 2.9 (SD2.3) 4.1(SD2.5) 3.7(SD0) 0.16 (-0.16,0.93) 
        
 
 
OUTCOME – Adverse effects 
Study Sample size Serious adverse effects Minor adverse effects Relative risk (Any 
adverse event)  probiotic control probiotic control Probiotic control 
Brophy et al   76 71 0 0 6 5 1.12 
        
 
 
OUTCOME – Disease manifestations – systemic inflammation 
Study Marker Outcome Probiotic Outcome Control Stats 
  baseline End baseline End Effect 
size 
range 
Jenks et al   CRP 6.6(SD6.7) 6.7 (SD6.3) 10 (SD11.3) 11.3 (SD11.2) 0.504 (-1.01,-0.01) 
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Discussion- no supply 
probiotic 
2 Can gut bacteria improve your health? Harvard Men's Health Watch. 
2016;21(4):1-7. 
Discussion- no supply 
probiotic 
3  Abdollahi-Roodsaz S, Abramson SB, Scher JU. The metabolic role of 
the gut microbiota in health and rheumatic disease: mechanisms and 
interventions. Nat Rev Rheumatol. 2016;12(8):446-55. 
Discussion- no supply 
probiotic 
4 Alavi A, Goodfellow L, Fraser O, Tarelli E, Bland M, Axford J. A 
double-blind, randomized, placebo-controlled study to explore the 
efficacy of a dietary plant-derived polysaccharide supplement in 
patients with rheumatoid arthritis. Rheumatology (Oxford). 
2011;50(6):1111-9. 
prebiotic only 
5 Alberda C, Gramlich L, Meddings J, Field C, McCargar L, 
Kutsogiannis D, et al. Effects of probiotic therapy in critically ill 
patients: A randomized, double-blind, placebo-controlled trial. 
American Journal of Clinical Nutrition. 2007;85(3):816-23. 
not Inflammatory 
Arthritis 
6 Altomare R, Damiano G, Gioviale MC, Palumbo VD, Maione C, 
Spinelli G, et al. The intestinal ecosystem and probiotics. Progress in 
Nutrition. 2016;18(1):8-15. 
Discussion- no supply 
probiotic 
7 Aqaeinezhad Rudbane SM, Rahmdel S, Abdollahzadeh SM, Zare M, 
Bazrafshan A, Mazloomi SM. The efficacy of probiotic 
supplementation in rheumatoid arthritis: a meta-analysis of 
randomized, controlled trials. Inflammopharmacology. 2018;26(1):67-
76. 
Discussion- no supply 
probiotic 
8 Bansal T, Garg S. Probiotics: From functional foods to pharmaceutical 
products. Current Pharmaceutical Biotechnology. 2008;9(4):267-87. 
Discussion- no supply 
probiotic 
9  Bedaiwi MK, Inman RD. Microbiome and probiotics: link to arthritis. 
Curr Opin Rheumatol. 2014;26(4):410-5. 
Discussion- no supply 
probiotic 
10 Bennett DM, Shekhel T, Radelet M, Miller MD. Isolated Lactobacillus 
chronic prosthetic knee infection. Orthopedics. 2014;37(1):e83-6. 
not Inflammatory 
Arthritis 
11 Berntson L. Anti-inflammatory effect by exclusive enteral nutrition 
(EEN) in a patient with juvenile idiopathic arthritis (JIA): brief report. 
Clin Rheumatol. 2014;33(8):1173-5. 
Not probiotic 
12 Berntson L, Agback P, Dicksved J. Changes in fecal microbiota and 
metabolomics in a child with juvenile idiopathic arthritis (JIA) 
responding to two treatment periods with exclusive enteral nutrition 
(EEN). Clin Rheumatol. 2016;35(6):1501-6. 
Not probiotic 
13 Berntson L, Hedlund-Treutiger I, Alving K. Anti-inflammatory effect 
of exclusive enteral nutrition in patients with juvenile idiopathic 
arthritis. Clin Exp Rheumatol. 2016;34(5):941-5. 
Not probiotic 
14 Bhakta NR. Pitfalls of probiotics. Science Translational Medicine. 
2016;8(368). 
Murine 
15 Bhardwaj SB. Gut flora and its modification as a therapy. Reviews in 
Medical Microbiology. 2013;24(3):52-4. 
Not probiotic 
16 Bravo-Blas A, Wessel H, Milling S. Microbiota and arthritis: 
correlations or cause? Curr Opin Rheumatol. 2016;28(2):161-7. 
Discussion- no supply 
probiotic 
17  Bush LM, De Almeida KNF, Martin G, Perez MT. Probiotic-
associated bifidobacterium septic prosthetic joint arthritis. Infectious 
Diseases in Clinical Practice. 2014;22(4):e39-e41. 
not Inflammatory 
Arthritis 
18 Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns 
GA, et al. Nutrition and inflammatory processes. Proceedings of the 
Nutrition Society. 2008;67(OCE):E9. 
Discussion- no supply 
probiotic 
19 Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns 
GA, et al. Inflammatory disease processes and interactions with 




20 Cammarota G, Ianiro G, Cianci R, Bibbò S, Gasbarrini A, Currò D. 
The involvement of gut microbiota in inflammatory bowel disease 




21 Ceccarelli G, Vullo V, d'Ettorre G. Single-strain versus multistrain 
probiotic supplementation treatment strategy for rheumatoid arthritis: 
comment on the article by Marietta et al. Arthritis and Rheumatology. 
2018;70(2):320-1. 
Letter re murine study 
22 Cénit MC, Matzaraki V, Tigchelaar EF, Zhernakova A. Rapidly 
expanding knowledge on the role of the gut microbiome in health and 
disease. Biochimica et Biophysica Acta - Molecular Basis of Disease. 
2014;1842(10):1981-92. 
Discussion- no supply 
probiotic 
23 Cerrato PL. Can "healthy" bacteria ward off disease? RN. 
2000;63(4):71-4. 
Discussion- no supply 
probiotic 
24 Chatfield SM, Dharmage SC, Boers A, Martin BJ, Buchanan RR, 
Maksymowych WP, et al. Complementary and alternative medicines in 
ankylosing spondylitis: a cross-sectional study. Clin Rheumatol. 
2009;28(2):213-7. 
Not probiotic 
25 Chiavaroli C, Moore A. An hypothesis to link the opposing 
immunological effects induced by the bacterial lysate OM-89 in 
urinary tract infection and rheumatoid arthritis. BioDrugs. 
2006;20(3):141-9. 
Discussion- no supply 
probiotic 
26 Chow J, Mazmanian SK. Getting the Bugs out of the Immune System: 
Do Bacterial Microbiota "Fix" Intestinal T Cell Responses? Cell Host 
and Microbe. 2009;5(1):8-12. 
Not probiotic 
27 Clancy R. Immunobiotics and the probiotic evolution. FEMS 
Immunology and Medical Microbiology. 2003;38(1):9-12. 
Discussion- no supply 
probiotic 
28 Clemente JC, Manasson J, Scher JU. The role of the gut microbiome in 
systemic inflammatory disease. BMJ (Online). 2018;360. 
Discussion- no supply 
probiotic 
29 Collado MC, Gueimonde M, Pérez-Martínez G. Current and future 
applications of probiotics. Current Nutrition and Food Science. 
2011;7(3):170-80. 
Discussion- no supply 
probiotic 
30 Cooksey R, Brophy S, Gravenor MB, Brooks CJ, Burrows CL, Siebert 
S. Frequency and characteristics of disease flares in ankylosing 
spondylitis. Rheumatology. 2010 Feb 1;49(5):929-32. 
Discussion- no supply 
probiotic 
31 Costello ME, Robinson PC, Benham H, Brown MA. The intestinal 
microbiome in human disease and how it relates to arthritis and 
spondyloarthritis. Best Pract Res Clin Rheumatol. 2015;29(2):202-12. 
Discussion- no supply 
probiotic 
32 de Oliveira GLV, Leite AZ, Higuchi BS, Gonzaga MI, Mariano VS. 
Intestinal dysbiosis and probiotic applications in autoimmune diseases. 
Immunology. 2017;152(1):1-12. 
Discussion- no supply 
probiotic 
33 de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. 
Adv Biochem Eng Biotechnol. 2008;111:1-66. 
Discussion- no supply 
probiotic 
34 Decker C. Lactobacillus casei Supplementation Improves 
Inflammatory Markers and Disease Activity Scores in Rheumatoid 
Arthritis. Integrative Medicine Alert. 2015;18(5):56-8. 
duplication of article by 
Vaghref-Mehraby 
35 Dejoras EMM, Remalante PPM, Santiago ATM. Probiotic 
supplementation and its effect on disease activity in rheumatoid 
arthritis: A systematic review and meta-analysis. International Journal 
of Rheumatic Diseases. 2017;20:92. 
Discussion- no supply 
probiotic 
36 Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T. 
Mechanisms and therapeutic effectiveness of lactobacilli. Journal of 
Clinical Pathology. 2016;69(3):187-203. 
Discussion- no supply 
probiotic 
37 Diamanti AP, Manuela Rosado M, Lagana B, D'Amelio R. Microbiota 
and chronic inflammatory arthritis: an interwoven link. J Transl Med. 
2016;14(1):233. 
Discussion- no supply 
probiotic 
38 Diamanti AP, Manuela Rosado M, Laganà B, D'Amelio R. Microbiota 
and chronic inflammatory arthritis: An interwoven link. Journal of 
Translational Medicine. 2016;14(1). 




39 Dieleman LA. Additive effects of antibiotics, probiotics and prebiotics. 
EOS Rivista di Immunologia ed Immunofarmacologia. 2004;24(1-
2):89-90. 
Discussion- no supply 
probiotic 
40 Doron S, Gorbach SL. Probiotics: their role in the treatment and 
prevention of disease. Expert Rev Anti Infect Ther. 2006;4(2):261-75. 
not Inflammatory 
Arthritis 
41 Doron S, Snydman DR, Gorbach SL. Lactobacillus GG: Bacteriology 
and clinical applications. Gastroenterology Clinics of North America. 
2005;34(3):483-98. 
Discussion- no supply 
probiotic 
42 Dwivedi M, Kumar P, Laddha NC, Kemp EH. Induction of regulatory 
T cells: A role for probiotics and prebiotics to suppress autoimmunity. 
Autoimmunity Reviews. 2016;15(4):379-92. 
not Inflammatory 
Arthritis 
43 Ernst E. Complementary treatments in rheumatic diseases. Rheum Dis 
Clin North Am. 2008;34(2):455-67. 
Not probiotic 
44 Ezendam J, van Loveren H. Probiotics: immunomodulation and 
evaluation of safety and efficacy. Nutrition Reviews. 2006;64(1):1-14. 
Discussion- no supply 
probiotic 
45 Fernández-Llanio Comella N, Fernández Matilla M, Castellano Cuesta 
JA. Have complementary therapies demonstrated effectiveness in 
rheumatoid arthritis? Reumatologia Clinica. 2016;12(3):151-7. 
Discussion- no supply 
probiotic 
46 Fijan S. Microorganisms with claimed probiotic properties: An 
overview of recent literature. International Journal of Environmental 
Research and Public Health. 2014;11(5):4745-67. 
Discussion- no supply 
probiotic 
47 Fung I, Garrett JPD, Shahane A, Kwan M. Do bugs control our fate? 
the influence of the microbiome on autoimmunity. Current Allergy and 
Asthma Reports. 2012;12(6):511-9. 
Discussion- no supply 
probiotic 
48 Gaston JSH. Recent advances in understanding spondyloarthritis. 
F1000Research. 2017;6. 
Discussion- no supply 
probiotic 
49 Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. 
Adv Exp Med Biol. 2008;606:423-54. 
Discussion- no supply 
probiotic 
50 Goldin BR, Gorbach SL. Clinical indications for probiotics: an 




51 Gorbach SL. Probiotics in the Third Millennium. Digestive and Liver 
Disease. 2002;34(SUPPL. 2):S2-S7. 
Discussion- no supply 
probiotic 
52 Groeger D, O’Mahony L, Murphy EF, et al. Bifidobacterium infantis 
35624 modulates host inflammatory processes beyond the gut. Gut 
Microbes 2013;4:325-39. doi:10.4161/gmic.25487 pmid:23842110.  
not Inflammatory 
Arthritis 
53 Grover HS, Luthra S. Probiotics - the nano soldiers of oral health. 
Journal, Indian Academy of Clinical Medicine. 2012;13(1):48-54. 
Discussion- no supply 
probiotic 
54 Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii 
in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 
1462-4.  
No arthralgia component 
considered 
55 Hart AL, Stagg AJ, Frame M, Graffner H, Glise H, Falk P, et al. The 
role of the gut flora in health and disease, and its modification as 
therapy. Aliment Pharmacol Ther. 2002;16(8):1383-93. 
Discussion- no supply 
probiotic 
56 Hart AL, Stagg AJ, Frame M, Graffner H, Glise H, Falk P, et al. 
Review article: The role of the gut flora in health and disease, and its 
modification as therapy. Alimentary Pharmacology and Therapeutics. 
2002;16(8):1383-93. 
Discussion- no supply 
probiotic 
57 Heeney DD, Gareau MG, Marco ML. Intestinal Lactobacillus in health 
and disease, a driver or just along for the ride? Current Opinion in 
Biotechnology. 2018;49:140-7. 
Discussion- no supply 
probiotic 
58 Jethwa H, Abraham S. The evidence for microbiome manipulation in 
inflammatory arthritis. Rheumatology (Oxford). 2017;56(9):1452-60. 
Discussion- no supply 
probiotic 
59 Kang Y, Cai Y, Zhang X, Kong X, Su J. Altered gut microbiota in RA: 
implications for treatment. Zeitschrift fur Rheumatologie. 
2017;76(5):451-7. 
Discussion- no supply 
probiotic 
60 Karimi O, Pena AS. Probiotics in arthralgia and spondyloarthropathies 
in patients with inflammatory bowel disease. Prospective randomized 
trials are necessary. Rev Esp Enferm Dig. 2005;97(8):570-4. 




61 Karimi O, Pena AS. Indications and challenges of probiotics, 
prebiotics, and synbiotics in the management of arthralgias and 
spondyloarthropathies in inflammatory bowel disease. J Clin 
Gastroenterol. 2008;42 Suppl 3 Pt 1:S136-41. 
Discussion- no supply 
probiotic 
62 Karimi O, Pena AS, van Bodegraven AA. Probiotics (VSL#3) in 
arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot 
study. Drugs Today (Barc). 2005;41(7):453-9. 
active inflammatory 
arthritis excluded  
63 Keeney KM, Yurist-Doutsch S, Arrieta MC, Finlay BB. Effects of 
antibiotics on human microbiota and subsequent disease. Annu Rev 
Microbiol. 2014;68:217-35. 
Discussion- no supply 
probiotic 
64 Kelly D, Mulder IE. Microbiome and immunological interactions. 
Nutrition Reviews. 2012;70(SUPPL. 1):S18-S30. 
Discussion- no supply 
probiotic 
65 Keshwani A, Malhotra B, Kharkwal H. Nutraceutical: A drug, dietary 
supplement, and food ingredient. Current Pharmacogenomics and 
Personalized Medicine. 2015;13(1):14-22. 
Discussion- no supply 
probiotic 
66 Keyser FD, Mielants H, Veys EM. Current use of biologicals for the 
treatment of spondyloarthropathies. Expert Opin Pharmacother 2001 
Jan; 2 (1): 85-93  
Not including probiotics 
67 Kim D, Zeng MY, Nunez G. The interplay between host immune cells 
and gut microbiota in chronic inflammatory diseases. Exp Mol Med. 
2017;49(5):e339. 
Discussion- no supply 
probiotic 
68 Lomax AR, Calder PC. Probiotics, immune function, infection and 
inflammation: a review of the evidence from studies conducted in 
humans. Curr Pharm Des. 2009;15(13):1428-518. 
Discussion- no supply 
probiotic 
69 Lukaczer D. An integrative nutritional approach to the treatment of 
rheumatoid arthritis. Integrative Medicine: A Clinician's Journal. 
2005;4(2):16-22. 
No usable outcomes 
70 Malchow HA. Crohn's disease and Escherichia coli: a new approach in 
therapy to maintain remission of colonic Crohn's disease? J Clin Gas- 
troenterol 1997; 25:653-8.  
out of timeline 
71 Mattila-Sandholm T, Blum S, Collins JK, et al. Probiotics: towards 
demonstrating efficacy. Trends Food Sci Technol 1999; 10:393-9. 
out of timeline 
72 Mahajan B, Singh V. Recent trends in probiotics and health 
management: A review. International Journal of Pharmaceutical 
Sciences and Research. 2014;5(5):1643-52. 
Discussion- no supply 
probiotic 
73 Manasson J, Scher JU. Spondyloarthritis and the microbiome: new 
insights from an ancient hypothesis. Curr Rheumatol Rep. 
2015;17(2):10. 
Discussion- no supply 
probiotic 
74 McKean J, Naug H, Nikbakht E, Amiet B, Colson N. Probiotics and 
Subclinical Psychological Symptoms in Healthy Participants: A 
Systematic Review and Meta-Analysis. Journal of Alternative and 
Complementary Medicine. 2017;23(4):249-58. 
not Inflammatory 
Arthritis 
75 Mohammed AT, Khattab M, Ahmed AM, Turk T, Sakr N, A MK, et al. 
The therapeutic effect of probiotics on rheumatoid arthritis: a 
systematic review and meta-analysis of randomized control trials. 
Clinical Rheumatology. 2017;36(12):2697-707. 
Systematic review 
76  Mohsen Mazidi 1,2 , Peyman Rezaie 3 , Gordon A. Ferns 4  and 
Hassan Vatanparas Impact of Probiotic Administration on Serum C-
Reactive Protein Concentrations: Systematic Review and Meta-
Analysis of Randomized control trials 
Systematic review 
77 Montrose DC, Floch MH. Probiotics used in human studies. Journal of 
Clinical Gastroenterology. 2005;39(6):469-84. 
Systematic review 
78 Moriarty B, Bourke JF, Groeger D, Wycherly C, O'Mahony L, Malik 
M, et al. Bifidobacterium infantis 35624 in patients with mild to 




79 Moriarty B, Groeger D, Wycherley C, O'Mahony L, Malik M, 





35624 in patients with mild to moderate chronic plaque psoriasis: A 
pilot study. British Journal of Dermatology. 2012;167:47. 
80 Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. 
Probiotics for maintenance of remission in ulcerative colitis. Cochrane 
Database Syst Rev. 2011(12):CD007443. 
not Inflammatory 
Arthritis 
81 Neville BA, Otoole P. Probiotic properties of Lactobacillus salivarius 




82 Nousiainen P, Merras-Salmio L, Aalto K, Kolho KL. Complementary 
and alternative medicine use in adolescents with inflammatory bowel 
disease and juvenile idiopathic arthritis. BMC Complement Altern 
Med. 2014;14:124. 
Survey of use - no supply 
of probiotics 
83 O'Hara AM, Shanahan F. Mechanisms of action of probiotics in 
intestinal diseases. TheScientificWorldJournal. 2007;7:31-46. 
Discussion- no supply 
probiotic 
84 Parvez S, Malik KA, Ah Kang S, Kim HY. Probiotics and their 
fermented food products are beneficial for health. Journal of Applied 
Microbiology. 2006;100(6):1171-85. 
Discussion- no supply 
probiotic 
85 Paulus L. Probiotics, saw palmetto, kampo and cannabis discussed in 
latest FACT. Pharmaceutical Journal. 2006;277(7418):347. 
Discussion- no supply 
probiotic 
86 Pan H, Li R, Li T, Wang J, Liu L. Whether probiotic supplementation 
benefits rheumatoid arthritis patients: a systematic review and meta-
analysis. Engineering. 2017 Feb 1;3(1):115-21. 
Systematic review 
87 Presterl E, Kneifel W, Mayer HK, Zehetgruber M, Makristathis A, 
Graninger W. Endocarditis by Lactobacillus rhamnosus due to yogurt 
ingestion? Scand J Infect Dis. 2001;33(9):710-4. 
not Inflammatory 
Arthritis 
88 Reardon S. Microbiome therapy gains market traction. Nature. 
2014;509(7500):269-70. 
Discussion- no supply 
probiotic 
89 Reimold AM, Chandran V. Nonpharmacologic therapies in 
spondyloarthritis. Best Pract Res Clin Rheumatol. 2014;28(5):779-92. 
Discussion- no supply 
probiotic 
90 Rodriguez-Castaño GP, Caro-Quintero A, Reyes A, Lizcano F. 
Advances in gut microbiome research, opening new strategies to cope 
with a western lifestyle. Frontiers in Genetics. 2017;7(JAN). 
not Inflammatory 
Arthritis 
91 Rohatgi S, Ahuja V, Makharia GK, Rai T, Das P, Dattagupta S, et al. 
VSL#3 induces and maintains shortterm clinical response in patients 
with active microscopic colitis: a two-phase randomised clinical trial. 
BMJ Open Gastroenterology. 2015;2(1). 
not Inflammatory 
Arthritis 
92 Rovensky J, Stancikova M, Svik K, Uteseny J, Bauerova K, 
Jurcovicova J. Treatment of adjuvant-induced arthritis with the 
combination of methotrexate and probiotic bacteria Escherichia coli 
O83 (Colinfant). Folia Microbiol (Praha). 2009;54(4):359-63. 
Murine 
93 Ruiz-Quezada SL, Martínez-Bonilla GE, De La Cruz-Castro AA, 
Estrada-Martínez KP, González-Diaz V, Castãeda Urea M, et al. Effect 
of probiotic lactobacillus casei shirota on clinical manifestations and 
serum cytokines in patients with rheumatoid arthritis. Annals of the 
Rheumatic Disease. 2013;71. 
abstract only 
94 Saarela M, Lähteenmäki L, Crittenden R, Salminen S, Mattila-
Sandholm T. Gut bacteria and health foods - The European 
perspective. International Journal of Food Microbiology. 2002;78(1-
2):99-117. 
Discussion- no supply 
probiotic 
95 Sanders ME. Considerations for use of probiotic bacteria to modulate 
human health. Journal of Nutrition. 2000;130(2 SUPPL.):384S-90S. 
Discussion- no supply 
probiotic 
96 Sandhya P, Danda D, Sharma D, Scaria V. Does the buck stop with the 
bugs?: an overview of microbial dysbiosis in rheumatoid arthritis. Int J 
Rheum Dis. 2016;19(1):8-20. 
Discussion- no supply 
probiotic 
97 Sanges M, Valente G, Rea M, Della Gatta R, De Franchis G, Sollazzo 
R, et al. Probiotics in spondyloarthropathy associated with ulcerative 




98 Saxelin M, Tynkkynen S, Mattila-Sandholm T, De Vos WM. Probiotic 
and other functional microbes: From markets to mechanisms. Current 
Opinion in Biotechnology. 2005;16(2):204-11. 
Discussion- no supply 
probiotic 
99 Schorpion A, Kolasinski SL. Can Probiotic Supplements Improve 
Outcomes in Rheumatoid Arthritis? Current Rheumatology Reports. 
2017;19(11). 
Discussion- no supply 
probiotic 
100 Semerano L, Julia C, Aitisha O, Boissier MC. Nutrition and chronic 
inflammatory rheumatic disease. Joint Bone Spine. 2017;84(5):547-52. 
Discussion- no supply 
probiotic 
101 Sharpe PA, Wilcox S, Schoffman DE, Hutto B, Ortaglia A. 
Association of complementary and alternative medicine use with 
symptoms and physical functional performance among adults with 
arthritis. Disabil Health J. 2016;9(1):37-45. 
Not probiotic 
102 Sheikhi A, Nazarian M, Khadem-Al-Melleh A, Nasab NM, 
Esmaeilzadeh A, Yahaghi N, et al. In-vitro effects of Mycobacterium 
bovis BCG-lysate and its derived heat shock proteins on cytokines 
secretion by blood mononuclear cells of rheumatoid arthritis patients in 
comparison with healthy controls. Int Immunopharmacol. 
2008;8(6):887-92. 
Not live 
103 Singh DD, Amdekar S, Singh V. Probiotics: Defenders of 
gastrointestinal habitats. Gastroenterology Insights. 2012;4(2):90-104. 
Discussion- no supply 
probiotic 
104 Singh P, Rani B, Chauhan AK, Maheshwari R. Healthy living with 
nutraceuticals. International Research Journal of Pharmacy. 
2011;2(12):12-4. 
Not probiotic 
105 Slingerland AE, Schwabkey Z, Wiesnoski DH, Jenq RR. Clinical 
evidence for the microbiome in inflammatory diseases. Frontiers in 
Immunology. 2017;8(APR). 
Discussion- no supply 
probiotic 
106 Snydman DR. The safety of probiotics. Clinical Infectious Diseases. 
2008;46(SUPPL. 2):S104-S11. 
Discussion- no supply 
probiotic 
107  Song SC, An YM, Shin JH, Chung MJ, Seo JG, Kim E. Beneficial 
effects of a probiotic blend on gastrointestinal side effects induced by 
leflunomide and amlodipine in a rat model. Beneficial Microbes. 
2017;8(5):801-8. 
Murine 
108 Stebbings SM, Taylor C, Tannock GW, Baird MA, Highton J. The 
immune response to autologous bacteroides in ankylosing spondylitis 
is characterized by reduced interleukin 10 production. J Rheumatol. 
2009;36(4):797-800. 
Discussion- no supply 
probiotic 
109 Steves CJ, Bird S, Williams FM, Spector TD. The Microbiome and 
Musculoskeletal Conditions of Aging: A Review of Evidence for 
Impact and Potential Therapeutics. J Bone Miner Res. 2016;31(2):261-
9. 
Discussion- no supply 
probiotic 
110  Stoll ML, Cron RQ. The microbiota in pediatric rheumatic disease: 
epiphenomenon or therapeutic target? Curr Opin Rheumatol. 
2016;28(5):537-43. 
Discussion- no supply 
probiotic 
111 Thygesen JB, Glerup H, Tarp B. Saccharomyces boulardii fungemia 
caused by treatment with a probioticum. BMJ Case Rep. 2012;2012. 
not Inflammatory 
Arthritis 
112 Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, Tuckova L, 
Cukrowska B, Lodinova-Zadnikova R, et al. Commensal bacteria 
(normal microflora), mucosal immunity and chronic inflammatory and 
autoimmune diseases. Immunol Lett. 2004;93(2-3):97-108. 
Discussion- no supply 
probiotic 
113 Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, Tuckova L, 
Cukrowska B, Lodinova-Zadnikova R, et al. Commensal bacteria 
(normal microflora), mucosal immunity and chronic inflammatory and 
autoimmune diseases. Immunol Lett. 2004;93(2-3):97-108. 
Discussion- no supply 
probiotic 
114 Tournadre A, Tatar Z, Coxam V, Soubrier M. Gut microbiota and diet 
in rheumatoid arthritis. Revue du Rhumatisme Monographies. 
2018;85(1):52-6. 
Discussion- no supply 
probiotic 
115 Toussirot E, Robinet E, Saas P, Chabod J, Auge B, Cozma G, et al. 




immunomodulation in rheumatoid arthritis patients. Autoimmunity. 
2006;39(4):299-306. 
116 Toussirot É, Robinet É, Saas P, Chabod J, Augé B, Cozma G, et al. 
Bacterial extract (OM-89) specific and non specific 
immunomodulation in rheumatoid arthritis patients. Autoimmunity. 
2006;39(4):299-306. 
Not live 
117 Toussirot EA. Oral tolerance in the treatment of rheumatoid arthritis. 
Curr Drug Targets Inflamm Allergy. 2002;1(1):45-52. 
Not probiotic 
118 Vaghef-Mehrabany E, Homayouni-Rad A, Alipour B, Sharif SK, 
Vaghef-Mehrabany L, Alipour-Ajiry S. Effects of Probiotic 
Supplementation on Oxidative Stress Indices in Women with 
Rheumatoid Arthritis: A Randomized Double-Blind Clinical Trial. J 
Am Coll Nutr. 2016;35(4):291-9. 
Outcome exclusion 
119 Van Bodegraven AA, Karimi O, Peña AS. IBD-related 
spondylarthropathy and probiotics. EOS Rivista di Immunologia ed 
Immunofarmacologia. 2004;24(1-2):52-5. 
Unable to obtain in 
English 
120  Van de Wiele T, Van Praet JT, Marzorati M, Drennan MB, Elewaut D. 
How the microbiota shapes rheumatic diseases. Nat Rev Rheumatol. 
2016;12(7):398-411. 
Discussion- no supply 
probiotic 
121 Van den Nieuwboer M, Brummer RJ, Guarner F, Morelli L, Cabana M, 
Claassen E. The administration of probiotics and synbiotics in immune 
compromised adults: Is it safe? Beneficial Microbes. 2015;6(1):3-17. 
Discussion- no supply 
probiotic 
122 van der Meulen TA, Harmsen H, Bootsma H, Spijkervet F, Kroese F, 
Vissink A. The microbiome-systemic diseases connection. Oral Dis. 
2016;22(8):719-34. 
Discussion- no supply 
probiotic 
123 Vanderhoof JA, Young RJ. Use of probiotics in childhood 
gastrointestinal disorders. Journal of Pediatric Gastroenterology and 
Nutrition. 1998;27(3):323-32. 
Discussion- no supply 
probiotic 
124 Vanderhoof JA, Young RJ. Current and potential uses of probiotics. 
Annals of Allergy, Asthma and Immunology. 2004;93(5 SUPPL.):S33-
S7. 
Discussion- no supply 
probiotic 
125 Vitaliti G, Pavone P, Guglielmo F, Spataro G, Falsaperla R. The 
immunomodulatory effect of probiotics beyond atopy: an update. J 
Asthma. 2014;51(3):320-32. 
Discussion- no supply 
probiotic 
126 Vitetta L, Cicuttini F, Sali A. Alternative therapies for musculoskeletal 
conditions. Best Pract Res Clin Rheumatol. 2008;22(3):499-522. 
Discussion- no supply 
probiotic 
127 Vitetta L, Coulson S, Thomsen M, Nguyen T, Hall S. Probiotics, D–




128 Vitetta L, Manuel R, Zhou JY, Linnane AW, Hall S, Coulson S. The 
overarching influence of the gut microbiome on end-organ function: 
The role of live probiotic cultures. Pharmaceuticals. 2014;7(9):954-89. 
Discussion- no supply 
probiotic 
129 Wang H, Lee IS, Braun C, Enck P. Effect of probiotics on central 
nervous system functions in animals and humans: A systematic review. 
Journal of Neurogastroenterology and Motility. 2016;22(4):589-605. 
not Inflammatory 
Arthritis 
130 Wang P, Tao JH, Pan HF. Probiotic bacteria: a viable adjuvant therapy 
for relieving symptoms of rheumatoid arthritis. 
Inflammopharmacology. 2016;24(5):189-96. 
Discussion- no supply 
probiotic 
131 Wędrychowicz A, Zając A, Tomasik P. Advances in nutritional therapy 




132 Wendling D. The gut in spondyloarthritis. Joint Bone Spine. 
2016;83(4):401-5. 
Discussion- no supply 
probiotic 
133 Wendling D, Vuitton L, Koch S, Prati C. Spondyloarthritis and the gut: 
a new look. Joint Bone Spine. 2015;82(2):77-9. 
Discussion- no supply 
probiotic 
134 Wu X, He B, Liu J, Feng H, Ma Y, Li D, et al. Molecular Insight into 
Gut Microbiota and Rheumatoid Arthritis. Int J Mol Sci. 
2016;17(3):431. 




135 Xu Y, Liu Y, Liu Y, Pei J, Yao S, Cheng C. Bacteriophage therapy 
against Enterobacteriaceae. Virologica Sinica. 2015;30(1):11-8. 
Discussion- no supply 
probiotic 
136  Xu YY, Tan X, He YT, Zhou YY, He XH, Huang RY. Role of gut 
microbiome in ankylosing spondylitis: an analysis of studies in 
literature. Discov Med. 2016;22(123):361-70. 
Discussion- no supply 
probiotic 
137 Yan F, Polk DB. Commensal bacteria in the gut: Learning who our 
friends are. Current Opinion in Gastroenterology. 2004;20(6):565-71. 
Discussion- no supply 
probiotic 
138 Yang L, Wang L, Wang X, Xian CJ, Lu H. A Possible Role of 
Intestinal Microbiota in the Pathogenesis of Ankylosing Spondylitis. 
Int J Mol Sci. 2016;17(12). 
Discussion- no supply 
probiotic 
139 Yeoh N, Burton JP, Suppiah P, Reid G, Stebbings S. The role of the 
microbiome in rheumatic diseases. Curr Rheumatol Rep. 
2013;15(3):314. 
Discussion- no supply 
probiotic 
140 Zashin SJ. Complementary and alternative therapies for arthritis: 
science or fiction? Journal of Musculoskeletal Medicine. 
2000;17(6):330-45. 
Discussion- no supply 
probiotic 
141 Zhang F, Zhu H. Reply to Jia. American Journal of Gastroenterology. 
2015;110(12):1731-2. 
Discussion- no supply 
probiotic 
142 Zhong D, Wu C, Zeng X, Wang Q. The role of gut microbiota in the 
pathogenesis of rheumatic diseases. Clinical Rheumatology. 2017:1-
10. 
Discussion- no supply 
probiotic 
 
 
 
